MEK inhibitors and their therapeutic uses
Novel MEK inhibitors targeting specific kinase regions address the ineffectiveness of current cachexia treatments by enhancing pathological recovery and overcoming inhibitor resistance, effectively treating cancer cachexia and cancer with balanced metabolism and CRAF bypass resistance.
Patent Information
- Application Number
- JP2022542404
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-01-10
- Filing Date
- 2021-01-07
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2041-01-07
AI Technical Summary
Current treatments for cancer-related cachexia, a debilitating condition characterized by muscle wasting and weight loss, are ineffective, and existing MEK inhibitors have not reached the expected clinical efficacy, necessitating the development of new MEK inhibitors that can maximize pathological recovery of the MAPK/ERK pathway while minimizing drug-related toxicity.
The development of novel MEK inhibitors with specific structural formulas (I, Ia, Ib, Ic, Id, II, IIa, IIb, IIc, and IId) that target the MEK kinase, interacting with regions such as L115, V127, and M143, and S212, I215, and M219, to effectively treat cancer cachexia and cancer, including resistance to RAF protein kinase inhibitors, by administering compounds in therapeutically effective amounts.
These MEK inhibitors demonstrate improved efficacy in treating cancer cachexia and cancer by inhibiting cell proliferation, inducing apoptosis, and overcoming resistance to MEK and RAF inhibitors, with balanced metabolism and resistance to MEK reactivation by CRAF bypass, providing a therapeutic window for dual RAF/MEK inhibition.
Smart Images

Figure 0007582694000304 
Figure 0007582694000305 
Figure 0007582694000306
Abstract
Description
[Technical Field]
[0001] The present invention relates to the fields of chemistry and medicine. More specifically, the present invention relates to MEK inhibitors, techniques for designing and synthesizing such MEK inhibitors, compositions comprising MEK inhibitors, and methods of treating diseases comprising administering MEK inhibitors. [Background technology]
[0002] 2. Description of Related Art Cancer is one of the most common causes of death in the United States, accounting for approximately one in four deaths. The five-year relative survival rate for cancer patients diagnosed between 1996 and 2003 was approximately two-thirds, up from approximately half between 1975 and 1977 (Cancer Facts & Figures, American Cancer Society: Atlanta, Ga. (2008)). The rate of new cancer cases decreased by an average of 0.6% per year between 2000 and 2009 in men, but remained the same in women. From 2000 to 2009, the combined mortality rate from all cancers decreased by an average of 1.8% per year in men and 1.4% per year in women. This improvement in survival reflects advances in early diagnosis and improved treatment, which are still needed. Finding highly effective, low-toxicity anticancer drugs is a major goal of cancer research.
[0003] Furthermore, cancer-related cachexia is a debilitating condition associated with muscle loss, fatigue, weakness, and decreased appetite in cancer patients. Cachexia is also associated with severe clinical consequences, including muscle weakness that can lead to difficulty walking and pulmonary complications. Cachexia is a significant factor in the deaths of cancer patients.
[0004] Cachexia is characterized, in part, by a depletion of skeletal muscle mass that is not restored by conventional nutritional support, resulting in significant weight loss that severely impacts patient morbidity and mortality. Cachexia has been identified in over 80% of patients with gastric, pancreatic, and esophageal cancer, approximately 70% of patients with head and neck cancer, and approximately 60% of patients with lung, colorectal, and prostate cancer. See Muscle (2012) 3, 245-51. Despite the impact of cachexia on cancer patient mortality, no effective treatments have been developed to prevent or hinder its progression. For example, it is estimated that over 85% of pancreatic cancer patients, including those with early-stage disease, lose an average of 14% of their pre-disease body weight. See BMC Cancer, 2010 Jul. 8; 10:363. Cachectic pancreatic cancer patients are often weak and fatigued, tolerate treatment relatively poorly, and have relatively poor surgical outcomes. As a result, cachexia is a major factor contributing to the increased mortality rate of pancreatic cancer. Unfortunately, the 5-year survival rate for pancreatic cancer has not exceeded 6% in the past 40 years, the lowest survival rate of all malignancies.
[0005] Although considerable efforts have been made to design treatments for cachexia syndrome, unfortunately, no single treatment is completely satisfactory for reversing weight loss associated with cancer cachexia. The development of various therapeutic strategies has focused on two goals: resolving anorexia and alleviating metabolic disorders. However, providing complete nutritional requirements through total parenteral nutrition does not prevent weight loss. Alternatively, many drugs have been proposed and are being used in clinical trials to reverse metabolic changes, while others are still being investigated in experimental animals. See Toledo, et al. 2014 PloS One. One study found that the MEK inhibitor selumetinib promoted muscle strength gain in patients with intrahepatic cholangiocarcinoma. See British Journal of Cancer, (2012), 106, 1583-1586. Another study found that the MEK inhibitor binimetinib promoted muscle strength gain in patients with BTC. See Inv New Drugs (2018) 36, 1037-1043.
[0006] In addition to its potential role in cachexia, MEK is a key signaling intermediate in the MAPK / ERK pathway and is inappropriately activated across a wide range of human tumors, including those derived from the lung, pancreas, ovary, skin, and colon. Although several MEK inhibitors have received regulatory approval, these MEK inhibitors have yet to achieve the expected clinical efficacy. Identifying a new class of MEK inhibitors that maximizes pathological reversal of the MAPK / ERK pathway while limiting drug-associated toxicity would have a significant impact on the morbidity and mortality of cancer patients. Summary of the Invention
[0007] The compounds disclosed in the present application have been found to exhibit surprising and unexpected biological effects: they are MEK inhibitors that maximize pathological reversal of the MAPK / ERK pathway, and are effective anti-cancer and anti-cachexia agents suitable for use in anti-cancer and anti-cachexia pharmaceutical formulations.
[0008] Some embodiments are of formula (I): [ka] The present invention provides a compound having the structure (including pharmaceutically acceptable salts thereof) of the formula: Ring A is [ka] and; R 1 , R 2 , R 3 , R 4 , and R 6is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] and; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5 are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 is heteroaryl; Y is CH2, NH, or O (However, R1 is not pyrimidyl).
[0009] In some embodiments of Formula (I), ring A is [ka] In some embodiments, R 2 is -CH3. In some embodiments, R 2 is L. In some embodiments, L is -Z1-Z2. In some embodiments, Z1 is -CH2-. In some embodiments, Z2 is optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , —CHCH, or —CHCN. In some embodiments, R 5 is selected from H or CH3. In some embodiments, L is -Z1-Z2-Z3. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2- (optionally substituted aryl). In some embodiments, Z1 is -CH2-, and Z2 is an optionally substituted [ka] wherein n is 1, 2, 3, or 4. In some embodiments, Z is —CH—, and Z is optionally substituted. [ka] is.
[0010] Some embodiments are of formula (Ia): [ka] (including pharmaceutically acceptable salts thereof), wherein Ring A is [ka] and; R 2 , R 3 , R 4 , and R 6 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] and; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5 are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 is heteroaryl; Y is CH2, NH, or O (However, R1 is not pyrimidyl).
[0011] In some embodiments of Formula (Ia), ring A is [ka] In some embodiments, R 2 is -CH3. In some embodiments, R 2 is L. In some embodiments, L is -Z1-Z2. In some embodiments, Z1 is -CH2-. In some embodiments, Z2 is optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , —CHCH, or —CHCN. In some embodiments, R 5 is selected from H or CH3. In some embodiments, L is -Z1-Z2-Z3. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2- (optionally substituted aryl). In some embodiments, Z1 is -CH2-, and Z2 is an optionally substituted [ka] wherein n is 1, 2, 3, or 4. In some embodiments, Z is —CH—, and Z is optionally substituted. [ka] is.
[0012] Some embodiments are of formula (Ib): [ka] (including pharmaceutically acceptable salts thereof), wherein Ring A is [ka] and; R 2 , R 3 , R 4 , and R 6 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5 are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 Heteroaryl (However, R 1 is not pyrimidyl).
[0013] In some embodiments of Formula (Ib), ring A is [ka] In some embodiments, R 2 is -CH3. In some embodiments, R 2 is L. In some embodiments, L is -Z1-Z2. In some embodiments, Z1 is -CH2-. In some embodiments, Z2 is optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , —CHCH, or —CHCN. In some embodiments, R 5 is selected from H or CH3. In some embodiments, L is -Z1-Z2-Z3. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2-(optionally substituted aryl).
[0014] Some embodiments are of formula (Ic): [ka] (including pharmaceutically acceptable salts thereof), wherein Ring A is [ka] and; R 1 , R 2 , R 3 , R 4 , and R 6is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] and; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5 are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 is heteroaryl; Y is CH2, NH, or O (However, R 1 is not pyrimidyl).
[0015] In some embodiments of Formula (Ic), ring A is [ka] In some embodiments, R 2 is -CH3. In some embodiments, R 2 is L. In some embodiments, L is -Z1-Z2. In some embodiments, Z1 is -CH2-. In some embodiments, Z2 is optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , —CHCH, or —CHCN. In some embodiments, R 5 is selected from H or CH3. In some embodiments, L is -Z1-Z2-Z3. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2- (optionally substituted aryl). In some embodiments, Z1 is -CH2-, and Z2 is an optionally substituted [ka] wherein n is an integer selected from 1, 2, 3, and 4. In some embodiments, Z is —CH—, and Z is optionally substituted. [ka] is.
[0016] Formula (Id): [ka] A compound of formula (I) having the structure shown in (including pharmaceutically acceptable salts thereof), wherein: Ring A is [ka] and; R 3 and R 4 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, and L; R 6 is selected from the group consisting of H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, and optionally substituted C2-C6 alkynyl; R 9 and R 10 is hydrogen, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); X 1 is selected from the group consisting of CH, B, N, or PO4; n is selected from 1, 2, 3, or 4; Each R 5 and R 5’ is H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 Aryl, optionally substituted C3-C8 heterocyclyl, and optionally substituted C3-C 10 independently selected from heteroaryl; Y is CH2, NH, or O (However, R 1 is not pyrimidyl), a compound.
[0017] In some embodiments, n is 1 or 2. In some embodiments, X 1 is CH or N. In some embodiments, R 9 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 In some embodiments, R is selected from heteroaryl. 10 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C10 heteroaryl.
[0018] Some embodiments are of formula (II): [ka] (including pharmaceutically acceptable salts thereof), wherein Q A , Q B , Q C are independently C or N; R 1 , R 2 , R 3 , R 6 , and R 7 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] and; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 is heteroaryl; Y is CH, NH, or O; Z is C or N (However, R 1 is not pyrimidyl).
[0019] In some embodiments of Formula (II), R 2 is -CH3. In some embodiments, R 2 is L. In some embodiments, L is -Z1-Z2. In some embodiments, Z1 is -CH2-. In some embodiments, Z2 is optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , —CHCH, or —CHCN. In some embodiments, R 5 is selected from H or CH3. In some embodiments, L is -Z1-Z2-Z3. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2- (optionally substituted aryl). In some embodiments, Z1 is -CH2-, and Z2 is an optionally substituted [ka] wherein n is an integer selected from 1, 2, 3, and 4. In some embodiments, Z is —CH—, and Z is optionally substituted. [ka] is.
[0020] Some embodiments are represented by formula (IIa): [ka] (including pharmaceutically acceptable salts thereof), wherein R 2 , R 3 , R 6 , and R 8 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] and; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are each independently selected from the group consisting of halo, -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, and -NR 5 R 5’ , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5’ -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); R 5 and R 5’each of which is selected from H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 independently selected from heteroaryl; Y is CH, NH, or O; Z is C or N.
[0021] In some embodiments of Formula (IIa), R 2 is -CH3. In some embodiments, R 2 is L. In some embodiments, L is -Z1-Z2. In some embodiments, Z1 is -CH2-. In some embodiments, Z2 is optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , —CHCCH, or —CHCN. In some embodiments, R 5 is selected from H or CH3. In some embodiments, L is -Z1-Z2-Z3. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2- (optionally substituted aryl). In some embodiments, Z1 is -CH2-, and Z2 is an optionally substituted [ka] wherein n is selected from 1, 2, 3, and 4. In some embodiments, Z1 is -CH2- and Z2 is optionally substituted. [ka] is.
[0022] Some embodiments are represented by formula (IIb): [ka] (including pharmaceutically acceptable salts thereof), wherein: R 2 is L; R 6 is H, deuterium, halo, or optionally substituted C1-C6 alkyl; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5-, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5 are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 is heteroaryl; Z is C or N.
[0023] In some embodiments of Formula (IIb), L is -Z1-Z2. In some embodiments, Z1 is -CH2-. In some embodiments, Z2 is an optionally substituted C3-C8 cycloalkyl, an optionally substituted C3-C8 heterocyclyl, an optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , —CHCCH, or —CHCN. In some embodiments, R 5 is selected from H or CH3. In some embodiments, L is -Z1-Z2-Z3. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2- (optionally substituted aryl). In some embodiments, Z1 is -CH2-, and Z2 is an optionally substituted [ka] wherein n is 1, 2, 3, or 4. In some embodiments, Z is —CH—, and Z is optionally substituted. [ka] is.
[0024] In some embodiments, the compound of Formula (II) has the formula (IIc): [ka] (including pharmaceutically acceptable salts thereof), wherein: R 1 and R 2 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5’ , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5’ -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -NHCHCO-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5 and R 5’are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 is heteroaryl; Z is C or N (However, R 1 is not pyrimidyl).
[0025] In some embodiments, R 2 is not -CH. In some embodiments, R 2 is L. In some embodiments, L is -Z1-Z2. In some embodiments, Z1 is -CH2-. In some embodiments, Z2 is optionally substituted C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5’ , —CHCCH, or —CHCN. In some embodiments, R 5 and R 5’ are each selected from H or CH3. In some embodiments, L is -Z1-Z2-Z3. In some embodiments, Z1 is -CH2, -Z2 is selected from N or optionally substituted C3-C8 heterocyclyl, and Z3 is optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6 ... 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl.
[0026] In some embodiments, the compound of Formula (II) has the formula (IId): [ka] (including pharmaceutically acceptable salts thereof), wherein: R 3 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 selected from the group consisting of heteroaryl; R 6 is selected from the group consisting of H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, and optionally substituted C2-C6 alkynyl; R 8is H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl; R 9 and R 10 is hydrogen, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); X 1 is selected from the group consisting of CH, B, and N.
[0027] In some embodiments, R 3 is H, deuterium, halogen, C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl.
[0028] In some embodiments, R 6is selected from H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl.
[0029] In some embodiments, R 8 is selected from H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl.
[0030] In some embodiments, R 9 is H, deuterium, halogen, C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl.
[0031] In some embodiments, R 10 is H, deuterium, halogen, C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl.
[0032] In some embodiments, the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId) is selected from the compounds of Table A. In some embodiments, the compound of Formula (I) or Formula (II) is [ka] [ka] and pharmaceutically acceptable salts thereof.
[0033] In some embodiments, the pharmaceutically acceptable salt is an alkaline metal salt or an ammonium salt.
[0034] Some embodiments provide a therapeutically effective amount of a compound of formula (I): [ka] and a pharmaceutical composition comprising at least one compound having the structure (including pharmaceutically acceptable salts thereof) of the formula: Ring A is [ka] and; R 1 , R 2 , R 3 , R 4 , and R 6 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] and; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5 are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 is heteroaryl; Y is CH2, NH, or O (However, R 1 is not pyrimidyl).
[0035] Some embodiments provide a therapeutically effective amount of a compound of formula (II): [ka] and a pharmaceutical composition comprising at least one compound having the structure (including pharmaceutically acceptable salts thereof) of the formula: Q A , Q B , Q C are independently C or N; R 1 , R 2 , R 3 , R 6 , and R 7is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L; X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] and; L is -Z1-Z2 or -Z1-Z2-Z3; Z1, Z2, and Z3 are independently -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl); Each R 5 are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, or optionally substituted C3-C 10 is heteroaryl; Y is CH, NH, or O; Z is C or N (However, R 1 is not pyrimidyl).
[0036] Some embodiments relate to methods of treating a mammal having a disease or disorder. In some embodiments, the method comprises administering to the mammal a therapeutically effective amount of a compound described herein. Some embodiments relate to methods of treating a mammal having a disease or disorder. In one embodiment, the method comprises administering to the mammal a therapeutically effective amount of a pharmaceutical composition described herein. In some embodiments, the mammal is a human. In some embodiments, the method further comprises administering to the mammal an additional agent. In some embodiments, the method comprises administering to a subject suffering from the disease or disorder an effective amount of any one of the compounds described herein, or a pharmaceutically acceptable salt thereof.
[0037] Some embodiments relate to methods for treating a disease. In some embodiments, the method comprises administering an effective amount of a pharmaceutical composition described herein to a subject suffering from the disease. In some embodiments, the disease is cancer. In some embodiments, the cancer is selected from the group consisting of brain cancer, breast cancer, lung cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, gastric cancer, prostate cancer, renal cancer, colorectal cancer, or leukemia. In further or additional embodiments, the fibrotic disorder is scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis, or pulmonary fibrosis. In some embodiments, the cancer is associated with a RAS mutation. In some embodiments, the RAS mutation is a KRAS mutation selected from the group consisting of G12C, G12S, G12R, G12F, G12L, G12N, G12A, G12D, G12V, G13C, G13S, G13D, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, and Q61H. In some embodiments, the disease is cancer cachexia.
[0038] Some embodiments relate to methods of inhibiting proliferation of a cell, in some embodiments, the method comprises contacting the cell with an effective amount of a compound described herein or a pharmaceutical composition described herein, in some embodiments, the cell has a RAS mutation.
[0039] Some embodiments relate to methods of inducing apoptosis in a cell, hi some embodiments, the method comprises contacting the cell with an effective amount of a compound described herein or a pharmaceutical composition described herein.
[0040] Some embodiments relate to methods of treating a subject having a cancer that is resistant to treatment with a MEK protein kinase inhibitor, hi some embodiments, the method comprises contacting a cell with an effective amount of a compound described herein or a pharmaceutical composition described herein.
[0041] Some embodiments relate to methods of treating a subject having a cancer that is resistant to treatment with a RAF protein kinase inhibitor, hi some embodiments, the method comprises contacting a cell with an effective amount of a compound described herein or a pharmaceutical composition described herein.
[0042] Some embodiments relate to methods of treating cancer cachexia in a mammal having cancer, hi some embodiments, the method comprises administering an effective amount of a compound described herein or a pharmaceutical composition described herein.
[0043] In some embodiments, the compounds described herein or pharmaceutical compositions described herein can be administered in a single dose. In some embodiments, the compounds described herein or pharmaceutical compositions described herein can be administered in a single dose once daily.
[0044] In some embodiments, the compounds described herein or pharmaceutical compositions described herein may be administered in multiple doses more than once per day. In some embodiments, the compounds described herein or pharmaceutical compositions described herein may be administered twice per day. In some embodiments, the compounds described herein or pharmaceutical compositions described herein may be administered three times per day. In some embodiments, the compounds described herein or pharmaceutical compositions described herein may be administered at a dose of 0.1 mg to 2000 mg. In some embodiments, the compounds described herein or pharmaceutical compositions described herein may be administered at a dose of about 0.001 to about 1000 mg / kg body weight / day.
[0045] In some embodiments, the compounds described herein have a drug profile that is RAF-resistant, BID dosing, balanced metabolism, and active for about 3 to about 6 hours.
[0046] In some embodiments, the compounds described herein interact with a first region of MEK kinase that includes L115, L118, V127, and M143.
[0047] In some embodiments, the compound interacts with a second region of MEK kinase that includes K97.
[0048] In some embodiments, the compounds described herein interact with a third region of MEK kinase that includes S212, I215, and M219.
[0049] In some embodiments, methods are described herein for developing molecules based on the evaluation and balancing of two downstream molecular targets.
[0050] In some embodiments, the methods may include administering a compound that targets pERK(T202 / Y204) and pSTAT3(S727).
[0051] In some embodiments, methods are described herein for preventing MEK reactivation by CRAF bypass.
[0052] In some embodiments, the methods can include administering an effective amount of any one of the compounds or pharmaceutical compositions described herein.
[0053] In some embodiments, methods for designing the therapeutic window of dual RAF / MEK inhibitors are described herein.
[0054] In some embodiments, the methods may include administration of a therapeutic agent that has a plasma half-life of less than 12 hours, is administered QD or BID, is resistant to MEK reactivation by CRAF bypass, and has an optimal metabolic balance between pERK inhibition and pSTAT3(S727) inhibition. [Brief explanation of the drawings]
[0055] [Figure 1] Figure 1 shows the pERK (T202 / Y204):total ERK ratio versus pSTAT3 (S727):total STAT3 ratio for Reference-1, Reference-2, Compound (Cmpd)-7, Compound-10, Compound-9, Compound-11, Compound-12, Compound-13, Compound-14, Compound-15, and Compound-16 in A549 KRAS mutant lung cancer. [Figure 2] Figure 1 shows CRAF bypass due to increased pMEK:total MEK ratio in A549 KRAS mutant lung cancer after treatment with selected reference MEK inhibitors. [Figure 3] Figure 1 shows gastrocnemius pharmacokinetic (PK) results from a single 2 hour time point for Reference-1, Reference-2, Compound-7, Compound-10, Compound-9, Compound-11, Compound-12, Compound-13, Compound-14, Compound-15, and Compound-16 in the C26 tumor model. [Figure 4]Figure 1 shows tumor pharmacokinetic (PK) results from a single 2-hour time point for Reference-1, Reference-2, Compound-7, Compound-10, Compound-9, Compound-11, Compound-12, Compound-13, Compound-14, Compound-15, and Compound-16 in the C26 tumor model. [Figure 5] Figure 1 shows plasma pharmacokinetic (PK) results from a single 2-hour time point for Reference-1, Reference-2, Compound-7, Compound-10, Compound-9, Compound-11, Compound-12, Compound-13, Compound-14, Compound-15, and Compound-16 in the C26 tumor model. [Figure 6] Figure 1 shows hepatic pharmacokinetic (PK) results from a single 2-hour time point for Reference-1, Reference-2, Compound-7, Compound-10, Compound-9, Compound-11, Compound-12, Compound-13, Compound-14, Compound-15, and Compound-16 in the C26 tumor model. [Figure 7A] Figure 1 shows a comparison of Reference-1 and Compound-9 at 100 mg / kg QD in a C26 tumor-bearing MTD study. [Figure 7B] 1 shows a comparison of Compound 13 and Compound 14 at 100 mg / kg QD in a C26 tumor-bearing MTD study. [Figure 8A] Figure 1 shows a comparison of Reference-1 and Compound-9 at 100 mg / kg BID in a C26 tumor-bearing MTD study. [Figure 8B] 1 shows a comparison of Compound-13 and Compound-14 at 100 mg / kg BID in a C26 tumor-bearing MTD study. [Figure 9] Dose response of A549(KRAS-G12S)pERK is shown. [Figure 10] 1 shows graphs for the Colon-26 model of efficacy and safety in KRAS G12D CRC. [Figure 11A] 1 shows graphs of tumor growth in KRAS G12D CRC from the C-26 pharmacology study. [Figure 11B] 1 shows graphs of weight loss in KRAS G12D CRC from the C-26 pharmacology study. [Figure 12]Graphs showing activity in the Colon-26 KRAS mutant CRC model are shown. [Figure 13] Graphs are shown for dual RAF / MEK resistant to CRAF bypass. [Figure 14] A shows a graph of the time course of dual RAF / MEK:CRAF bypass for A459 KRAS pERK:total ERK and B shows pMEK:total MEK in the NSCLC model A549 KRAS(G12S). [Figure 15A] 1 shows a graph of pERK:total ERK (activated) in a BRAF V600E mutant A375 melanoma model. [Figure 15B] pERK in the KRAS G12S mutant A549 model: Paradoxical activation by total ERK and RAF inhibitors. [Figure 16] 1 shows a graph of the plasma single dose pharmacokinetic profile. [Figure 17] 1 shows a graph of the single dose pharmacokinetic profile of the CRC model Colon-26 tumor. [Figure 18] 1 shows a graph of relative body weight corrected for NSCLC model A549 tumor volume. DETAILED DESCRIPTION OF THE INVENTION
[0056] In some embodiments, MEK inhibitors are provided. Various embodiments of these compounds include compounds having the structure of Formula I, as described herein, or pharmaceutically acceptable salts thereof. In some embodiments, prodrugs, metabolites, stereoisomers, hydrates, solvates, polymorphs, and pharmaceutically acceptable salts of the compounds disclosed herein are provided.
[0057] In certain aspects, therapeutic methods or uses are provided herein for treating, preventing, or alleviating a disease or condition in a subject, the methods comprising administering at least one compound disclosed herein to the subject. In some embodiments, therapeutic methods or uses are provided for treating, preventing, or alleviating cancer, comprising administering a compound having a structure of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId) described herein. In some embodiments, therapeutic methods or uses are provided for treating cancer cachexia, comprising administering a compound having a structure of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId) described herein.
[0058] definition Unless expressly defined otherwise, technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In the event that there are multiple definitions for terms herein, those in this section prevail unless stated otherwise. As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, and pharmacology are employed unless otherwise indicated. The use of either the conjunction "or" or "and" means "and / or" unless otherwise stated. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," and "comprised," is not limiting. As used herein, whether in transitional phrases or in the body of the claims, the terms "comprise(s)" and "comprising" should be construed as having an open-ended meaning. That is, these terms should be interpreted synonymously with the phrases "having at least" or "including at least." When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the recited features or components, but may also include additional features or components.
[0059] While the present disclosure has been illustrated and described in detail in the foregoing description, such description is to be considered illustrative or exemplary and not restrictive. The present disclosure is not limited to the disclosed embodiments. Variations of the disclosed embodiments can be understood and effected by those skilled in the art in practicing the claimed disclosure, from a study of the present disclosure and the appended claims.
[0060] With regard to the use of virtually any plural and / or singular term herein, those skilled in the art can convert from plural to singular and / or from singular to plural as appropriate to the context and / or application. For clarity, various singular / plural permutations may be expressly stated herein. The indefinite article "a" or "an" does not exclude a plurality. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage.
[0061] All references cited herein are incorporated by reference in their entirety. To the extent that publications and patents or patent applications incorporated by reference conflict with the disclosure contained herein, the present specification is intended to supersede and / or override any such conflicting material.
[0062] Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meaning to those of ordinary skill in the art and are not to be limited to any special or particular meaning unless expressly so defined herein. It should be noted that the use of a particular terminology in describing a particular feature or aspect of the present disclosure should not be construed as meaning that the terminology is redefined herein to be limited to include any particular feature of the feature or aspect of the present disclosure with which the terminology is associated.
[0063] When a range of values is provided, it is understood that the upper and lower limits, and every intervening value between the upper and lower limits of the range, are encompassed within the embodiments.
[0064] As used herein, the term "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. For example, a prodrug may be bioavailable by oral administration, whereas the parent drug is not. A prodrug may also have improved solubility in pharmaceutical compositions compared to the parent drug. Examples of prodrugs include, but are not limited to, compounds that are administered as esters ("prodrugs") to facilitate delivery across cell membranes, where water solubility adversely affects mobility, but are subsequently metabolically hydrolyzed to a carboxylic acid (the active entity) once inside cells, where water solubility is advantageous. Another example of a prodrug may be a short-chain peptide (polyamino acid) bonded to an acid group, which is metabolized to reveal the active moiety. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in *Design of Prodrugs* (ed. H. Bundgaard, Elsevier, 1985), incorporated herein by reference in its entirety.
[0065] Metabolites of the compounds disclosed herein include active species produced upon introduction of the compounds into the biological milieu.
[0066] Compounds disclosed herein having at least one chiral center may exist as racemates or individual enantiomers, or as enantiomerically enriched mixtures of enantiomers. It is noted that all such isomers and mixtures thereof are within the scope of the present invention. Furthermore, crystalline forms of compounds disclosed herein may exist as different polymorphs. Such polymorphs are included in one embodiment of the present invention. In addition, some of the compounds of the present invention may form solvates with water (i.e., hydrates) or common organic solvents. Such solvates are included in one embodiment of the present invention.
[0067] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some embodiments, the salt is an acid addition salt of the compound. Pharmaceutical salts can be obtained by reacting a compound with an inorganic acid such as a hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), sulfuric acid, nitric acid, phosphoric acid, etc. Pharmaceutical salts can also be obtained by reacting a compound with an organic acid such as an aliphatic or aromatic carboxylic acid or sulfonic acid, for example, acetic acid, succinic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, nicotinic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, or naphthalenesulfonic acid. Pharmaceutical salts can also be obtained by reacting a compound with a base to form a salt, for example, an alkali metal salt such as an ammonium salt, a sodium salt, or a potassium salt, an alkaline earth metal salt such as a calcium salt or a magnesium salt, a salt of an organic base such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, C1-C7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine, and the like, and a salt with an amino acid such as arginine or lysine.
[0068] When the manufacture of a pharmaceutical formulation involves intimate mixing of a pharmaceutical excipient with an active ingredient in salt form, it may be desirable to use pharmaceutical excipients that are non-basic, i.e., either acidic or neutral excipients.
[0069] In various embodiments, the compounds disclosed herein may be used alone, in combination with other compounds disclosed herein, or in combination with one or more other agents active in the therapeutic areas described herein.
[0070] As used herein, the term "halogen atom" means any one of the radioactive stable atoms in column 7 of the periodic table of the elements, e.g., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
[0071] As used herein, the term "ester" refers to an ester of the formula -(R) n refers to a chemical moiety having the formula -COOR', where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heteroalicyclic (bonded through a ring carbon), and n is 0 or 1.
[0072] As used herein, the term "amide" refers to a group of the formula -(R) n -C(O)NHR' or -(R) n refers to a chemical moiety having the formula -NHC(O)R', where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heteroalicyclic (bonded through a ring carbon), and n is 0 or 1. An amide can be an amino acid or peptide molecule attached to a molecule of the invention, thereby forming a prodrug.
[0073] Any amine, hydroxyl, or carboxyl side chain on the compounds disclosed herein can be esterified or amidated. Procedures and specific groups used to achieve this purpose are known to those skilled in the art and are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein in its entirety.
[0074] As used herein, the term "aromatic" refers to an aromatic group having at least one ring with a conjugated π-electron system, including both carbocyclic aryl groups (e.g., phenyl) and heterocyclic aryl groups (e.g., pyridine). The term includes monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) groups. The term "carbocyclic" refers to a compound containing one or more covalently closed ring structures, in which the atoms forming the backbone of the ring are all carbon atoms. Thus, the term distinguishes between carbocyclic rings and heterocyclic rings containing at least one atom other than carbon in the ring backbone. The term "heteroaromatic" refers to an aromatic group containing at least one heterocyclic ring.
[0075] As used herein, "C a ~C b(where "a" and "b" are integers) refers to the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of carbon atoms in a ring of a cycloalkyl, aryl, heteroaryl, or heterocyclyl group. That is, the alkyl, alkenyl, alkynyl, cycloalkyl ring, aryl ring, heteroaryl ring, or heterocyclyl ring can contain from "a" to "b" (inclusive) carbon atoms. Thus, for example, a "C1-C4 alkyl" group or a "C1-C4 alkyl" group refers to all alkyl groups having one to four carbons, i.e., CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2CH2-, CH3CH2CH(CH3)-, and (CH3)3C-. Similarly, for example, a cycloalkyl group can contain all atoms from "a" through "b" (inclusive), e.g., a C3-C8 cycloalkyl group, 3 to 8 carbon atoms in the ring(s). When "a" and "b" are not specified with respect to alkyl, cycloalkyl, or cycloalkenyl, the broadest range described by those definitions is assumed. Similarly, a "4- to 7-membered heterocyclyl" group refers to all heterocyclyl groups having a total of 4 to 7 ring atoms, e.g., azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, etc. As used herein, the term "C1-C6" includes C1, C2, C3, C4, C5, and C6, as well as the range defined by any two of the foregoing numbers. For example, C1-C6 alkyl includes C1, C2, C3, C4, C5, and C6 alkyl, C2-C6 alkyl, C1-C3 alkyl, etc. Similarly, a C3-C8 carbocyclyl or cycloalkyl includes hydrocarbon rings containing 3, 4, 5, 6, 7, and 8 carbon atoms, respectively, or a range defined by either two numbers, such as C3-C7 cycloalkyl or C5-C6 cycloalkyl. As another example, a 3- to 10-membered heterocyclyl includes 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, or a range defined by any two of the foregoing numbers, such as a 4- to 6-membered or 5- to 7-membered heterocyclyl.
[0076] As used herein, "alkyl" refers to a straight or branched hydrocarbon chain of a fully saturated (no double or triple bonds) hydrocarbon group. The alkyl group can have 1 to 20 carbon atoms. (Whenever provided herein, a numerical range, such as "1 to 20," refers to each integer within the given range. For example, "1 to 20 carbon atoms" means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, and so on, up to 20 carbon atoms. However, this definition also encompasses the occurrence of the term "alkyl" without a specified numerical range.) The alkyl group can also be a medium-sized alkyl having 1 to 10 carbon atoms. The alkyl group can also be a lower alkyl having 1 to 5 carbon atoms. The alkyl group of a compound can be designated as "C1-C4 alkyl" or similar designation. By way of example only, "C1-C4 alkyl" indicates that there are 1 to 4 carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, and the like.
[0077] An alkyl group can be substituted or unsubstituted. If substituted, the substituent(s) can be alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, or the like. and one or more group(s) individually and independently selected from aryl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino (including mono- and di-substituted amino groups, and protected derivatives thereof). Whenever a substituent is described as "optionally substituted," that substituent can be substituted with one of the above substituents.
[0078] As used herein, "alkenyl" refers to an alkyl group containing one or more double bonds in the straight or branched hydrocarbon chain. Alkenyl groups can be unsubstituted or substituted. If substituted, the substituent(s) can be selected from the same groups disclosed above for alkyl group substitution. Alkenyl groups can have 2 to 20 carbon atoms, although this definition also encompasses the occurrence of the term "alkenyl" where no numerical range is specified. Alkenyl groups can also be medium-sized alkenyls having 2 to 9 carbon atoms. Alkenyl groups can also be lower alkenyls having 2 to 4 carbon atoms. The alkenyl group of a compound is defined as "C 2-4 Alkenyl" or similar designations. 2-4"Alkenyl" indicates that there are 2 to 4 carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, buta-1,3-dienyl, buta-1,2-dienyl, and buta-1,2-dien-4-yl. Typical alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, and the like.
[0079] As used herein, "alkynyl" refers to an alkyl group containing one or more triple bonds in the straight or branched hydrocarbon chain. Alkynyl groups can be unsubstituted or substituted. If substituted, the substituent(s) can be selected from the same groups disclosed above for alkyl group substitution. Alkynyl groups can have from 2 to 20 carbon atoms, although this definition also encompasses the occurrence of the term "alkynyl" where no numerical range is specified. Alkynyl groups can also be medium-sized alkynyls having from 2 to 9 carbon atoms. Alkynyl groups can also be lower alkynyls having from 2 to 4 carbon atoms. The alkynyl group of a compound is defined as "C 2-4 By way of example only, "C 2-4 "Alkynyl" indicates that there are 2 to 4 carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-3-yl, butyn-4-yl, and 2-butynyl. Typical alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
[0080] As used herein, "heteroalkyl" refers to a straight or branched hydrocarbon chain containing one or more heteroatoms, i.e., elements other than carbon, in the chain backbone, including, but not limited to, nitrogen, oxygen, and sulfur. Heteroalkyl groups can have from 1 to 20 carbon atoms, although this definition also encompasses the occurrence of the term "heteroalkyl" where no numerical range is specified. Heteroalkyl groups can also be medium-sized heteroalkyls, having from 1 to 9 carbon atoms. Heteroalkyl groups can also be lower heteroalkyls, having from 1 to 4 carbon atoms. The heteroalkyl group of a compound is defined as "C 1-4 A heteroalkyl group may contain one or more heteroatoms. By way of example only, "C 1-4 "Heteroalkyl" indicates that the heteroalkyl chain has from 1 to 4 carbon atoms and at least one heteroatom in the backbone of the chain.
[0081] As used herein, "aryl" refers to a carbocyclic (all carbon) ring or two or more fused rings (rings sharing two adjacent carbon atoms) having a completely delocalized π-electron system. Examples of aryl groups include, but are not limited to, benzene, naphthalene, and azulene. Aryl groups can be substituted or unsubstituted. When substituted, a hydrogen atom can be substituted with an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido. , N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino (including mono- and di-substituted amino groups, and protected derivatives thereof). When substituted, substituents on the aryl group can form a non-aromatic ring fused to the aryl group, including cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
[0082] As used herein, "heteroaryl" refers to a monocyclic or polycyclic aromatic ring system (a ring system having a fully delocalized π-electron system), one or two or more fused ring(s) containing one or more heteroatoms, i.e., elements other than carbon, including, but not limited to, nitrogen, oxygen, and sulfur. Examples of heteroaryl rings include, but are not limited to, furan, thiophene, phthalazine, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, triazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and triazine. Heteroaryl groups can be substituted or unsubstituted. When substituted, a hydrogen atom may be substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido , N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino (including mono- and di-substituted amino groups, and protected derivatives thereof). When substituted, substituents on the heteroaryl group can form a non-aromatic ring fused to the aryl group, including cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl.
[0083] As used herein, "aralkyl" or "arylalkyl" refers to an aryl group linked as a substituent via an alkylene group. The alkylene and aryl groups of the aralkyl may be substituted or unsubstituted. Examples include, but are not limited to, benzyl, substituted benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group.
[0084] As used herein, a "heteroaralkyl" or "heteroarylalkyl" is a heteroaryl group linked as a substituent via an alkylene group. The alkylene and heteroaryl groups of a heteroaralkyl can be substituted or unsubstituted. Examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl, as well as substituted and benzo-fused analogs thereof. In some cases, the alkylene group is a lower alkylene group.
[0085] As used herein, "alkylene" refers to a branched or straight-chain fully saturated diradical chemical group (i.e., alkanediyl) containing only carbon and hydrogen attached to the rest of the molecule through two points of attachment. Alkylene groups can have from 1 to 20 carbon atoms, although this definition also encompasses the occurrence of the term alkylene where no numerical range is specified. Alkylene groups can also be medium-sized alkylenes having from 1 to 9 carbon atoms. Alkylene groups can also be lower alkylenes having from 1 to 4 carbon atoms. An alkylene group is also referred to as "C 1-4 By way of example only, "C alkylene" or similar designations may be used. 1-4"Alkylene" indicates that there are 1 to 4 carbon atoms in the alkylene chain, i.e., the alkylene chain is selected from the group consisting of methylene, ethylene, ethane-1,1-diyl, propylene, propane-1,1-diyl, propane-2,2-diyl, 1-methyl-ethylene, butylene, butane-1,1-diyl, butane-2,2-diyl, 2-methyl-propane-1,1-diyl, 1-methyl-propylene, 2-methyl-propylene, 1,1-dimethyl-ethylene, 1,2-dimethyl-ethylene, and 1-ethyl-ethylene.
[0086] As used herein, "alkenylene" refers to a straight or branched chain diradical chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond attached to the rest of the molecule through two points of attachment. An alkenylene group can have from 2 to 20 carbon atoms, although this definition also encompasses the occurrence of the term "alkenylene" where no numerical range is specified. An alkenylene group can also be a medium-sized alkenylene having from 2 to 9 carbon atoms. An alkenylene group can also be a lower alkenylene having from 2 to 4 carbon atoms. An alkenylene group can also be a "C 2-4 Alkenylene" or similar designations. 2-4 "Alkenylene" indicates that there are 2 to 4 carbon atoms in the alkenylene chain, i.e., the alkenylene chain is selected from the group consisting of ethenylene, ethene-1,1-diyl, propenylene, propen-1,1-diyl, prop-2-ene-1,1-diyl, 1-methyl-ethenylene, but-1-enylene, but-2-enylene, buta-1,3-dienylene, butene-1,1-diyl, buta-1,3-dien-1,1-diyl, buta-2- 1,1-ene-1,1-diyl, but-3-ene-1,1-diyl, 1-methyl-prop-2-ene-1,1-diyl, 2-methyl-prop-2-ene-1,1-diyl, 1-ethyl-ethenylene, 1,2-dimethyl-ethenylene, 1-methyl-propenylene, 2-methyl-propenylene, 3-methyl-propenylene, 2-methyl-propen-1,1-diyl, and 2,2-dimethyl-ethen-1,1-diyl.
[0087] As used herein, "alkylidene" refers to a divalent group such as =CR'R" that is attached to a carbon of another group to form a double bond; alkylidene groups include, but are not limited to, methylidene (=CH2) and ethylidene (=CHCH3). As used herein, "arylalkylidene" refers to an alkylidene group where either R' or R" is an aryl group. Alkylidene groups can be substituted or unsubstituted.
[0088] As used herein, "alkoxy" refers to a group of the formula -OR, where R is alkyl as defined above, e.g., methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, amoxy, tert-amoxy, etc. Alkoxy can be substituted or unsubstituted.
[0089] As used herein, "alkylthio" refers to a group of the formula -SR, where R is alkyl as defined above, e.g., methyl mercapto, ethyl mercapto, n-propyl mercapto, 1-methylethyl mercapto (isopropyl mercapto), n-butyl mercapto, iso-butyl mercapto, sec-butyl mercapto, tert-butyl mercapto, etc. Alkylthio can be substituted or unsubstituted.
[0090] As used herein, "aryloxy" and "arylthio" refer to RO- and RS-, respectively, where R is aryl, such as, but not limited to, phenyl. Both aryloxy and arylthio can be substituted or unsubstituted.
[0091] As used herein, "acyl" refers to -C(=O)R, where R is hydrogen, C, as defined herein. 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 3-7 carbocyclyl, aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl. Non-limiting examples include formyl, acetyl, propanoyl, benzoyl, and acryl.
[0092] As used herein, "cycloalkyl" refers to a monocyclic or polycyclic hydrocarbon ring system that is fully saturated (no double bonds). When composed of two or more rings, the rings may be joined together in a fused, bridged, or spiro-connected manner. Cycloalkyl groups include C3 to C6. 10 Although the carbon number of the cycloalkyl group may range from 0 to 6, in other embodiments, the cycloalkyl group may range from C3 to C6. The cycloalkyl group may be unsubstituted or substituted. Typical cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. If substituted, the substituent(s) may be alkyl or may be selected from those described above for alkyl group substitution, unless otherwise specified. If substituted, the substituents on the cycloalkyl group may form an aromatic ring fused to the cycloalkyl group, including aryl and heteroaryl.
[0093] As used herein, "cycloalkenyl" refers to a cycloalkyl group containing one or more double bonds within the ring, provided that, if more than one is present, they cannot form a completely delocalized π-electron system within the ring (otherwise, the group is an "aryl" as defined herein). When composed of more than one ring, the rings can be fused, bridged, or spiro-connected. A cycloalkenyl group can be unsubstituted or substituted. If substituted, the substituent(s) can be alkyl or selected from the groups disclosed above for alkyl group substitution, unless otherwise specified. When substituted, the substituents on the cycloalkenyl group can form an aromatic ring fused to the cycloalkenyl group, including aryl and heteroaryl.
[0094] As used herein, "cycloalkynyl" refers to a cycloalkyl group containing one or more triple bonds within the ring. When composed of more than one ring, the rings may be joined together in a fused, bridged, or spiro-linked manner. A cycloalkynyl group may be unsubstituted or substituted. If substituted, the substituent(s) may be alkyl or may be selected from the groups disclosed above for alkyl group substitution, unless otherwise specified. When substituted, the substituents on the cycloalkynyl group may form an aromatic ring fused to the cycloalkynyl group, including aryl and heteroaryl.
[0095] As used herein, "heteroalicyclic" or "heteroalicyclyl" refers to a stable 3- to 18-membered ring composed of carbon atoms and one to five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. A "heteroalicyclic" or "heteroalicyclyl" can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can be fused, bridged, or spiro-connected. The nitrogen, carbon, and sulfur atoms in a "heteroalicyclic" or "heteroalicyclyl" can also be optionally oxidized. The nitrogen can be optionally quaternized. The ring can also contain one or more double bonds, as long as they do not form a completely delocalized π-electron system throughout the entire ring. A heteroalicyclyl group can be unsubstituted or substituted. When substituted, the substituent(s) can be one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, ester, mercapto, alkylthio, arylthio, cyano, halogen, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, and amino (including mono- and di-substituted amino groups, and protected derivatives thereof). Examples of such "heteroalicyclic" or "heteroalicyclyl" include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, morpholinyl, oxiranyl, piperidinyl N-oxide, piperidinyl, piperazinyl, pyrrolidinyl, 4-piperidonyl, pyrazolidinyl, 2-oxopyrrolidinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and thiamorpholinyl sulfone.When substituted, the substituents on a heteroalicyclyl group may form an aromatic ring fused to the heteroalicyclyl group, including aryl and heteroaryl.
[0096] As used herein, the term "(cycloalkenyl)alkyl" refers to a cycloalkenyl group connected as a substituent via an alkylene group. The alkylene and cycloalkenyl of a (cycloalkenyl)alkyl can be substituted or unsubstituted. In some cases, the alkylene group is a lower alkylene group.
[0097] As used herein, the term "(cycloalkynyl)alkyl" refers to a cycloalkynyl group connected as a substituent via an alkylene group. The alkylene and cycloalkynyl of a (cycloalkynyl)alkyl can be substituted or unsubstituted. In some cases, the alkylene group is a lower alkylene group.
[0098] As used herein, the term "O-carboxy" refers to the group "RC(=O)O-," where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein. O-carboxy can be substituted or unsubstituted.
[0099] As used herein, the term "C-carboxy" refers to the group "-C(=O)R", where R can be the same as defined for O-carboxy. C-carboxy can be substituted or unsubstituted.
[0100] As used herein, the term "trihalomethanesulfonyl" refers to an "X3CSO2-" group where X is a halogen.
[0101] As used herein, the term "cyano" refers to a "-CN" group.
[0102] As used herein, the term "cyanato" refers to an "-OCN" group.
[0103] As used herein, the term "isocyanato" refers to an "-NCO" group.
[0104] As used herein, the term "thiocyanato" refers to a "-SCN" group.
[0105] As used herein, the term "isothiocyanato" refers to an "-NCS" group.
[0106] As used herein, the term "sulfinyl" refers to the group "-S(=O)-R", where R can be the same as defined for O-carboxy. Sulfinyl can be substituted or unsubstituted.
[0107] As used herein, the term "sulfonyl" refers to the group "-S0R," where R can be the same as defined for O-carboxy. The sulfonyl can be substituted or unsubstituted.
[0108] As used herein, the term "S-sulfonamide" refers to "-SONR A R B " group, where R A and R B can be the same as defined for O-carboxy. S-sulfonamide can be substituted or unsubstituted.
[0109] As used herein, the term "N-sulfonamide" refers to "-SO2N(R A )(R B ) group, wherein R, R A , and R Bcan be the same as defined for O-carboxy. Sulfonyl can be substituted or unsubstituted.
[0110] As used herein, the term "trihalomethanesulfonamide" refers to an "X3CSON(R)-" group, where X is a halogen and R can be the same as defined for O-carboxy. Trihalomethanesulfonamides can be substituted or unsubstituted.
[0111] As used herein, the term "O-carbamyl" refers to "-OC(=O)NR A R B " group, where R A and R B can be the same as defined for O-carboxy. O-carbamyl can be substituted or unsubstituted.
[0112] As used herein, the term "N-carbamyl" refers to "ROC(=O)NR A - group, where R and R A can be the same as defined for O-carboxy. N-carbamyl can be substituted or unsubstituted.
[0113] As used herein, the term "O-thiocarbamyl" refers to "-OC(=S)-NR A R B " group, where R A and R B can be the same as defined for O-carboxy. O-thiocarbamyl can be substituted or unsubstituted.
[0114] As used herein, the term "N-thiocarbamyl" refers to "ROC(=S)NR A - group, where R and R Acan be the same as defined for O-carboxy. N-thiocarbamyl can be substituted or unsubstituted.
[0115] As used herein, the term "C-amide" refers to "-C(=O)NR A R B " group, where R A and R B can be the same as defined for O-carboxy. C-amido can be substituted or unsubstituted.
[0116] As used herein, the term "N-amide" refers to "RC(=O)NR A - group, where R and R A can be the same as defined for O-carboxy. N-amido can be substituted or unsubstituted.
[0117] As used herein, the term "amino" refers to "-NR A R B " group, where R A and R B is defined herein, hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclyl, C 6-10 are each independently selected from aryl, 5- to 10-membered heteroaryl, and 5- to 10-membered heterocyclyl.
[0118] As used herein, the term "aminoalkyl" refers to an amino group linked via an alkylene group.
[0119] As used herein, the term "ester" refers to the group "-C(=O)OR", where R can be the same as defined for O-carboxy. Esters can be substituted or unsubstituted.
[0120] As used herein, the term "lower aminoalkyl" refers to an amino group linked via a lower alkylene group. A lower aminoalkyl may be substituted or unsubstituted.
[0121] As used herein, the term "lower alkoxyalkyl" refers to an alkoxy group linked via a lower alkylene group. A lower alkoxyalkyl may be substituted or unsubstituted.
[0122] As used herein, the term "acetyl" refers to a -C(=O)CH3 group.
[0123] As used herein, the term "trihalomethanesulfonyl" refers to a X3CS(=O)2- group where X is a halogen.
[0124] As used herein, the term "O-carbamyl" refers to -OC(=O)-NR, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein. O-carbamyl can be substituted or unsubstituted.
[0125] As used herein, the term "N-carbamyl" refers to the group ROC(=O)NH-, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein. N-carbamyl can be substituted or unsubstituted.
[0126] As used herein, the term "O-thiocarbamyl" refers to -OC(=S)-NR, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein. O-thiocarbamyl can be substituted or unsubstituted.
[0127] As used herein, the term "N-thiocarbamyl" refers to the group ROC(=S)NH-, where R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein. N-thiocarbamyl can be substituted or unsubstituted.
[0128] As used herein, the term "perhaloalkyl" refers to an alkyl group in which all hydrogen atoms have been replaced with halogen atoms.
[0129] As used herein, the term "halogen" or "halo" refers to any one of the radioactive stable atoms in column 7 of the periodic table of the elements, e.g., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
[0130] As used herein, the term "carbocyclyl" refers to a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system backbone. When a carbocyclyl is a ring system, two or more rings can be joined to each other in a fused, bridged, or spiro-linked manner. A carbocyclyl can have any degree of saturation, as long as at least one ring in the ring system is not aromatic. Thus, carbocyclyl includes cycloalkyl, cycloalkenyl, and cycloalkynyl. A carbocyclyl group can have 3 to 20 carbon atoms, although this definition also encompasses the occurrence of the term "carbocyclyl" without specifying a numerical range. A carbocyclyl group can also be a medium-sized carbocyclyl having 3 to 10 carbon atoms. A carbocyclyl group can also be a carbocyclyl having 3 to 6 carbon atoms. A carbocyclyl group is defined as "C 3-6 Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicyclo[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.
[0131] As used herein, the term "(cycloalkyl)alkyl" refers to a cycloalkyl group connected as a substituent via an alkylene group. The alkylene and cycloalkyl of a (cycloalkyl)alkyl can be substituted or unsubstituted. Examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like. In some cases, the alkylene group is a lower alkylene group.
[0132] As used herein, the term "cycloalkyl" refers to a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0133] As used herein, the term "cycloalkenyl" means a carbocyclyl ring or ring system having at least one double bond, and no aromatic rings in the ring system. An example is cyclohexenyl.
[0134] As used herein, the term "heterocyclyl" refers to 3-, 4-, 5-, 6-, 7-, 8-, or more-membered rings formed by carbon atoms together with 1 to 3 heteroatoms. However, a heterocyclyl may optionally contain one or more unsaturated bonds positioned such that an aromatic π-electron system does not result. The heteroatoms are independently selected from oxygen, sulfur, and nitrogen.
[0135] Heterocyclyl can further include one or more carbonyl or thiocarbonyl functionalities, such that the definition includes oxo and thio systems such as lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, and the like.
[0136] As used herein, "heterocyclyl" refers to a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. Heterocyclyls can be joined to each other in fused, bridged, or spiro-linked forms. Heterocyclyls can have any degree of saturation, so long as at least one ring in the ring system is aromatic. The heteroatom(s) can be present in either the non-aromatic or aromatic ring of the ring system. Heterocyclyl groups can have 3 to 20 ring members (i.e., the number of atoms comprising the ring backbone, including carbon atoms and heteroatoms), although this definition also encompasses the occurrence of the term "heterocyclyl" without specifying a numerical range. Heterocyclyl groups can also be medium-sized heterocyclyls having 3 to 10 ring members. Heterocyclyl groups can also be heterocyclyls having 3 to 6 ring members. Heterocyclyl groups can be referred to as "3- to 6-membered heterocyclyl" or similar designations. In preferred 6-membered monocyclic heterocyclyls, the heteroatom(s) are selected from 1 to a maximum of 3 of O, N, or S, and in preferred 5-membered monocyclic heterocyclyls, the heteroatom(s) are selected from 1 or 2 heteroatoms selected from O, N, or S.Examples of heterocyclyl rings include azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidionyl, pyrrolidionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxanyl, 1,4-dioxinyl, 1,4-dioxanyl, 1,3-oxathianyl, 1,4-oxathiinyl, 1,4-oxathianyl, 2,4-dioxan ... H-1,2-oxazinyl, trioxanyl, hexahydro-1,3,5-triazinyl, 1,3-dioxolyl, 1,3-dioxolanyl, 1,3-dithiolyl, 1,3-dithiolanyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinonyl, thiazolinyl, thiazolidinyl, 1,3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydro-1,4-thiazinyl, thiamorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl, and tetrahydroquinoline.
[0137] As used herein, the term "(heterocyclyl)alkyl" refers to a heterocyclyl group linked as a substituent via an alkylene group. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.
[0138] As used herein, the terms "purified," "substantially purified," and "isolated" refer to compounds disclosed herein that are free of other distinct compounds that normally accompany the compounds of the invention in their natural state, such that the compounds of the invention comprise at least 0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75%, by weight of the mass of a given sample.
[0139] A substituent is based on or derived from an unsubstituted parent group in which one or more hydrogen atoms have been replaced with another atom or group. Unless otherwise specified, when a group is considered to be "substituted," that group includes C-C alkyl, C-C alkenyl, C-C alkynyl, C-C heteroalkyl, C-C carbocyclyl (optionally substituted with halo, C-C alkyl, C-C alkoxy, C-C haloalkyl, and C-C haloalkoxy), C-C-carbocyclyl-C-C-alkyl (optionally substituted with halo, C-C alkyl, C-C alkoxy, C-C haloalkyl, and C-C haloalkoxy). 5-10 membered heterocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), 5-10 membered heterocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), aryl (halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), aryl(C1-C6)alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), 5-10 membered heteroaryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), 5-10 membered heteroaryl(C1-C6)alkyl (halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6 haloalkoxy), haloalkyl, and optionally substituted with C1-C6 haloalkoxy), halo, cyano, hydroxy, C1-C6 alkoxy, C1-C6 alkoxy(C1-C6)alkyl (i.e., ether), aryloxy, sulfhydryl (mercapto), halo(C1-C6)alkyl (e.g., —CF3), halo(C1-C6)alkoxy (e.g., —OCF3), C1-C6 alkylthio, arylthio, amino, amino(C1-C6)alkyl, nitro, O-carbamyl, N-carbamyl, O-thiocarbamyl,Substituted with one or more substituents independently selected from N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, acyl, cyanato, isocyanato, thiocyanato, isothiocyanato, sulfinyl, sulfonyl, and oxo (=O). Whenever a group is described as "optionally substituted," that group can be substituted with the above substituents.
[0140] In some embodiments, substituted groups are substituted with one or more substituent(s) individually and independently selected from C1-C4 alkyl, amino, hydroxy, and halogen.
[0141] It is understood that a particular radical naming convention can include either a monoradical or a diradical, depending on the context. For example, if a substituent requires two points of attachment to the rest of the molecule, the substituent is understood to be a diradical. For example, a substituent specified as alkyl, which requires two points of attachment, includes diradicals such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, etc. Other radical naming conventions explicitly indicate that the radical is a diradical, such as "alkylene" or "alkenylene."
[0142] Unless otherwise specified, when a substituent is deemed to be "optionally substituted," it is meant that the "substituent" can be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxyl, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino (including mono- and di-substituted amino groups, and protected derivatives thereof). Protecting groups that can form the protective derivatives of the above substituents are known to those of skill in the art and can be found in references such as Greene and Wuts, above.
[0143] As used herein, the term "agent" or "test agent" includes any substance, molecule, element, compound, entity, or combination thereof. This includes, but is not limited to, for example, proteins, polypeptides, peptides or mimetics, small organic molecules, polysaccharides, polynucleotides, etc. It can be a natural product, synthetic compound, or chemical compound, or a combination of two or more substances. Unless otherwise specified, the terms "agent," "substance," and "compound" are used interchangeably herein.
[0144] As used herein, the term "analog" refers to a molecule that is structurally similar to a reference molecule, but that has been modified in a targeted and controlled manner by replacing certain substituents of the reference molecule with alternative substituents. One skilled in the art would expect an analog to exhibit the same, similar, or improved utility compared to the reference molecule. The synthesis and screening of analogs to identify variants of known compounds with improved properties (such as higher binding affinity for a target molecule) is a well-known approach in pharmaceutical chemistry.
[0145] As used herein, the term "mammal" is used in its ordinary biological sense, and thus specifically includes, but is not limited to, primates, including simians (chimpanzees, apes, monkeys) and humans, cows, horses, sheep, goats, pigs, rabbits, dogs, cats, rats, and mice, but also includes many other species.
[0146] As used herein, the term "microbial infection" refers to the invasion of a host organism by a pathogenic microorganism, whether that organism is a vertebrate, invertebrate, fish, plant, bird, or mammal. This includes the overgrowth of microorganisms normally present in or on the body of a mammal or other organism. More generally, a microbial infection can be any situation in which the presence of a microbial population(s) causes damage to the host mammal. Thus, a mammal is "suffering" from a microbial infection when an excessive number of microbial populations are present in or on the mammal's body, or when the effects of the presence of a microbial population(s) cause damage to the mammal's cells or other tissues. Specifically, this description applies to bacterial infections. It should be noted that the compounds of the preferred embodiments are also useful in treating microbial growth or contamination of cell cultures or other media, or inanimate surfaces or objects, and the preferred embodiments should not be limited herein to the treatment of higher organisms, except where expressly so set forth in the claims.
[0147] As used herein, the term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Any conventional media or agent is contemplated for use in therapeutic compositions except insofar as it is incompatible with the active ingredient. In addition, various auxiliary substances commonly used in the art may be included. Considerations for including various ingredients in pharmaceutical compositions are described, for example, in Gilman et al. (Eds.) (1990); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press (incorporated herein by reference in its entirety).
[0148] As used herein, the term "subject" refers to a human or non-human mammal, e.g., a dog, cat, mouse, rat, cow, sheep, pig, goat, non-human primate, or bird, e.g., a chicken, as well as any other vertebrate or invertebrate.
[0149] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a therapeutic agent effective to alleviate to some extent one or more symptoms of a disease or condition or to reduce the likelihood of its occurrence, including curing the disease or condition. "Cure" means that the symptoms of the disease or condition are gone. However, even after a cure is achieved, certain long-term or permanent effects may exist (such as extensive tissue damage).
[0150] As used herein, the terms "treat," "treatment," or "treating" refer to administering a pharmaceutical composition for prophylactic and / or therapeutic purposes. The term "prophylactic treatment" refers to treating a subject who does not yet exhibit symptoms of the disease or condition, but who is susceptible to or otherwise at risk of a particular disease or condition, whereby treatment reduces the likelihood that the patient will develop the disease or condition. The term "therapeutic treatment" refers to administering a treatment to a subject.
[0151] It is understood that if the compounds disclosed herein have unsatisfied valences, the valences should be filled with hydrogen and / or deuterium.
[0152] It is understood that the compounds described herein can be isotopically or by other means (including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels). Substitution with isotopes such as deuterium can confer certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Each chemical element represented in a compound structure can include any isotope of that element. For example, in a compound structure, a hydrogen atom may be explicitly disclosed or understood to be present in the compound. At any position in a compound where a hydrogen atom can be present, the hydrogen atom may be any isotope of hydrogen, including, but not limited to, hydrogen 1 (protium), hydrogen 2 (deuterium), and hydrogen 3 (tritium). Therefore, reference to a compound herein encompasses all possible isotopic forms unless the context clearly indicates otherwise.
[0153] As used herein, the term "about" refers to an amount, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by about 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% relative to a reference amount, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. When a value is preceded by the term about, it is not intended that the element be strictly limited to that value, but rather that amounts different from the value are included.
[0154] compound Some embodiments are of formula (I): [ka] The present invention provides a compound of the formula:
[0155] In some embodiments, Formula (I) is a pharmaceutically acceptable salt described herein.
[0156] In some embodiments, Formula (I) is Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id): [ka] is expressed by
[0157] In some embodiments, Formula (Ia), Formula (Ib), Formula (Ic), or Formula (Id) is a pharmaceutically acceptable salt as described herein.
[0158] In some embodiments, ring A is [ka] is.
[0159] In some embodiments of compounds of Formula (I) or (Ic), R 1is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, O-aryl, O-heteroaryl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L.
[0160] In some embodiments, R 1 is not O-pyrimidinyl. In some embodiments, R 1 is not an ether-linked pyrimidyl.
[0161] In some embodiments of compounds of Formula (I), (Ia), or (Ib), R 2is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L. In some further embodiments, R 2 is L. In some further embodiments, R 2 is -CH3.
[0162] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), or (Id), R 3is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L.
[0163] In some embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), or (Id), R 4is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L.
[0164] In some embodiments of compounds of Formula (I), (Ia), (Ib), or (Ic), R 5 may be selected from H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, and optionally substituted C2-C6 alkynyl. In some embodiments, R 5 is H, deuterium, halo, or optionally substituted C1-C6 alkyl.
[0165] In some embodiments of compounds of Formula (I), (Ia), (Ib), or (Ic), R 5’may be selected from H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, and optionally substituted C2-C6 alkynyl. In some embodiments, R 5’ is H, deuterium, halo, or optionally substituted C1-C6 alkyl.
[0166] In some embodiments of compounds of Formula (I), (Ia), (Ib), or (Ic), R 6 may be selected from H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, and optionally substituted C2-C6 alkynyl. In some embodiments, R 6 is H, deuterium, halo, or optionally substituted C1-C6 alkyl.
[0167] In some embodiments of compounds of Formula (I) or (Ia), X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] In some further embodiments, X is —CH or —O—. In some further embodiments, X is —O—.
[0168] In some embodiments of compounds of Formula (I), (Ia), (Ib), or (Ic), L can be selected from -Z1-Z2. In some embodiments of compounds of Formula (I), (Ia), (Ib), or (Ic), L can be selected from -Z1-Z2-Z3.
[0169] In some embodiments of the compound of Formula (I), (Ia), (Ib), or (Ic), Z is —CH—, —O—, —S—, S═O, —SO—, C═O, —CO—, —NO, —NH—, —CHCCH, —CHCN, —NR 5 R 5’ , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5’ -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -NHCH2CO-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl). In some further embodiments, Z1 is -CH2-.
[0170] In some embodiments of the compound of Formula (I), (Ia), (Ib), or (Ic), Z2 is hydrogen, deuterium, halo, -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR2 5 R 5’ , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NHCH2CO-, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10In some further embodiments, Z2 may be selected from C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , -CH2CH, or -CH2CN. In some further embodiments, Z2 is optionally substituted C3-C8 heterocyclyl. In some embodiments, Z2 is -CH2-, and Z2 is -NR 5 R 5’ In some embodiments, Z2 is an optionally substituted C3-C8 heterocyclyl.
[0171] In some embodiments of the compounds of Formula (I), (Ia), (Ib), or (Ic), Z3 is hydrogen, deuterium, halo, -COH, -CO2H, -NO2, -CH2CCH, -CH2CN, -NR 5 R 5’ , -(CO)NH2, -(CO)NR 5 R 5’ , -SO2-NH2, -R 5 CH3, -R 5 -COH, -R 5 CO2H, -R 5 NH2, -R 5 NH(COH), -R 5 (CO)NH2, -R 5 NH-SO2H, -R 5 SO2-NH2, -CH2R 5 , -OR 5 , -SO2R 5 -, -CO2R 5 , -NHR 5 , -NH(CO)R 5 , -(CO)NHR 5 , -NH-SO2R 5 , -SO2-NHR 5 , optionally substituted amino, optionally substituted C1-C4 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl).
[0172] In some embodiments of compounds of Formula (Id), n is 1, 2, 3, or 4. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1 or 2. In some embodiments, n is 2 or 3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.
[0173] In some embodiments of the compound of Formula (Id), X 1 may be selected from -CH, B, N, or PO. In some embodiments, X 1 is —CO—, N, or —SO—. In some embodiments, X 1 is N.
[0174] In some embodiments of compounds of Formula (Id), R 9 is hydrogen, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10In some further embodiments, Z2 may be selected from C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5’ , -CH2CH, or -CH2CN.
[0175] In some embodiments of compounds of Formula (Id), R 10 is hydrogen, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 In some further embodiments, Z2 may be selected from C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5’ , -CH2CH, or -CH2CN.
[0176] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, n is 1, 2, 3, or 4. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1 or 2. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, Z2 is [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] is.
[0177] In some embodiments, Z1 is -CH2-, Z2 is optionally substituted C3-C8 heterocyclyl, and Z3 is optionally substituted aryl. In some embodiments, Z1 is -CH2-, Z2 is optionally substituted C3-C8 heterocyclyl, and Z3 is hydrogen. In some embodiments, Z1 is -CH2-, Z2 is optionally substituted C3-C8 heterocyclyl, and Z3 is optionally substituted alkyl. In some embodiments, Z1 is -CH2-, Z2 is optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2- (optionally substituted aryl). In some embodiments, Z1 is -CH2-, and Z2 is [ka] is.
[0178] In some embodiments of the compounds of Formula (I) or (Ia), Y is CH 2 , NH, or O.
[0179] In some embodiments, Formula (I) is a compound of a disclosed formula, e.g., Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (II), Formula (IIa), Formula (IIb), Formula (IIc), or Formula (IId), with the proviso that the compound: [ka] In some embodiments, Formula (I) is a compound of a disclosed formula, e.g., Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (II), Formula (IIa), Formula (IIb), Formula (IIc), or Formula (IId), except that R as C1-C6 alkyl 2 In some embodiments, Formula (I) is a compound of a disclosed formula, e.g., Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (II), Formula (IIa), Formula (IIb), Formula (IIc), or Formula (IId), except that R as methyl 2 In some embodiments, Formula (I) is a compound of a disclosed formula, e.g., Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (II), Formula (IIa), Formula (IIb), Formula (IIc), or Formula (IId), except that R as ethyl 2 (Except).
[0180] Some embodiments are of formula (II): [ka] The present invention provides a compound of the formula:
[0181] In some embodiments, Formula (II) is a pharmaceutically acceptable salt described herein.
[0182] In some embodiments, Formula (II) can be any of Formulas (IIa), (IIb), (IIc): [ka] is expressed by
[0183] In some embodiments, Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId) can be a pharmaceutically acceptable salt as described herein.
[0184] In some embodiments of Formula (II), Q A , Q B , Q C are independently C or N.
[0185] In some embodiments of compounds of Formula (II) or (IIc), R 1 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, O-aryl, O-heteroaryl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L.
[0186] In some embodiments, R 1 is not O-pyrimidinyl. In some embodiments, R 1 is not an ether-linked pyrimidyl.
[0187] In some embodiments of compounds of Formula (II), (IIa), or (IIb), R 2 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L. In some further embodiments, R 2 is L. In some further embodiments, R 2 is -CH3.
[0188] In some embodiments of compounds of Formula (II), (IIa), or (IId), R 3is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L.
[0189] In some embodiments of compounds of Formula (II) or (IIa), R 4is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L.
[0190] In some embodiments of compounds of Formula (II), (IIa), (IIb), or (IIc), R 5 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl. In some embodiments, R 5 is H, deuterium, halo, or optionally substituted C1-C6 alkyl.
[0191] In some embodiments of compounds of Formula (II), (IIa), (IIb), or (IIc), R 5’is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl. In some embodiments, R 5 is H, deuterium, halo, or optionally substituted C1-C6 alkyl.
[0192] In some embodiments of compounds of Formula (II), (IIa), (IIb), (IIc), or (IId), R 6 is H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl. In some embodiments, R 6 is H, deuterium, halo, or optionally substituted C1-C6 alkyl.
[0193] In some embodiments of compounds of Formula (II) or (IIa), X is C(R 5 )2, CH(R 5 ), CH2, -O-, [ka] In some further embodiments, X is —CH or —O—. In some further embodiments, X is —O—.
[0194] In some embodiments of compounds of Formula (II), (IIa), (IIb), or (IIc), L is -Z1-Z2. In some embodiments of compounds of Formula (II), (IIa), or (IIb), L is -Z1-Z2-Z3.
[0195] In some embodiments of the compound of Formula (II), (IIa), (IIb), or (IIc), Z is —CH—, —O—, —S—, S═O, —SO—, C═O, —CO—, —NO, —NH—, —CHCCH, —CHCN, —NR 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 In some further embodiments, Z1 is -CH2-.
[0196] In some embodiments of the compound of Formula (II), (IIa), (IIb), or (IIc), Z2 is halo, -CH2-, -O-, -S-, S=O, -SO2-, C=O, -CO2-, -NO2, -NH-, -CH2CCH, -CH2CN, -NR2 5 R 5 , -NH(CO)-, -(CO)NH-, -(CO)NR 5 R 5 -, -NH-SO2-, -SO2-NH-, -R 5 CH2-, -R 5 O-, -R 5 S-, R 5 -S=O, -R 5 SO2-, R 5 -C=O, -R 5 CO2-, -R 5 NH-, -R 5 NH(CO)-, -R 5 (CO)NH-, -R 5 NH-SO2-, -R 5 SO2-NH-, -CH2R 5 -, -OR 5 -, -SR 5 -, S=OR 5 , -SO2R 5 -, C=OR 5 , -CO2R 5 -, -NHR 5 -, -NH(CO)R 5 -, -(CO)NHR 5 -, -NH-SO2R 5 -, -SO2-NHR 5 -, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10In some further embodiments, Z2 is C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5 , -CH2CH, or -CH2CN. In some further embodiments, Z2 is an optionally substituted C3-C8 heterocyclyl. In some embodiments, Z1 is -CH2- and Z2 is -NR 5 R 5 In some embodiments, Z2 is an optionally substituted C3-C7 heterocyclyl.
[0197] In some embodiments of the compound of Formula (II), (IIa), (IIb), or (IIc), Z3 is hydrogen, halo, -COH, -CO2H, -NO2, -CH2CCH, -CH2CN, -NR 5 R 5 , -(CO)NH2, -(CO)NR 5 R 5 , -SO2-NH2, -R 5 CH3, -R 5 -COH, -R 5 CO2H, -R 5 NH2, -R 5 NH(COH), -R 5 (CO)NH2, -R 5 NH-SO2H, -R 5 SO2-NH2, -CH2R 5 , -OR 5 , -SO2R 5 -, -CO2R 5 , -NHR 5 , -NH(CO)R 5 , -(CO)NHR 5 , -NH-SO2R 5 , -SO2-NHR 5 , optionally substituted amino, optionally substituted C1-C4 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 heteroaryl).
[0198] In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is an optionally substituted aryl. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is hydrogen. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is an optionally substituted alkyl. In some embodiments, Z1 is -CH2-, Z2 is an optionally substituted C3-C8 heterocyclyl, and Z3 is -CH2-(optionally substituted aryl). In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, n is 1, 2, 3, or 4. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1 or 2. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is optionally substituted [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is optionally substituted [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] In some embodiments, Z2 is [ka] In some embodiments, the optionally substituted C3-C8 heterocyclyl is [ka] is.
[0199] In some embodiments of the compound of Formula (II), R 7 are independently H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, or L. In some further embodiments, R7 is halo, H, or CH3.
[0200] In some embodiments of the compound of Formula (IIa), R 8 is H, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 carbocyclyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 In some further embodiments, R 8 is selected from halo, H, deuterium, or CH3.
[0201] In some embodiments of the compound of Formula (Id), X 1 may be selected from -CH, -CO2-, N, or -SO2-. In some embodiments, X 1 is —CO—, N, or —SO—. In some embodiments, X 1 is N.
[0202] In some embodiments of compounds of Formula (Id), R 9 is hydrogen, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 In some further embodiments, Z2 may be selected from C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5R 5’ , -CH2CH, or -CH2CN.
[0203] In some embodiments of compounds of Formula (Id), R 10 is hydrogen, deuterium, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C 10 aryl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C 10 heteroaryl, -CH2- (optionally substituted aryl), -CH2- (optionally substituted C3-C8 cycloalkyl), or -CH2- (optionally substituted C3-C 10 In some further embodiments, Z2 may be selected from C3-C8 cycloalkyl, optionally substituted C3-C8 heterocyclyl, optionally substituted C3-C8 heteroaryl, -NR 5 R 5’ , -CH2CH, or -CH2CN.
[0204] In some embodiments of the compound of Formula (II) or (IIa), Y is CH 2 , NH, or O.
[0205] In some embodiments of the compound of Formula (II) or (IIa), X is CH 2 or O.
[0206] In some embodiments of the compounds of Formula (II), (IIa), or (IId), Z is C or N.
[0207] In some embodiments, formula (II) is [ka] In some embodiments, Formula (II), (IIa), (IIb), or (IIc) excludes R as CH. 2 Exclude.
[0208] In some embodiments of the compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), or (IIc), the compound is selected from the compounds of Table A, and pharmaceutically acceptable salts thereof.
[0209] Table A. Exemplary compounds of formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId): [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14] [Table 1-15] [Table 1-16] [Table 1-17] [Table 1-18] [Table 1-19] [Table 1-20] [Table 1-21] [Table 1-22] [Table 1-23] [Table 1-24] [Table 1-25]
[0210] In some embodiments, the pharmaceutically acceptable salt may be an alkaline metal salt. In some embodiments, the pharmaceutically acceptable salt may be an alkali metal salt. In some embodiments, the pharmaceutically acceptable salt may be an alkaline earth metal salt. In some embodiments, the pharmaceutically acceptable salt may be an ammonium salt.
[0211] synthesis The compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), and (IId) described herein, or pharmaceutically acceptable salts thereof, can be prepared by a variety of methods, including those known to those skilled in the art. The routes shown and described herein are exemplary only and are not intended to, nor should they be construed to, limit the scope of the claims in any manner. Those skilled in the art will recognize modifications of the synthesis of this disclosure and will be able to devise alternative routes based on the disclosure herein. All such modifications and alternative routes are within the scope of the claims. Exemplary methods are described in the Examples below.
[0212] Preparation method The compounds disclosed herein can be synthesized by the methods described below or by modifications of these methods. Modifications to the procedures include, among other things, temperature, solvents, reagents, and the like, and will be apparent to those skilled in the art. Generally, during any of the processes for the preparation of the compounds disclosed herein, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved. This can be accomplished using conventional protecting groups, such as those described in Protective Groups in Organic Chemistry (ed. J.F.W. McOmie, Plenum Press, 1973), and Greene & Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991 (both of which are incorporated herein by reference in their entireties). The protecting groups can be removed at a convenient subsequent stage using methods known in the art. Synthetic chemical transformations useful for synthesizing applicable compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers, 1989, or L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons, 1995, both of which are incorporated herein by reference in their entireties.
[0213] When the processes for preparing the compounds disclosed herein give rise to mixtures of stereoisomers, such isomers can be separated by conventional techniques, such as preparative chiral chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared by stereoselective synthesis or resolution. The compounds can be resolved into their component enantiomers by standard techniques, for example, by forming diastereomeric pairs by salt formation with optically active acids such as (-)-di-p-toluoyl-d-tartaric acid and / or (+)-di-p-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The compounds can also be resolved by forming diastereomeric derivatives, such as esters, amides, or ketals, using a chiral auxiliary, followed by chromatographic resolution and removal of the chiral auxiliary.
[0214] Pharmaceutical Composition In another aspect, a pharmaceutical composition is disclosed that comprises a physiologically acceptable surfactant, carrier, diluent, excipient, lubricant, suspending agent, film-forming agent, and coating aid, or a combination thereof, and a compound disclosed herein. Carriers or diluents acceptable for therapeutic use are well known in the pharmaceutical field and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990) (incorporated herein by reference in its entirety). Preservatives, stabilizers, dyes, sweeteners, flavors, flavoring agents, etc. may be provided in the pharmaceutical composition. For example, sodium benzoate, ascorbic acid, and esters of p-hydroxybenzoic acid may be added as preservatives. Additionally, antioxidants and suspending agents may be used. In various embodiments, alcohols, esters, sulfated fatty alcohols, and the like can be used as surfactants; sucrose, glucose, lactose, starch, crystallized cellulose, mannitol, light anhydrous silicates, magnesium aluminate, magnesium aluminometasilicate, synthetic aluminum silicate, calcium carbonate, sodium carbonate, calcium hydrogen phosphate, calcium carboxymethylcellulose, and the like can be used as excipients; magnesium stearate, talc, hydrogenated oils, and the like can be used as lubricants; coconut oil, olive oil, sesame oil, peanut oil, soybean oil can be used as suspending agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate (e.g., cellulose or sugar), or methyl acetate-methacrylate copolymer as a derivative of polyvinyl can be used as a suspending agent; and plasticizers such as phthalate esters can be used as suspending agents.
[0215] As used herein, the term "pharmaceutical composition" refers to a mixture of a compound disclosed herein with other chemical components, such as a diluent or carrier. Pharmaceutical compositions facilitate the administration of a compound to an organism. Multiple techniques for administering a compound exist in the art, including, but not limited to, oral, injection, aerosol, parenteral, and topical administration. Pharmaceutical compositions can also be obtained by reacting a compound with an inorganic or organic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc.
[0216] As used herein, the term "carrier" refers to a chemical compound that facilitates the introduction of a compound into cells or tissues. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier because it facilitates the uptake of many organic compounds into the cells or tissues of living organisms.
[0217] As used herein, the term "diluent" refers to a chemical compound diluted with water that dissolves the compound of interest and stabilizes the compound in its biologically active form. Salts dissolved in buffer solutions are utilized as diluents in the art. One commonly used buffer solution is phosphate buffered saline, because it mimics the salt conditions of human blood. Because buffer salts can control the pH of the solution at low concentrations, buffer diluents rarely alter the biological activity of the compound.
[0218] As used herein, the term "physiologically acceptable" refers to a carrier or diluent that does not abrogate the biological activity and properties of the compound.
[0219] As used herein, "excipient" refers to an inert substance added to a pharmaceutical composition to impart to the composition, without limitation, bulk, uniformity, stability, binding ability, lubricity, disintegration ability, etc. A "diluent" is a type of excipient.
[0220] For each of the compounds described herein, and for each class or subclass of compounds described herein, pharmaceutical compositions are also described that include the compound alone or in admixture with other compounds of that class or subclass, or in admixture with other compounds described herein, or in admixture with one or more other pharmaceutically active compounds, and one or more pharmaceutically acceptable carriers, diluents, excipients, or combinations thereof. The pharmaceutical compositions described herein can be administered to a human patient by themselves, or in pharmaceutical compositions admixed with other active ingredients as a combination therapy, or in admixture with carriers, diluents, excipients, or combinations thereof. The appropriate formulation will depend on the route of administration selected. Techniques for formulating and administering the compounds described herein are known to those skilled in the art.
[0221] The pharmaceutical compositions disclosed herein can be prepared by any method known per se, for example, by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or tabletting processes. Furthermore, the active ingredient is contained in an amount effective to achieve its intended purpose. Many of the compounds used in the pharmaceutical combinations disclosed herein can be provided as salts containing pharmaceutically compatible counterions.
[0222] The pharmaceutical compositions described herein can be administered to a human patient by themselves, or mixed with other active ingredients as a combination therapy, or in pharmaceutical compositions mixed with suitable carriers or excipient(s). Techniques for formulating and administering the compounds of the present application can be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, 18th edition, 1990.
[0223] Suitable routes of administration can include, for example, oral, rectal, transmucosal, topical, or enteral administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary, and intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections. Compounds can also be administered in sustained- or controlled-release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for extended and / or timed pulse administration at a predetermined rate.
[0224] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, for example, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or tabletting processes.
[0225] Therefore, the pharmaceutical composition for use according to the present invention can be formulated in a conventional manner using one or more physiologically acceptable carriers, including excipients and auxiliaries, which facilitate the processing of active compounds into pharmaceutically usable preparations.Appropriate formulations depend on the selected route of administration.Any well-known techniques, carriers, and excipients can be used as appropriate and as understood in the art, for example, as described in Remington's Pharmaceutical Sciences above.
[0226] Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for dissolution or suspension in liquid prior to injection, or as emulsions. Suitable excipients include, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like. Furthermore, injectable pharmaceutical compositions may optionally contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffers, and the like. Physiologically compatible buffers include, but are not limited to, Hank's solution, Ringer's solution, or physiological saline buffer. Absorption-enhancing preparations (e.g., liposomes) can be utilized, if desired.
[0227] For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation.
[0228] Pharmaceutical formulations for parenteral administration (e.g., by bolus injection or continuous infusion) include aqueous solutions of the active compound in water-soluble form. Furthermore, suspensions of the active compound can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or other organic oils such as soybean, grapefruit, or almond oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compound, allowing for the preparation of highly concentrated solutions. Injectable formulations can be provided in unit dosage form, e.g., in ampoules or multi-dose containers, with an added preservative. The compositions can take the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing, and / or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, eg, sterile pyrogen-free water, before use.
[0229] For oral administration, the compounds can be easily formulated by combining the active compound with pharmaceutically acceptable carriers well known in the art. Such carriers allow the compounds of the present invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc., for oral ingestion by the patient to be treated. Pharmaceutical preparations for oral use can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, and processing the granular mixture to obtain tablets or dragee cores, optionally after adding suitable excipients. Suitable excipients are, in particular, fillers such as sugars including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and / or polyvinylpyrrolidone (PVP). If desired, disintegrants such as cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof (e.g., sodium alginate) can be added. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and / or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures, can be used. Dyes or pigments can be added to the tablet or dragee coating for identification or to characterize different combinations of active compound doses. For this purpose, concentrated sugar solutions, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and / or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures, can be used. Dyes or pigments can be added to the tablet or dragee coating for identification or to characterize different combinations of active compound doses.
[0230] Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin and soft, sealed capsules made of gelatin and a plasticizer (such as glycerol or sorbitol). Push-fit capsules can contain the active ingredient in a mixture with a filler such as lactose, a binder such as starch, and / or a lubricant such as talc or magnesium stearate, and optionally, a stabilizer. In soft capsules, the active compound can be dissolved or suspended in a suitable liquid, such as fatty oils, liquid paraffin, or liquid polyethylene glycol. Additionally, stabilizers can be added. All formulations for oral administration should be in dosages suitable for such administration.
[0231] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
[0232] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray provided by a pressurized pack or nebulizer using a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base, such as lactose or starch.
[0233] Further disclosed herein are various pharmaceutical compositions well known in the pharmaceutical art for applications including intraocular, intranasal, and intraauricular delivery. Penetrants suitable for these applications are generally known in the art. Pharmaceutical compositions for intraocular delivery include aqueous eye solutions of the active compound in a water-soluble form, such as eye drops, or in gellan gum (Shedden et al., Clin. Ther., 23(3):440-50 (2001)) or hydrogels (Mayer et al., Ophthalmologica, 210(2):101-3 (1996)); eye ointments; suspension eye drops, such as microparticles, drug-containing small polymer particles (Joshi, A., J. Ocul. Pharmacol., 10(1):29-45 (1994)), lipid-soluble formulations (Alm et al., Prog. Clin. Biol. Res., 312:447-58 (1989)), and microspheres (Mordenti, Toxicol. Sci., 52(1):101-6 (1999)), suspended in a liquid carrier medium; and intraocular inserts. All of the above references are incorporated herein by reference in their entireties. Such suitable pharmaceutical formulations are most often, and preferably, formulated to be sterile, isotonic, and buffered for stability and comfort. Pharmaceutical compositions for intranasal delivery may also include drops and sprays, which are often prepared to mimic nasal secretions in many respects to ensure normal ciliary action is maintained. As disclosed in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990) (incorporated herein by reference in its entirety), and as known to those skilled in the art, suitable formulations are most often, and preferably, isotonic, slightly buffered to maintain a pH of 5.5 to 6.5, and most often, and preferably, contain antimicrobial preservatives and appropriate drug stabilizers. Pharmaceutical formulations for intraauricular delivery include suspensions and ointments for topical application to the ear. Common solvents for such otic formulations include glycerin and water.
[0234] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter or other glycerides.
[0235] In addition to the above-mentioned preparation, compound can also be formulated as depot preparation.Such long-acting preparation can be administered by implantation (for example, subcutaneous or intramuscular) or intramuscular injection.Therefore, for example, compound can be formulated with suitable polymeric material or hydrophobic material (for example, as emulsion in acceptable oil) or ion exchange resin, or as poorly soluble derivative, for example as poorly soluble salt.
[0236] For hydrophobic compounds, a suitable pharmaceutical carrier may be a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. A common cosolvent system used is the VPD cosolvent system, which is a solution of 3 wt.% benzyl alcohol, 8 wt.% of the nonpolar surfactant Polysorbate 80™, and 65 wt.% polyethylene glycol 300, made up to volume with absolute ethanol. Of course, the proportions of the cosolvent system can be varied significantly without compromising its solubility and toxicity characteristics. Furthermore, the identity of the cosolvent components can be altered. For example, other low-toxicity nonpolar surfactants can be substituted for Polysorbate 80™, the fraction size of the polyethylene glycol can be varied, other biocompatible polymers can be substituted for polyethylene glycol, such as polyvinylpyrrolidone, and other sugars or polysaccharides can be substituted for dextrose.
[0237] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds can be used. Liposomes and emulsions are well-known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents, such as dimethyl sulfoxide, can also be used, but usually at the expense of relatively high toxicity. Furthermore, compounds can be delivered using sustained-release systems, such as semipermeable matrices of solid hydrophobic polymers containing therapeutic agents. Various sustained-release materials have been established and are well known to those skilled in the art. Sustained-release capsules can release compounds for several weeks up to 100 days, depending on their chemical nature. Depending on the chemical nature and biological stability of the therapeutic reagent, additional strategies for protein stabilization may be used.
[0238] Drugs intended for intracellular administration can be administered using techniques well known to those skilled in the art. For example, such drugs can be encapsulated in liposomes. All molecules present in aqueous solution at the time of liposome formation are incorporated into the aqueous interior. All liposomal contents are protected from the external microenvironment and are efficiently delivered into the cytoplasm because liposomes fuse with the cell membrane. Liposomes can be coated with tissue-specific antibodies. Liposomes can be targeted to and selectively taken up by desired organs. Alternatively, hydrophobic small organic molecules can be administered directly intracellularly.
[0239] Additional therapeutic or diagnostic agents can be incorporated into the pharmaceutical composition. Alternatively, or in addition, the pharmaceutical composition can be combined with other compositions containing other therapeutic or diagnostic agents.
[0240] Parenteral Pharmaceutical Compositions To prepare a parenteral pharmaceutical composition suitable for administration by injection (subcutaneous, intravenous, etc.), 0.1 mg to 120 mg of a water-soluble salt / soluble substance / solubilized complex of a compound of a preferred embodiment is dissolved in sterile water and then mixed with 10 μL of 0.9% sterile saline, and the mixture is then incorporated into a dosage unit form suitable for administration by injection.
[0241] Injectable pharmaceutical composition To prepare the injectable formulation, mix 0.1 mg to 100 mg of a compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), or (IIc), 2.0 mL of sodium acetate buffer (0.4 M), HCl (1 N), or NaOH (1 M) (qs. to the appropriate pH), and water (distilled, sterile) (qs. to 20 mL). Combine all of the above ingredients except water, stir, and heat slightly if necessary. Then, add a sufficient amount of water.
[0242] Oral Pharmaceutical Composition To prepare a pharmaceutical composition for oral administration, 0.1 mg to 120 mg of a compound of one embodiment is mixed with 750 mg of starch. The mixture is placed in an oral dosage unit such as a hard gelatin capsule, or 0.1 mg to 120 mg of the compound is granulated with a binder solution such as a starch solution together with a suitable diluent such as microcrystalline cellulose and a disintegrant such as croscarmellose sodium, and the resulting mixture is dried and compressed into tablets suitable for oral administration with the addition of a lubricant.
[0243] Sublingual (hard lozenge) pharmaceutical composition To prepare a pharmaceutical composition for buccal delivery, such as a hard lozenge, 0.1 mg to 120 mg of a compound of the preferred embodiments is mixed with 420 mg of powdered sugar / mannitol / xylitol or a sugar that provides a negative heat of solution, 1.6 mL of light corn syrup, 2.4 mL of distilled water, and 0.42 mL of mint extract or other flavoring. The mixture is blended and poured into a mold to form a lozenge suitable for buccal administration.
[0244] Rapidly disintegrating sublingual tablets Rapidly disintegrating sublingual tablets are prepared by mixing 48.5% by weight of a compound of the preferred embodiment, 20% by weight of microcrystalline cellulose (KG-802), 24.5% by weight of either mannitol or modified dextrose, which helps the compressed tablet dissolve faster in the oral cavity, 5% by weight of low-substituted hydroxypropyl cellulose (50 μm), and 2% by weight of magnesium stearate. The tablets are prepared by direct compression (AAPS PharmSciTech. 2006;7(2):E41). The total weight of the compressed tablets is maintained at 150 mg. The amount of the compound of the preferred embodiment is mixed with the total amount of microcrystalline cellulose (MCC) and mannitol / modified dextrose or a combination, and two-thirds of the amount of low-substituted hydroxypropyl cellulose (L-HPC) using a three-dimensional manual mixer (Inversina, Bioengineering AG, Switzerland) for 4.5 minutes to prepare the formulation. Add all of the magnesium stearate (MS) and the remaining one-third of the L-HPC 30 seconds before the end of mixing.
[0245] Inhaled pharmaceutical composition To prepare a pharmaceutical composition for inhalation delivery, 0.1 mg to 100 mg of a compound of a preferred embodiment is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is introduced into an inhalation delivery unit, such as a nebulizer, suitable for inhalation administration.
[0246] Pharmaceutical composition for nebulizer suspension In another embodiment, a compound of the preferred embodiments (0.1 mg to 100 mg) is suspended in sterile water (100 mL). Span 85 (1 g) is added, followed by dextrose (5.5 g) and ascorbic acid (10 mg). Benzalkonium chloride (3 mL of a 1:750 aqueous solution) is added, and the pH is adjusted to 7 with phosphate buffer. The suspension is loaded into a sterile nebulizer.
[0247] Pharmaceutical composition for transdermal patch To prepare a pharmaceutical composition for transdermal delivery, 0.1 mg to 100 mg of a compound of the preferred embodiments is embedded in or deposited onto a single adhesive patch, and the resulting patch is then attached to the skin via the adhesive surface for transdermal administration.
[0248] Pharmaceutical composition for topical gel To prepare a pharmaceutical topical gel composition, 0.1 mg to 100 mg of a compound of the preferred embodiments is mixed with 1.75 g of hydroxypropyl cellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate, and 100 mL of purified alcohol (USP). The resulting gel mixture is then placed in a container, such as a tube, suitable for topical administration.
[0249] eye drops To prepare a pharmaceutical eye drop composition, 0.1 mg to 100 mg of a compound of the preferred embodiments is mixed with 0.9 g of NaCl in 100 mL of purified water and filtered through a 0.2 micron filter. The resulting isotonic solution is then introduced into an ocular delivery unit, such as an eye dropper, suitable for ocular administration.
[0250] nasal spray solution To prepare a pharmaceutical nasal spray solution, 0.1 mg to 100 mg of a compound of the preferred embodiments is mixed with 30 mL of 0.05 M phosphate buffer (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 μl of spray per application.
[0251] Treatment / Usage Embodiments disclosed herein relate to administering to a subject in need thereof an effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising one or more compounds described herein (e.g., one or more compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof).
[0252] As disclosed elsewhere herein, some embodiments relate to treating a disease or condition, such as cancer, by administering a compound or composition disclosed herein. Subjects who need to receive a compound or composition disclosed herein to improve their health need not necessarily be identified before receiving their first treatment with the compound or composition. For example, a subject can be pre-determined to develop a disease or condition, such as cancer, before they exhibit any symptoms of the disease or condition. Alternatively, a subject can be treated prophylactically if they are at risk or have not yet developed a disease or condition, such as cancer (e.g., after the patient exhibits symptoms of another disease or condition related to cancer). Thus, in some embodiments, a compound or composition can be administered to a subject after the subject has been diagnosed with an early stage disease. In some embodiments, not all subjects are candidates for such administration, and it may be desirable to identify subjects for treatment. It is understood that patient selection depends on many factors within the skill of a physician of ordinary skill. Accordingly, some embodiments disclosed herein further include identifying a subject as one who would benefit from administration of an effective amount of at least one compound or composition for life extension, survival time extension, or longevity extension.
[0253] In another aspect, the present disclosure relates to a method for the treatment, prevention, or prophylactic treatment of cancer, which may include administering to a subject in need thereof an effective amount of one or more compounds described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition comprising a compound described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof). In certain embodiments, the cancer may be selected from brain cancer, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, gastric cancer, prostate cancer, renal cancer, colorectal cancer, or leukemia. In further or additional embodiments, the cancer is brain cancer or adrenocortical carcinoma. In further or additional embodiments, the cancer is breast cancer. In further or additional embodiments, the cancer is ovarian cancer. In further or additional embodiments, the cancer is pancreatic cancer. In further or additional embodiments, the cancer is gastric cancer. In further or additional embodiments, the cancer is prostate cancer. In further or additional embodiments, the cancer is renal cancer. In further or additional embodiments, the cancer is colorectal cancer. In further or additional embodiments, the cancer is myeloid leukemia. In further or additional embodiments, the cancer is glioblastoma. In further or additional embodiments, the cancer is follicular lymphoma. In further or additional embodiments, the cancer is pre-B acute leukemia. In further or additional embodiments, the cancer is chronic B lymphocytic leukemia. In further or additional embodiments, the cancer is mesothelioma. In further or additional embodiments, the cancer is small cell lung cancer.
[0254] Some embodiments relate to a method of inhibiting proliferation of cells with a RAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is associated with a RAS mutation. Some embodiments relate to a method of inducing apoptosis of cells with a RAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof. Some embodiments relate to a method of inhibiting proliferation of cells having a KRAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is associated with a KRAS mutation. Some embodiments relate to a method of inducing apoptosis of cells having a KRAS mutation, comprising administering a compound of Formula (I), (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof. Some embodiments relate to a method of inhibiting proliferation of cells harboring an NRAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is associated with an NRAS mutation. Some embodiments relate to a method of inducing apoptosis of cells harboring a KRAS mutation, comprising administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof. In some embodiments, the KRAS mutation is at codon 12, 13, 59, 61, and / or 146.In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12C, G12S, G12R, G12F, G12L, G12N, G12A, G12D, G12V, G13C, G13S, G13D, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, and Q61H. In some embodiments, the mutant form of the KRAS protein has one or more amino acid substitutions selected from the group consisting of G12C, G12R, G12S, G12A, G12D, G12V, G13C, G13R, G13S, G13A, G13D, G13V, A59E, A59G, A59T, Q61K, Q61L, Q61R, Q61H, K117N, K117R, K117E, A146P, A146T, and A146V.
[0255] In certain embodiments, the cancer is resistant to treatment with a MEK protein kinase inhibitor. In other embodiments, the cancer is resistant to treatment with a RAF protein kinase inhibitor. In yet other embodiments, the resistance is acquired resistance. In other embodiments, the resistance is de novo resistance. In further or additional embodiments, the cancer is resistant to an anti-cancer drug.
[0256] In some aspects, provided herein are compounds or pharmaceutical compositions and methods for treating cancer comprising a therapeutically effective amount of a RAF / MEK protein kinase dual inhibitor. In some embodiments, administration of the RAF / MEK protein kinase dual inhibitor increases the area under the serum concentration-time curve (AUC) of the RAF / MEK protein kinase dual inhibitor. In some embodiments, the cancer is resistant to treatment with a RAF protein kinase inhibitor. In further embodiments, the cancer is resistant to a RAF protein kinase inhibitor, and the RAF protein kinase inhibitor includes an A-RAF inhibitor, a B-RAF inhibitor, or a C-RAF inhibitor. In further embodiments, the cancer is resistant to a RAF protein kinase inhibitor, and the RAF protein kinase inhibitor includes a B-RAF inhibitor.
[0257] In some embodiments, the resistant cancer is pancreatic cancer, melanoma, colon cancer, lung cancer, or gastric cancer. In further embodiments, the resistant cancer is pancreatic cancer. In additional embodiments, the resistant cancer is gastric cancer. In alternative embodiments, provided are combination pharmaceuticals and methods for resensitizing cancer cells to treatment in a patient having or suspected of having a cancer that is resistant to an anti-cancer agent, comprising administering to the patient a therapeutically effective amount of a MEK / RAF dual inhibitor disclosed herein.
[0258] Some embodiments disclosed herein relate to methods of treating a mammal having a disease, which may include administering to a subject in need thereof an effective amount of one or more compounds described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition comprising a compound described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof). Other embodiments disclosed herein relate to methods of treating a subject with cancer cachexia, which may include administering to the subject an effective amount of one or more compounds described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of any of the foregoing), or a pharmaceutical composition comprising a compound described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof).
[0259] Some embodiments described herein relate to the use of one or more compounds described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for alleviating and / or treating cancer or a cancerous condition, such as cancer cachexia, which may include administering to a subject an effective amount of one or more compounds described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof). Still other embodiments described herein relate to one or more compounds described herein (e.g., compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof), which can be used to alleviate and / or treat cancer or a cancerous condition, such as cancer cachexia, by administering an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt thereof, to a subject.
[0260] Some embodiments disclosed herein relate to methods of alleviating and / or treating cancer, which may include contacting cancer cells with an effective amount of one or more compounds described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition comprising one or more compounds described herein (e.g., a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof). In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may function as an inhibitor of MEK. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may function as an inhibitor of ERK. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may function as a mitoSTAT3 inhibitor. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may reduce inflammatory cachexia and muscle wasting.
[0261] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered in a single dose once daily. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered in multiple doses more than once daily. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered once daily. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered twice daily. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered three times daily. In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered four times daily.
[0262] In some aspects, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, can inhibit abnormal cell growth. In some embodiments, the abnormal cell growth occurs in a mammal. A method for inhibiting abnormal cell growth can include administering an effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, wherein abnormal cell growth is inhibited. A method for inhibiting abnormal cell growth in a mammal can include administering to the mammal a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof, in an amount of the compound effective to inhibit abnormal cell growth in the mammal.
[0263] In another aspect, the invention relates to a method of weakening, inhibiting the growth of, or killing a cancer cell, comprising contacting the cell with a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, effective to weaken, inhibit the growth of, or kill the cell. In some embodiments, the cancer cell comprises a brain, breast, lung, ovarian, pancreatic, stomach, prostate, kidney, or colorectal cancer cell.
[0264] In some embodiments, the cancer cells are weakened. In some embodiments, 1% of the cancer cells are weakened. In further or additional embodiments, 2% of the cancer cells are weakened. In further or additional embodiments, 3% of the cancer cells are weakened. In further or additional embodiments, 4% of the cancer cells are weakened. In further or additional embodiments, 5% of the cancer cells are weakened. In further or additional embodiments, 10% of the cancer cells are weakened. In further or additional embodiments, 20% of the cancer cells are weakened. In further or additional embodiments, 25% of the cancer cells are weakened. In further or additional embodiments, 30% of the cancer cells are weakened. In further or additional embodiments, 40% of the cancer cells are weakened. In further or additional embodiments, 50% of the cancer cells are weakened. In further or additional embodiments, 60% of the cancer cells are weakened. In further or additional embodiments, 70% of the cancer cells are weakened. In further or additional embodiments, 75% of the cancer cells are weakened. In further or additional embodiments, 80% of the cancer cells are weakened. In further or additional embodiments, 90% of the cancer cells are weakened. In further or additional embodiments, 100% of the cancer cells are weakened. In further or additional embodiments, substantially all of the cancer cells are weakened.
[0265] In some embodiments, the cancer cells are killed. In further or additional embodiments, 1% of the cancer cells are killed. In further or additional embodiments, 2% of the cancer cells are killed. In further or additional embodiments, 3% of the cancer cells are killed. In further or additional embodiments, 4% of the cancer cells are killed. In further or additional embodiments, 5% of the cancer cells are killed. In further or additional embodiments, 1.0% of the cancer cells are killed. In further or additional embodiments, 20% of the cancer cells are killed. In further or additional embodiments, 25% of the cancer cells are killed. In further or additional embodiments, 30% of the cancer cells are killed. In further or additional embodiments, 40% of the cancer cells are killed. In further or additional embodiments, 50% of the cancer cells are killed. In further or additional embodiments, 60% of the cancer cells are killed. In further or additional embodiments, 70% of the cancer cells are killed. In further or additional embodiments, 75% of the cancer cells are killed. In further or additional embodiments, 80% of the cancer cells are killed. In further or additional embodiments, 90% of the cancer cells are killed. In further or additional embodiments, 100% of the cancer cells are killed. In further or additional embodiments, substantially all of the cancer cells are killed.
[0266] In further or additional embodiments, the cancer cell growth is inhibited. In further or additional embodiments, the cancer cell growth is inhibited by about 1%. In further or additional embodiments, the cancer cell growth is inhibited by about 2%. In further or additional embodiments, the cancer cell growth is inhibited by about 3%. In further or additional embodiments, the cancer cell growth is inhibited by about 4%. In further or additional embodiments, the cancer cell growth is inhibited by about 5%. In further or additional embodiments, the cancer cell growth is inhibited by about 10%. In further or additional embodiments, the cancer cell growth is inhibited by about 20%. In further or additional embodiments, the cancer cell growth is inhibited by about 25%. In further or additional embodiments, the cancer cell growth is inhibited by about 30%. In further or additional embodiments, the cancer cell growth is inhibited by about 40%. In further or additional embodiments, the cancer cell growth is inhibited by about 50%. In further or additional embodiments, the cancer cell growth is inhibited by about 60%. In further or additional embodiments, the cancer cell growth is inhibited by about 70%. In further or additional embodiments, the cancer cell growth is inhibited by about 75%. In further or additional embodiments, the cancer cell proliferation is inhibited by about 80%, in further or additional embodiments, the cancer cell proliferation is inhibited by about 90%, and in further or additional embodiments, the cancer cell proliferation is inhibited by about 100%.
[0267] In some embodiments, tumor size is reduced by administering a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof. In further or additional embodiments, the tumor size is reduced by at least 1%. In further or additional embodiments, the tumor size is reduced by at least 2%. In further or additional embodiments, the tumor size is reduced by at least 3%. In further or additional embodiments, the tumor size is reduced by at least 4%. In further or additional embodiments, the tumor size is reduced by at least 5%. In further or additional embodiments, the tumor size is reduced by at least 10%. In further or additional embodiments, the tumor size is reduced by at least 20%. In further or additional embodiments, the tumor size is reduced by at least 25%. In further or additional embodiments, the tumor size is reduced by at least 30%. In further or additional embodiments, the tumor size is reduced by at least 40%. In further or additional embodiments, the tumor size is reduced by at least 50%. In further or additional embodiments, the tumor size is reduced by at least 60%. In further or additional embodiments, the tumor size is reduced by at least 70%. In further or additional embodiments, the tumor size is reduced by at least 75%. In further or additional embodiments, the tumor size is reduced by at least 80%. In further or additional embodiments, the tumor size is reduced by at least 85%. In further or additional embodiments, the tumor size is reduced by at least 90%. In further or additional embodiments, the tumor is reduced by at least 95%. In further or additional embodiments, the tumor is eradicated. In some embodiments, the tumor size does not increase.
[0268] In some embodiments, tumor growth is reduced by administering a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof. In some embodiments, tumor growth is reduced by at least 1%. In some embodiments, tumor growth is reduced by at least 2%. In some embodiments, tumor growth is reduced by at least 3%. In some embodiments, tumor growth is reduced by at least 4%. In some embodiments, tumor growth is reduced by at least 5%. In some embodiments, tumor growth is reduced by at least 10%. In some embodiments, tumor growth is reduced by at least 20%. In some embodiments, tumor growth is reduced by at least 25%. In some embodiments, tumor growth is reduced by at least 30%. In some embodiments, tumor growth is reduced by at least 40%. In some embodiments, tumor growth is reduced by at least 50%. In some embodiments, tumor growth is reduced by at least 60%. In some embodiments, tumor growth is reduced by at least 70%. In some embodiments, tumor growth is reduced by at least 75%. In some embodiments, tumor growth is reduced by at least 75%. In some embodiments, tumor growth is reduced by at least 80%. In some embodiments, tumor growth is reduced by at least 90%. In some embodiments, tumor growth is reduced by at least 95%. In some embodiments, tumor growth is prevented.
[0269] Administration method Compound or pharmaceutical composition can be administered to patient by any suitable means.Non-limiting examples of administration methods include, among others, those considered by those skilled in the art to be suitable for contacting the compound of the present invention with living tissue: (a) oral administration (this administration includes administration in capsules, tablets, granules, sprays, syrups or other such forms); (b) parenteral administration, such as rectal, vaginal, intraurethral, intraocular, intranasal or intraauricular administration (this administration includes administration as aqueous suspension, oily preparations etc., or as drops, sprays, suppositories, plasters, ointments etc.); (c) subcutaneous injection, intraperitoneal injection, intravenous injection, intramuscular injection, intradermal injection, intraorbital injection, intracapsular injection, intrathecal injection, intrasternal injection etc. (including delivery by infusion pump); (d) local administration, such as by direct injection into the kidney or heart region (for example, by depot implantation); and (e) local administration.
[0270] Pharmaceutical compositions suitable for administration include compositions containing an effective amount of the active ingredient to achieve its intended purpose. The therapeutically effective amount of the compounds disclosed herein required as a dose depends on the route of administration, the type of animal, including humans, being treated, and the physical characteristics of the specific animal under consideration. The dose can be adjusted to achieve the desired effect, but depends on factors such as body weight, diet, concomitant medications, and other factors recognized by those skilled in the medical field. More specifically, a therapeutically effective amount refers to an amount of compound effective to prevent, alleviate, or relieve symptoms of disease or prolong survival of the subject being treated. Determining a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0271] As will be readily apparent to those skilled in the art, the useful in vivo dosage and specific mode of administration will vary depending on the age, weight, and mammalian species being treated, the specific compound used, and the specific application for which these compounds are being used. Determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired results, can be performed by those skilled in the art using routine pharmacological methods. Typically, human clinical applications of a product begin at low dosage levels, with the dosage level increased until the desired effect is achieved. Alternatively, accepted in vitro tests can be used to establish useful doses and routes of administration for compositions identified by the methods of the present invention using established pharmacological methods.
[0272] In non-human animal studies, the application of the candidate product is initiated at a high dosage level and then decreased until the desired effect is no longer achieved or adverse side effects disappear. Dosages can range widely, depending on the desired effect and therapeutic indication. Typically, dosages can be about 10 micrograms / kg to 100 mg / kg body weight, preferably about 100 micrograms / kg to 10 mg / kg body weight. Alternatively, as will be understood by those skilled in the art, dosages can be calculated based on the patient's surface area.
[0273] The exact formulation, route of administration, and dosage of the pharmaceutical compositions of the present invention can be chosen by the individual physician in view of the patient's condition (see, e.g., "The Pharmacological Basis of Therapeutics" by Fingl et al. 1975, incorporated herein by reference in its entirety, especially see Chapter 1, page 1). Typically, the dosage range of the composition administered to a patient can be about 0.5 to 1000 mg per kg of the patient's body weight. Dosages can be given once or in two or more consecutive doses over one or more days, depending on the patient's needs. Where human dosages for a compound have been established for at least some indications, those same dosages, or dosages that are about 0.1% to 500%, more preferably about 25% to 250%, of the established human dosage, are used in the present invention. Where human dosages have not been established, such as for newly discovered pharmaceutical compounds, appropriate human dosages can be identified through animal toxicity and efficacy studies, ED 50 Value or ID 50 values, or other appropriate values derived from in vitro or in vivo tests.
[0274] It should be noted that the attending physician would know how and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunction. Conversely, the attending physician would also know to adjust treatment to higher levels (avoiding toxicity) if the clinical response is inadequate. The magnitude of the administered dose in managing the disorder of interest will vary depending on the severity of the condition being treated and the route of administration. The severity of the condition may be assessed, for example, in part, by standard prognostic evaluation methods. Furthermore, the dose, and perhaps dose frequency, will also vary depending on the age, weight, and response of the individual patient. A program equivalent to that described above can be used in veterinary medicines.
[0275] The exact dosage will be determined on a drug-by-drug basis, but in most cases, some generalizations regarding dosage can be made. A daily dosage regimen for an adult human patient may be, for example, an oral dose of 0.1 mg to 2000 mg, preferably 1 mg to 500 mg, e.g., 5 to 200 mg, of each active ingredient. In other embodiments, intravenous, subcutaneous, or intramuscular doses of 0.01 mg to 100 mg, preferably 0.1 mg to 60 mg, e.g., 1 to 40 mg, of each active ingredient are used. When administering a pharmaceutically acceptable salt, the dosage may be calculated as the free base. In some embodiments, the composition is administered one to four times per day. Alternatively, the compositions of the present invention may be administered by continuous intravenous infusion, preferably at a dose of up to 1000 mg of each active ingredient per day. As will be appreciated by those skilled in the art, certain circumstances may require the administration of amounts of the compounds disclosed herein above, or even far above, the preferred dosage ranges, to effectively and aggressively treat a particular invasive disease or infection. In some embodiments, the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
[0276] In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered in a range of about 0.001 to about 1000 mg / kg body weight / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered in a range of about 0.5 to about 50 mg / kg / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered at about 0.001 to about 7 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered at about 0.002 to about 6 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered at about 0.005 to about 5 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered at about 0.01 to about 5 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered at about 0.02 to about 5 g / day. In further or additional embodiments, the amount of the compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, may be administered at about 0.05 to about 2.5 g / day.In further or additional embodiments, the amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), (IId), or a pharmaceutically acceptable salt thereof, may be administered at about 0.1 to about 1 g per day. In further or additional embodiments, dosage levels below the lower end of the aforementioned range may be sufficient.
[0277] Dosage and administration intervals can be individually adjusted to achieve a plasma level of the active moiety sufficient to maintain the modulating effect, i.e., the minimum effective concentration (MEC). The MEC varies for each compound but can be estimated from in vitro data. The dose required to achieve the MEC depends on individual characteristics and the route of administration. However, plasma concentrations can be determined using HPLC assays or bioassays.
[0278] Dosage intervals can also be determined using the MEC value. Compositions should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.
[0279] In cases of local administration or selective uptake, the effective local concentration of drug may not be related to plasma concentration.
[0280] The amount of composition administered will be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician.
[0281] The compounds disclosed herein can be evaluated for efficacy and toxicity using known methods. For example, the toxicity of a particular compound, or a subset of compounds sharing a particular chemical moiety, can be established by determining in vitro toxicity on a cell line (e.g., a mammalian, preferably a human cell line). The results of such tests are often predictive of toxicity in animals, such as mammals, or more specifically, humans. Alternatively, the toxicity of a particular compound in an animal model, such as a mouse, rat, rabbit, or monkey, can be determined using known methods. The efficacy of a particular compound can be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials. Recognized in vitro models exist for almost every class of condition, including, but not limited to, cancer, cardiovascular disease, and various immune dysfunctions. Similarly, accepted animal models can be used to establish the efficacy of chemical agents for treating such conditions. When selecting a model to determine efficacy, one skilled in the art can rely on the state of the art to select the appropriate model, dose, route of administration, and regimen. Of course, human clinical trials can also be used to determine the efficacy of a compound in humans.
[0282] The compositions can be optionally provided in a pack or dispenser device, which can contain one or more unit dosage forms containing the active ingredient. For example, the pack can comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration. The pack or dispenser can also be accompanied by a notice, attached to the container, in the form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceuticals, which notice indicates the approval by the government agency of the drug form for administration to humans or animals. Such notice can be, for example, the label approved by the U.S. Food and Drug Administration for prescription drugs or an approved product insert. Compositions containing the compounds of the present invention formulated in a compatible pharmaceutical carrier can also be prepared, placed in an appropriate container, and labeled for the treatment of an indicated condition.
[0283] Administration and Pharmaceutical Compositions The compounds are administered in therapeutically effective doses. While specific human dosage levels for the compounds described herein have not yet been determined, generally, daily doses can range from about 0.25 mg / kg to about 120 mg / kg body weight or more, from about 0.5 mg / kg to about 70 mg / kg, from about 1.0 mg / kg to about 50 mg / kg body weight, or from about 1.5 mg / kg to about 10 mg / kg body weight. Thus, for a 70 kg person, the dosage ranges would be from about 17 mg per day to about 8,000 mg per day, from about 35 mg per day to about 7,000 mg per day or more, from about 70 mg per day to about 6,000 mg per day, from about 100 mg per day to about 5,000 mg per day, or from about 200 mg to about 3,000 mg per day. The amount of active compound administered will, of course, be dependent on the subject and disease condition being treated, the severity of the affliction, the manner and schedule of administration, and the judgment of the prescribing physician.
[0284] Administration of the compounds disclosed herein, or pharmaceutically acceptable salts thereof, can be by any of the accepted modes of administration for drugs that serve similar utilities, including, but not limited to, oral, subcutaneous, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, pulmonary, vaginal, rectal, or intraocular. Oral and parenteral administration are customary when treating the indications that are the subject of preferred embodiments.
[0285] The compounds useful as described above can be formulated into pharmaceutical compositions for use in treating these conditions. Standard pharmaceutical formulation techniques, such as those disclosed in Remington's The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (2005) (incorporated by reference in its entirety), are used. Thus, some embodiments include pharmaceutical compositions comprising: (a) a safe and therapeutically effective amount of a compound described herein (including enantiomers, diastereoisomers, tautomers, polymorphs, and solvates thereof), or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier, diluent, excipient, or a combination thereof.
[0286] In addition to the selected compounds useful as described above, some embodiments include compositions containing a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Any conventional media or agent is contemplated for use in therapeutic compositions except insofar as it is incompatible with the active ingredient. In addition, various auxiliary substances commonly used in the art may be included. Considerations for including various ingredients in pharmaceutical compositions are described, for example, in Gilman et al. (Eds.) (1990); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press, incorporated herein by reference in its entirety.
[0287] Some examples of substances that can function as pharmaceutically acceptable carriers or components thereof are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives (e.g., sodium carboxymethylcellulose, ethylcellulose, and methylcellulose); powdered tragacanth; malt; gelatin; talc; solid lubricants such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and cocoa oil; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers such as TWEEN®; wetting agents such as sodium lauryl sulfate; colorants; flavorings; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffers.
[0288] The choice of a pharmaceutically acceptable carrier to be used in conjunction with a subject compound is basically determined by the way the compound is to be administered.
[0289] The compositions described herein are preferably provided in unit dosage form. As used herein, a "unit dosage form" is a composition containing an amount of compound suitable for single-dose administration to an animal, preferably a mammalian subject, in accordance with good medical practice. However, the preparation of a single dosage form or unit dosage form does not imply that the dosage form is administered once per day or once per treatment course. Such dosage forms are contemplated for administration once, twice, three times, or more times per day, and may be administered as an infusion over a period of time (e.g., from about 30 minutes to about 2-6 hours) or as a continuous infusion, and may be administered multiple times during a treatment course (although single administrations are not specifically excluded). Those skilled in the art will recognize that the formulations are not specifically intended for an entire course of treatment, and such decisions are left to the practitioner of the art, not the formulation.
[0290] The compositions useful as described above can be in any of a variety of suitable forms for various routes of administration, such as oral, nasal, rectal, topical (including transdermal), ocular, intracerebral, intracranial, intrathecal, intraarterial, intravenous, intramuscular, or other parenteral routes. Those skilled in the art will understand that oral and nasal compositions include compositions prepared using available techniques for administration by inhalation. Depending on the particular route of administration desired, various pharmaceutically acceptable carriers known in the art can be used. Pharmaceutically acceptable carriers include, for example, solid or liquid fillers, diluents, hydrotropes, surfactants, and encapsulating materials. Optional pharmaceutically active materials may be included that do not substantially interfere with the inhibitory activity of the compound. The amount of carrier used in combination with the compound is sufficient to provide a practical amount of material for administration per unit dose of the compound. Techniques and compositions for making dosage forms useful in the methods described herein are described in the following references, all of which are incorporated herein by reference: Modern Pharmaceutics, 4th Ed., Chapters 9 and 10 (Banker & Rhodes, editors, 2002), Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1989), and Ansel, Introduction to Pharmaceutical Dosage Forms 8th Edition (2004).
[0291] A variety of oral dosage forms can be used, including solid forms such as tablets, capsules, granules, and bulk powders. Tablets can be compressed, tablet-pulverized, enteric-coated, sugar-coated, film-coated, or multiple-compressed, and can contain suitable binders, lubricants, diluents, disintegrants, colorants, flavorings, flow-inducing agents, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and / or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifiers, suspending agents, diluents, sweeteners, melting agents, colorants, and flavorings.
[0292] Pharmaceutically acceptable carriers suitable for preparing unit dosage forms for oral administration are well known in the art. Tablets usually contain conventional pharmaceutically compatible excipients as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose, and cellulose; binders such as starch, gelatin, and sucrose; disintegrants such as starch, alginic acid, and croscarmellose; and lubricants such as magnesium stearate, stearic acid, and talc. Glidants such as silicon dioxide can be used to improve the flow properties of powder mixtures. Coloring agents such as FD&C dyes can be added for appearance. Sweeteners and flavoring agents such as aspartame, saccharin, menthol, peppermint, and fruit flavors are useful excipients for chewable tablets. Capsules usually contain one or more solid diluents as disclosed above. The selection of carrier ingredients depends on secondary considerations such as taste, cost, and storage stability, which are not critical and can be easily determined by those skilled in the art.
[0293] Oral compositions also include liquid solutions, emulsions, suspensions, etc. Pharmaceutically acceptable carriers suitable for preparing such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions, and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol, and water. For suspensions, typical suspending agents include methylcellulose, sodium carboxymethylcellulose, AVICEL RC-591, tragacanth, and sodium alginate, typical wetting agents include lecithin and polysorbate 80, and typical preservatives include methylparaben and sodium benzoate. Oral liquid compositions may also contain one or more ingredients, such as sweeteners, flavoring agents, and coloring agents disclosed above.
[0294] Such compositions can also be coated by conventional methods, typically with pH or time-dependent coatings, so that the target compound is released in the gastrointestinal tract near the desired local application or over a variable period of time to prolong the desired effect. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, ethylcellulose, Eudragit coatings, waxes, and shellac.
[0295] The compositions described herein may optionally include other pharmaceutical active agents.
[0296] Other compositions useful for achieving systemic delivery of the target compound include sublingual dosage forms, buccal dosage forms, and nasal dosage forms.Such compositions typically comprise one or more of the following: soluble filler substances such as sucrose, sorbitol, and mannitol; binders such as gum arabic, microcrystalline cellulose, carboxymethylcellulose, and hydroxypropylmethylcellulose.The glidant, lubricant, sweetener, colorant, antioxidant, and flavoring agent disclosed above may also be included.
[0297] Liquid compositions formulated for topical ophthalmic use are formulated so that they can be administered topically to the eye. Comfort should be maximized as much as possible, but formulation considerations (e.g., drug stability) may sometimes force the patient to settle for less than optimal comfort. When maximizing comfort is not possible, the liquid must be formulated so that patients can tolerate topical ophthalmic use. Furthermore, ophthalmically acceptable liquids must be packaged for single use or contain preservatives to prevent contamination from multiple uses.
[0298] For ophthalmic use, solutions or medicaments are often prepared using saline solution as the main vehicle. Eye drops should preferably be maintained at a comfortable pH using an appropriate buffer system. The formulation may also contain conventional pharmaceutically acceptable preservatives, stabilizers, and surfactants.
[0299] Preservatives that can be used in the pharmaceutical compositions disclosed herein include, but are not limited to, benzalkonium chloride, PHMB, chlorobutanol, thimerosal, phenylmercuric acetate, and phenylmercuric nitrate. A useful surfactant is, for example, Tween 80. Similarly, various useful vehicles can be used in the ophthalmic preparations disclosed herein. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropylmethylcellulose, poloxamer, carboxymethylcellulose, hydroxyethylcellulose, and purified water.
[0300] Tonicity adjusters can be added as needed or readily available, including, but not limited to, salts, particularly sodium chloride, potassium chloride, mannitol, and glycerin, or any other suitable ophthalmically acceptable tonicity adjuster.
[0301] Various buffers and means for adjusting the pH can be used as long as the resulting preparation is ophthalmologically acceptable. In many compositions, the pH is between 4 and 9. Therefore, buffers include acetate buffer, citrate buffer, phosphate buffer, and borate buffer. Acids or bases can be used to adjust the pH of these formulations as needed.
[0302] Similarly, ophthalmically acceptable antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, and butylated hydroxytoluene.
[0303] Another excipient component that may be included in the ophthalmic preparation is a chelating agent. A useful chelating agent is edetate disodium, although other chelating agents may be used instead or in combination.
[0304] For topical use, creams, ointments, gels, solutions, or suspensions containing the compounds disclosed herein are employed. Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.
[0305] For intravenous administration, the compounds and compositions described herein can be dissolved or dispersed in a pharmaceutically acceptable diluent, such as saline or dextrose solution. Suitable excipients, including but not limited to NaOH, sodium carbonate, sodium acetate, HCl, and citric acid, can be included to achieve the desired pH. In various embodiments, the pH of the final composition ranges from 2 to 8, or preferably from 4 to 7. Antioxidant excipients can include sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylates, thiourea, and EDTA. Other non-limiting examples of suitable excipients found in the final intravenous composition can include sodium or potassium phosphate, citric acid, tartaric acid, gelatin, and carbohydrates (e.g., dextrose, mannitol, and dextran). Additional acceptable excipients are described in Powell, et al., Compendium of Excipients for Parenteral Formulations, PDA J Pharm Sci and Tech 1998, 52 238-311 and Nema et al., Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions, PDA J Pharm Sci and Tech 2011, 65 287-332, both of which are incorporated herein by reference in their entirety. Antimicrobial agents can also be included to provide a bacteriostatic or fungistatic solution, including, but not limited to, phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.
[0306] Compositions for intravenous administration may be provided to the caregiver in one or more solid forms that are reconstituted with a suitable diluent, such as sterile water, saline, or aqueous dextrose, immediately prior to administration. In other embodiments, the compositions are provided in a solution that can be administered parenterally. In still other embodiments, the compositions are provided in a solution that is further diluted before administration. In embodiments involving administering a combination of a compound described herein and another agent, the combination may be provided to the caregiver as a mixture, or the caregiver may mix the two agents prior to administration, or the two agents may be administered separately.
[0307] The actual dose of the active compounds described herein will depend on the particular compound and the condition being treated, and the selection of an appropriate dose is well within the knowledge of one of ordinary skill in the art.
[0308] Second (or other additional) medication In some embodiments, the second therapeutic agent is an anti-inflammatory agent. In some embodiments, the second therapeutic agent is a nonsteroidal anti-inflammatory agent. In some embodiments, the second therapeutic agent is an anti-cancer agent.
[0309] In some embodiments, the method comprises administering an effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId), or a pharmaceutically acceptable salt thereof, in combination with an amount of a chemotherapeutic agent, wherein the combination and the amount of the chemotherapeutic agent together are effective in inhibiting abnormal cell proliferation. Many chemotherapeutic agents are currently known in the art and can be used in combination. In some embodiments, the chemotherapeutic agent is selected from the group consisting of antimitotic agents, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antihormones, angiogenesis inhibitors, and antiandrogens. Also described are methods for inhibiting abnormal cell growth in a mammal, comprising administering to the mammal an amount of a MEK protein kinase inhibitor and / or a Raf protein kinase inhibitor in combination with radiation therapy, wherein the amount of the MEK protein kinase inhibitor and / or the Raf protein kinase inhibitor in combination with the radiation therapy is effective to inhibit abnormal cell growth or treat a hyperproliferative disorder in the mammal. Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapies described herein.
[0310] In some embodiments, the present disclosure also relates to a method for inhibiting abnormal cell growth in a mammal, which may include a compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa), (IIb), or (IIc), or a pharmaceutically acceptable salt thereof, and an amount of one or more substances selected from an antiangiogenic agent, a signal transduction inhibitor, and an antiproliferative agent. Antiangiogenic agents, such as MMP-2 (matrix metalloproteinase 2) inhibitors, MMP-9 (matrix metalloproteinase 9) inhibitors, and COX-11 (cyclooxygenase 11) inhibitors, can be used in combination with the compounds of the present invention and the pharmaceutical compositions described herein. Examples of useful COX-II inhibitors include CELEBREX™ (alecoxib), valdecoxib, and rofecoxib.Examples of useful matrix metalloproteinase inhibitors are disclosed in WO96 / 33172 (published October 24, 1996), WO96 / 27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO98 / 07697 (published February 26, 1998), and WO98 / 0 3516 (published January 29, 1998), WO98 / 34918 (published August 13, 1998), WO98 / 34915 (published August 13, 1998), WO98 / 33768 (published August 6, 1998), WO98 / 30566 (published July 16, 1998), European Patent Publication No. 606,046 (published July 13, 1994), European Patent Publication No. 931,788 (published July 2, 1999) WO90 / 05719 (published May 31, 1990), WO99 / 52910 (published October 21, 1999), WO99 / 52889 (published October 21, 1999), WO99 / 29667 (published June 17, 1999), PCT International Application No. PCT / IB98 / 01113 (filed July 21, 1991), European Patent Application No. 99302232.1 (filed March 8, 1999), No. 5,863,949 (issued January 26, 1999), U.K. Patent Application No. 9912961.1 (filed June 3, 1999), U.S. Provisional Patent Application No. 60 / 148,464 (filed August 12, 1999), U.S. Patent No. 5,863,949 (issued January 26, 1999), U.S. Patent No. 5,861,510 (issued January 19, 1999), and European Patent Publication No. 780,386 (published June 25, 1997). While some MMP-2 and MMP-9 inhibitors have little or no MMP-1 inhibitory activity, others selectively inhibit MMP-2 and / or MMP-9 relative to other matrix metalloproteinases (i.e., MAP-1, NEMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, and MMP-13). Some specific examples of M1v1P inhibitors useful in the present invention are AG-3340, RU 32-3555, and RS 13-0830.
[0311] In some embodiments, a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (II), (IIa), (IIb), (IIc), or (IId) or a pharmaceutically acceptable salt thereof is administered with at least one additional therapeutic agent. In some embodiments, the therapeutic agent is taxol, bortezomib, or both. In further or additional embodiments, the therapeutic agent is selected from the group consisting of cytotoxic agents, antiangiogenic agents, and anti-tumor agents. In further or additional embodiments, the anti-tumor agent is selected from the group consisting of alkylating agents, antimetabolites, epipodophyllotoxins, anti-tumor enzymes, topoisomerase inhibitors, procarbazine, mitoxantrone, platinum coordination complexes, biological response modifiers and growth inhibitors, hormone / anti-hormonal therapeutic agents, and hematopoietic growth factors.
[0312] Many chemotherapeutic agents are currently known in the art and can be used in combination with the compounds and compositions of the present disclosure, hi some embodiments, the chemotherapeutic agent is selected from the group consisting of antimitotic agents, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antihormones, angiogenesis inhibitors, and antiandrogens.
[0313] In some embodiments, the combination is administered in combination with an additional therapy. In further or additional embodiments, the additional therapy is radiation therapy, chemotherapy, surgery, or any combination thereof. In further or additional embodiments, the combination is administered in combination with at least one additional therapeutic agent. In further or additional embodiments, the therapeutic agent is selected from the group consisting of cytotoxic agents, antiangiogenic agents, and anti-tumor agents. In further or additional embodiments, the anti-tumor agent is selected from the group consisting of alkylating agents, antimetabolites, epipodophyllotoxins, anti-tumor enzymes, topoisomerase inhibitors, procarbazine, mitoxantrone, platinum coordination complexes, biological response modifiers and growth inhibitors, hormone / anti-hormonal therapeutic agents, and hematopoietic growth factors.
[0314] In some embodiments, the second therapeutic agent is an agent for co-regulating the MEK or RAF pathway. In some embodiments, the second therapeutic agent is a MEK or RAF inhibitor. In some embodiments, the RAF inhibitor is vemurafenib, dabrafenib, XL-281, LGX-818, CEP-32496, ARQ-736, MEK-162, selumetinib, refametinib, E-6201, pimasertib, WX-554, and GDC-0973.
[0315] In some embodiments, the second therapeutic agent is selected from aspirin, diflunisal, salsalate, acetaminophen, ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, diclofenac, aceclofenac, nabumetone, enolic acids, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, sulfonanilides, clonixin, licofelone, dexamethasone, and prednisone.
[0316] In some embodiments, the second therapeutic agent is selected from mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide, busulfan, N-nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU), semustine (MeCCNU), fotemustine, streptozotocin, dacarbazine, mitozolomide, temozolomide, thiotepa, mitomycin, diaziquone (AZQ), cisplatin, carboplatin, and oxaliplatin.
[0317] In some embodiments, the second therapeutic agent is selected from vincristine, vinblastine, vinorelbine, vindesine, vinflunine, paclitaxel, docetaxel, etoposide, teniposide, tofacitinib, ixabepilone, irinotecan, topotecan, camptothecin, doxorubicin, mitoxantrone, and teniposide.
[0318] In some embodiments, the second therapeutic agent is selected from actinomycin, bleomycin, plicamycin, mitomycin, daunorubicin, epirubicin, idarubicin, pirarubicin, aclarubicin, mitoxantrone, cyclophosphamide, methotrexate, 5-fluorouracil, prednisolone, folinic acid, methotrexate, melphalan, capecitabine, mechlorethamine, uramustine, melphalan, chlorambucil, ifosfamide, bendamustine, 6-mercaptopurine, and procarbazine.
[0319] In some embodiments, the second therapeutic agent is selected from cladribine, pemetrexed, fludarabine, gemcitabine, hydroxyurea, nelarabine, cladribine, clofarabine, ytarabine, decitabine, cytarabine, cytarabine liposomal, pralatrexate, floxuridine, fludarabine, colchicine, thioguanine, cabazitaxel, larotaxel, ortataxel, tesetaxel, aminopterin, pemetrexed, pralatrexate, raltitrexed, pemetrexed, carmofur, and floxuridine.
[0320] In some embodiments, the second therapeutic agent is selected from azacitidine, decitabine, hydroxycarbamide, topotecan, irinotecan, belotecan, teniposide, aclarubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin, mitoxantrone, pixantrone, mechlorethamine, chlorambucil, prednimustine, uramustine, estramustine, carmustine, lomustine, fotemustine, nimustine, ranimustine, carboquone, thiotepa, triaziquone, and triethylenemelamine.
[0321] In some embodiments, the second therapeutic agent is nedaplatin, satraplatin, procarbazine, dacarbazine, temozolomide, altretamine, mitobronitol, pipobroman, actinomycin, bleomycin, plicamycin, aminolevulinic acid, methyl aminolevulinate, efaproxiral, talaporfin, temoporfin, verteporfin, alvocidib, seliciclib, palbociclib, bortezomib, carfilzomib, anagrexamic acid, thiazolinone ... and selected from lido, masoprocol, olaparib, belinstat, panobinostat, romidepsin, vorinosta, idelalisib, atrasentan, bexarotene, testolactone, amsacrine, trabectedin, alitretinoin, tretinoin, demecolcine, elsamitrucin, etoglucide, lonidamine, lucantone, mitoguazone, mitotane, oblimersen, omacetaxine mepesuxinate, and eribulin.
[0322] In some embodiments, the second therapeutic agent is selected from the group consisting of azathioprine, mycophenolate, leflunomide, teriflunomide, tacrolimus, cyclosporine, pimecrolimus, avetimus, gusperimus, lenalidomide, pomalidomide, thalidomide, anakinra, sirolimus, everolimus, ridaforolimus, temsirolimus, umirolimus, zotarolimus, eculizumab, adalimumab, afelimomab, certolizumab pegol, and gonadotropin. and selected from limumab, infliximab, nerelimomab, mepolizumab, omalizumab, faralimomab, elsilimomab, lebrikizumab, ustekinumab, etanercept, otelixizumab, teplizumab, visilizumab, clenoliximab, keliximab, zanolimumab, efalizumab, erlizumab, obinutuzumab, rituximab, and ocrelizumab.
[0323] In some embodiments, the second therapeutic agent is selected from the group consisting of pascolizumab, gomiliximab, lumiliximab, teneliximab, toralizumab, aselizumab, galiximab, gavilimomab, ruplizumab, belimumab, blisibimod, ipilimumab, tremelimumab, bertilimumab, lerdelimumab, metelimumab, natalizumab, tocilizumab, odulimomab, basiliximab, Selected from daclizumab, inolimomab, zolimomab, atorolimumab, cedelizumab, fontolizumab, maslimomab, morolimumab, pexelizumab, reslizumab, rovelizumab, siplizumab, talizumab, telimomab, vapaliximab, vepalimomab, abatacept, belatacept, pegsunercept, aflibercept, alefacept, and rilonacept. [Example]
[0324] General Procedure Additional embodiments are disclosed in more detail in the following examples, which are not intended to limit the scope of the claims in any way.
[0325] The materials used in preparing the compounds of formula (I), (Ia), (Ib), or (Ic) described herein can be prepared by known methods or are commercially available. In these reactions, it is also possible to use variants that are known to those skilled in the art but are not mentioned in more detail. Given the literature and this disclosure, a person skilled in the art is sufficiently equipped to prepare any compound.
[0326] Those skilled in the art of organic chemistry will recognize that these manipulations can be readily performed without further instruction, i.e., are well within the scope and practice of the art. These include reduction of carbonyl compounds to the corresponding alcohols, oxidation, acylation, both electrophilic and nucleophilic aromatic substitution, etherification, esterification, saponification, and the like. These manipulations are discussed in standard texts such as March's Advanced Organic Chemistry (Wiley), Carey and Sundberg, Advanced Organic Chemistry, which are incorporated herein by reference in their entirety.
[0327] Those skilled in the art will readily understand that certain reactions are best performed when other functional groups are masked or protected within the molecule to avoid any undesired side reactions and / or improve the reaction yield. Often, those skilled in the art will utilize protecting groups to achieve such improved yields or avoid undesired reactions. These reactions can be found in the literature and are well within the purview of those skilled in the art. Many examples of these manipulations can be found, for example, in T. Greene and P. Wuts, Protecting Groups in Organic Synthesis, 4th Ed., John Wiley & Sons (2007), which is incorporated herein by reference in its entirety.
[0328] The following exemplary schemes are provided for the reader's guidance and represent preferred methods for making the compounds exemplified herein. These methods are not limiting, and it will be apparent that other routes can be used to prepare these compounds. Such methods specifically include solid-phase-based chemistry, including combinatorial chemistry. Those skilled in the art are fully equipped to prepare these compounds using the methods provided in the literature and this disclosure. The numbering of compounds used in the synthetic schemes shown below refers only to those specific schemes and should not be construed as or confused with the same numbering in other sections of this application.
[0329] The trademarks used herein are merely examples and reflect exemplary materials used at the time of the present invention. One skilled in the art will recognize that variations in lots, manufacturing processes, etc. are to be expected. Therefore, the examples and the trademarks used therein are non-limiting and are not intended to be limiting; they merely illustrate methods that one skilled in the art may choose to implement one or more embodiments of the present invention.
[0330] The following illustrative schemes are provided for the reader's guidance and, together, represent exemplary methods for making the compounds provided herein. Additionally, other methods for preparing the compounds described herein will be readily apparent to those of skill in the art in light of the following reaction schemes and examples. Unless otherwise specified, all variables are as defined above.
[0331] Example 1 General synthesis A [ka] Compound 2: To a solution of 2-fluoro-3-nitrotoluene 1 (153.9 g, 268 mmol, 1.0 equiv.) and NBS (57.8 g, 321 mmol, 1.20 equiv.) in MeCN (1340 mL) was added 1,1-azobis(cyclohexanecarbonitrile) (8.0 g, 32.1 mmol, 0.12 equiv.) under a nitrogen atmosphere. The resulting reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to give an orange suspension. EtO was added, and the resulting suspension was stirred at room temperature for 18 h. The suspension was filtered, and the residue was washed with some additional EtO. The combined organic layers were washed with saturated aqueous NaHCO and brine, dried over NaSO, filtered, and concentrated under reduced pressure to give a dark red oil that crystallized on standing. The product was recrystallized using heptane to give 1-(bromomethyl)-2-fluoro-3-nitrobenzene 2 (43.8 g, 186.7 mmol, yield: 70%, purity: 99%) as a white solid.
[0332] LCMS (Method K): tR=1.95 min; [M+H] + Calculated m / z for = 234.0, found = no mass; H NMR (400 MHz, DMSO) δ 8.14 (td, J = 7.8, 7.3, 1.7 Hz, 1H), 8.01 - 7.93 (m, 1H), 7.50 - 7.40 (m, 1H), 4.81 (d, J = 1.4 Hz, 2H).
[0333] Compound 3: Ethyl 2-(2-fluoro-3-nitrobenzyl)-3-oxobutanoate. To a solution of 3 (1.0 equiv.) in perchloric acid (10-20 equiv.) was added the diol (1.20 equiv.). The resulting reaction mixture was stirred at room temperature for 1-18 hours. Water was added to the reaction mixture, and the product was filtered and washed with water and EtO. The residue was dried to give the coumarin as a solid.
[0334] Compound 4: To a solution of coumarin (1.0 equiv.) in N,N-dimethylformamide (anhydrous) (0.13-0.2 M) was added 60% sodium hydride dispersion in mineral oil (1.60 equiv.) at 0°C under a N atmosphere. The resulting reaction mixture was stirred for 10 minutes, followed by the addition of dimethylcarbamoyl chloride (1.50-1.60 equiv.). The resulting reaction mixture was warmed to room temperature and stirred for 2-60 hours. Water was added to quench the reaction mixture. The resulting suspension was filtered and washed with water and EtO. The residue was dried to give the dimethyl carbamate as a solid.
[0335] Compound 5: Dimethyl carbamate (1.0 equiv.) was suspended in methanol (0.2 M), and in some cases, some CHCl was added to obtain a solution. Argon was bubbled through the solution for 10 minutes. Next, 50% Raney® nickel-water slurry (1.0 equiv.) or 10% palladium-charcoal (0.05 equiv.) was added. The resulting reaction mixture was purged with hydrogen and stirred at room temperature for 2–18 hours. The reaction mixture was filtered through diatomaceous earth and washed with MeCN, CHCl, and MeOH. The filtrate was concentrated under reduced pressure to give the primary amine as a solid.
[0336] Compound 6: To a suspension of a primary amine (1.0 equiv.) and pyridine (3.00 equiv.) in N,N-dimethylformamide (0.2 M) cooled in an ice bath (0 °C), a clear solution of methylsulfamoyl chloride (2.50 equiv.) in acetonitrile (anhydrous) (0.2 M) was added dropwise. After the addition was complete, the reaction mixture was warmed to room temperature and stirred for 1-16 h. Water was added to the reaction mixture, and the resulting suspension was stirred for 1 h. The suspension was filtered and washed with water and EtO. The residue was dried to give the sulfamoyl as a solid.
[0337] A solution of compound 7: sulfamoyl (1.0 equiv.) in tetrahydrofuran (anhydrous) (0.06-0.10 M) was cooled to -78 °C under a nitrogen atmosphere, and 1 M LiHMDS (3.00 equiv.) in THF was slowly added. After complete addition, the resulting reaction mixture was optionally diluted with some additional tetrahydrofuran (anhydrous), stirred for 30 minutes, and warmed to 0 °C. This was added dropwise via cannula over 15 minutes to a cooled (-78 °C) solution of NCS or NBS (1.20 equiv.) in tetrahydrofuran (anhydrous) (0.04 M). The resulting reaction mixture was stirred at -78 °C for 1 hour. At -78 °C, the reaction mixture was quenched with HCl 1 M and warmed to room temperature. Some additional water was added, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure products were purified by column chromatography using the "flash" method (heptane / EtOAc = 1:0 to 0:1) to give the bromide or chloride as a solid.
[0338] Example 2 General synthesis B [ka] Compound B.1: To a solution of ethyl 2-(2-fluoro-3-nitrobenzyl)-3-oxobutanoate 3 (6.54 g, 23.09 mmol, 1.0 equiv.) in perchloric acid (29.8 mL, 346 mmol, 15.0 equiv.), resorcinol (3.05 g, 27.7 mmol, 1.20 equiv.) was added. The resulting reaction mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the product was filtered and washed with water and EtO. The residue was dried under reduced pressure at 40 °C overnight to give 3-(2-fluoro-3-nitrobenzyl)-7-hydroxy-4-methyl-2H-chromen-2-one (15.224 g, 45.8 mmol, yield: 112%) as an off-white solid.
[0339] LCMS (Method I):t R =1.92 minutes;[M+H] +m / z calculated value = 330.1, measured value = 330.0; 1H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 8.03 - 7.92 (m, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.60 - 7.51 (m, 1H), 7.32 (t, J = 8.0 Hz, 1H), 6.83 (dd, J = 8.8, 2.4 Hz, 1H), 6.72 (d, J = 2.4 Hz, 1H), 4.02 (s, 2H), 2.43 (s, 3H).
[0340] Compound B.2: To a suspension of 3-(2-fluoro-3-nitrobenzyl)-7-hydroxy-4-methyl-2H-chromen-2-one (3 g, 7.74 mmol, 1.0 equiv.) in CHCl (0.6 M) was added DIPEA (5 ml, 28.6 mmol, 3.70 equiv.). MEM-Cl (1.8 ml, 15.90 mmol, 2.05 equiv.) was added, and the resulting reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was purified by column chromatography (heptane / EtOAc = 3:0 → 1:3) using the "flash" method to give 3-(2-fluoro-3-nitrobenzyl)-7-((2-methoxyethoxy)methoxy)-4-methyl-2H-chromen-2-one (2.71 g, 6.49 mmol, yield: 84%) as a colorless oil.
[0341] LCMS (Method I):t R =2.08 minutes;[M+H] + Calculated m / z for = 418.0, observed = 418.0.
[0342] Compound B.3: A solution of 3-(2-fluoro-3-nitrobenzyl)-7-((2-methoxyethoxy)methoxy)-4-methyl-2H-chromen-2-one (2.71 g, 6.49 mmol, 1.0 equiv.) in tetrahydrofuran (anhydrous) (0.04 M) was cooled to −78° C., and LiHMDS (1 M in THF, 7.79 ml, 7.79 mmol, 1.20 equiv.) was slowly added. The resulting reaction mixture was stirred at −78° C. for 30 minutes, followed by the slow addition of NBS (1.156 g, 6.49 mmol, 1.0 equiv.) dissolved in tetrahydrofuran (anhydrous) (75 ml). The resulting yellow solution was stirred at −78° C. for 30 minutes. The reaction mixture was quenched with saturated aqueous NH4Cl at −78° C. and warmed to room temperature. The product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give a yellow oil. The impure product was purified by column chromatography (heptane / EtOAc = 1:0 → 1:3) using the "flash" method to give 4-(bromomethyl)-3-(2-fluoro-3-nitrobenzyl)-7-((2-methoxyethoxy)methoxy)-2H-chromen-2-one (2.1 g, 4.23 mmol, yield: 65%) as an off-white fluffy solid.
[0343] LCMS (Method K):t R =1.94 minutes;[M+H] + Calculated m / z for = 496.0 / 498.0, observed = 496.0 / 498.0.
[0344] Compound B.4: 4-(Bromomethyl)-3-(2-fluoro-3-nitrobenzyl)-7-((2-methoxyethoxy)methoxy)-2H-chromen-2-one (1.5 g, 3.02 mmol, 1.0 equiv.) was suspended in dimethylamine (2.0 M in MeOH, 15 ml, 30.0 mmol, 10.0 equiv.) at room temperature. The reaction mixture formed was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure. The impure product was suspended in EtO. The solid was filtered off, and the residue was washed with EtO and dried to give 4-((dimethylamino)methyl)-3-(2-fluoro-3-nitrobenzyl)-7-((2-methoxyethoxy)methoxy)-2H-chromen-2-one (1.27 g, 2.59 mmol, yield: 86%) as an off-white solid.
[0345] LCMS (Method I):t R =2.11 minutes;[M+H] + Calculated m / z for = 461.1, found = 461.1.
[0346] Compound B.5: To a mixture of 4-((dimethylamino)methyl)-3-(2-fluoro-3-nitrobenzyl)-7-((2-methoxyethoxy)methoxy)-2H-chromen-2-one (1.27 g, 2.59 mmol, 1.0 equiv.) in methanol (0.26 M) was added Raney® Nickel (50% slurry in water, 0.5 ml, 2.59 mmol, 1.0 equiv.), and the resulting reaction mixture was placed under a hydrogen atmosphere for 4 hours. The reaction mixture was diluted with MeOH, and the resulting solution was filtered. The filtrate was concentrated under reduced pressure and stripped twice with toluene to give 3-(3-amino-2-fluorobenzyl)-4-((dimethylamino)methyl)-7-((2-methoxyethoxy)methoxy)-2H-chromen-2-one (1.116 g, 2.59 mmol, 100% yield) as a sticky solid.
[0347] LCMS (Method U):t R =2.02 minutes;[M+H] + m / z calculated for = 430.8, found = 430.8.
[0348] Compound B.6: To a solution of 3-(3-amino-2-fluorobenzyl)-4-((dimethylamino)methyl)-7-((2-methoxyethoxy)methoxy)-2H-chromen-2-one (1.1 g, 2.56 mmol, 1.0 equiv.) in N,N-dimethylformamide (anhydrous) (1.2 M) was added a solution of pyridine (0.413 ml, 5.11 mmol, 2.0 equiv.) and methylsulfamoyl chloride (0.268 ml, 3.07 mmol, 1.2 equiv.) in acetonitrile (anhydrous) (1.2 M). The formed reaction mixture was stirred at room temperature for 1 hour. 50% aqueous NaHCO3 solution was added to the reaction mixture, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure product was purified by column chromatography using the "flash" method (heptane / EtOAc = 3:2 -> 1:9) to give the sulfamide (1.35 g, 2.58 mmol, yield: 101%) as a yellow oil.
[0349] LCMS (Method U):t R =1.94 minutes;[M+H] + Calculated m / z for = 524.2, found = 524.1.
[0350] Compound B.7: To a solution of sulfamide (910 mg, 1.738 mmol, 1.0 equiv.) in methanol / THF (1:1) (0.17 mL) was added sulfuric acid (1.5 ml, 28.1 mmol, 16 equiv.). The reaction mixture formed was stirred at room temperature for 1 h. The reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure product was purified by column chromatography (CHCl2 / MeOH 1:0 to 95:5) using the "flash" method. The desired fractions were combined and concentrated under reduced pressure. The residue was dissolved in MeCN / water and lyophilized to give the phenol (510 mg, 1.171 mmol, yield: 67%) as a yellow solid.
[0351] LCMS (Method J):t R =2.68 minutes;[M+H]+ Calculated m / z for = 436.1, found = 436.0.
[0352] Example 3 General synthesis C [ka] Compound C.2: A solution of C1 (3.0 g, 7.49 mmol) in tetrahydrofuran (anhydrous) (100 mL) was cooled to −78° C. under a nitrogen atmosphere, and LiHMDS 1 M in THF (9.7 mL, 9.7 mmol, 1.3 equiv.) was slowly added. After complete addition, the formed reaction mixture was stirred at −78° C. for 30 minutes, followed by 0° C. for 30 minutes. Next, paraformaldehyde (3.4 g, 112 mmol, 15 equiv.) was added. The reaction mixture was stirred at 0° C. for 1 hour. The reaction mixture was then quenched with HCl 1 M, warmed to room temperature, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure product was purified by flash column chromatography (heptane / EtOAc = 1:0 to 3:7) to give C.2 (1.67 g, 3.41 mmol, purity: 88%, yield: 46%) as an off-white solid.
[0353] Compound C.3: tert-Butyldimethylsilyl chloride (338 mg, 2.24 mmol) and imidazole (162 mg, 2.37 mmol) were dissolved in N,N-dimethylformamide (20 mL), 3-(2-fluoro-3-nitrobenzyl)-4-(2-hydroxyethyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (645 mg, 1.32 mmol) was added, and the mixture was stirred overnight. The reaction mixture was then quenched with water, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure product was purified by flash column chromatography (heptane / EtOAc = 1:0 → 1:1) to give C.3 (502 mg, 0.92 mmol, yield: 70%) as a colorless oil.
[0354] Compound C.4: C.3 (2.3 g, 4.22 mmol) was dissolved in 150 mL of MeOH, and argon was bubbled through the solution for 10 min. Next, a 50% Raney Ni-in-water slurry (2 mL, 8.44 mmol) was added. The mixture was purged with hydrogen and stirred at room temperature for 1.5 h. The reaction was then quenched by purging with argon, and the mixture was filtered through Celite, concentrated, and stripped with EtOAc and DCM to give C.4 (2.41 g, 4.21 mmol, purity: 90%, yield: 100%) as a brown oil.
[0355] Compound C.5: To a suspension of a primary amine (1.0 equiv.) and pyridine (3.00 equiv.) in N,N-dimethylformamide (0.2 M) cooled in an ice bath (0 °C), a clear solution of methylsulfamoyl chloride (2.50 equiv.) in acetonitrile (anhydrous) (0.2 M) was added dropwise. After the addition was complete, the reaction mixture was warmed to room temperature and stirred for 1-16 h. Water was added to the reaction mixture, and the resulting suspension was stirred for 1 h. The suspension was filtered and washed with water and EtO. The residue was dried to give the sulfamoyl as a solid. 727 mg, 5.61 mmol of C.4 gave C.5 (1.97 g, 3.24 mmol, purity: 95%, yield: 87%) as an orange foam.
[0356] Compound 100: To a stirred solution of C.5 (1.97 g, 2.92 mmol) in 5 mL of 1,4-dioxane was added 2 mL of 4 N HCl in 1,4-dioxane. After 30 min, the solvent was evaporated, stripped with DCM, and purified by flash column chromatography (heptane / EtOAc = 1:0 → 0:1) to give 100 (1.45 g, 2.79 mmol, 96% yield) as an off-white foam.
[0357] Analysis: LCMS (Method P):t R =1.19 minutes;[M+H] + m / z calculated for = 494.1, observed = 494.1; 1H NMR 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.7 Hz, 1H), 7.34 (dt, 1H), 7.14 - 7.07 (m, 2H), 7.02 - 6.90 (m, 2H), 6.81 - 6.73 (m, 1H), 4.79 (q, J = 5.3 Hz, 1H), 4.09 (s, 2H), 3.67 (t, J = 7.3 Hz, 2H), 3.17 - 3.08 (m, 5H), 3.03 (s, 3H), 2.75 (d, J = 5.3 Hz, 3H), 2.27 (s, 1H).
[0358] Compound 101: To an ice-cold, stirred solution of 100 (100 mg, 203 mmol) and carbon tetrabromide (161 mg, 0.487 mmol, 2.4 equiv.) in 4 mL of DCM was added triphenylphosphine (117 mg, 0.446 mmol, 2.2 equiv.), and the reaction was allowed to warm to room temperature and stirred for 5 h. The solvent was evaporated, and the residue was redissolved in 1 mL of DCM and purified by "flash" column chromatography (heptane / EtOAc = 1:0 to 2:8) to give 101 (146 mg, 0.186 mmol, purity: 71%, yield: 92%) as a white foam.
[0359] Example 4 General synthesis D [ka] Compound D.2: 2-Chloro-3-fluoroisonicotinaldehyde hydrate (56.13 g, 316 mmol, 1.0 equiv.) was dissolved in methanol (630 ml), and the solution was then cooled to 0 °C. Sodium borohydride (11.96 g, 316 mmol, 1.0 equiv.) was added in portions, and the resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with 1000 mL of ice-water slurry and slowly acidified. The reaction mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give (2-chloro-3-fluoropyridin-4-yl)methanol (66.25 g, 410 mmol, 98% yield) as an off-white solid.
[0360] LCMS (Method K): tR=1.20 min; [M+H] + Calculated m / z for = 162.0, observed = 162.0.
[0361] Compound D.3: (2-Chloro-3-fluoropyridin-4-yl)methanol (30 g, 186 mmol, 1.0 equiv.) was dissolved in anhydrous tetrahydrofuran (460 mL), placed under a nitrogen atmosphere, and cooled to 0 °C. Lithium tert-butoxide in THF (2.2 M, 89 mL, 195 mmol, 1.05 equiv.) was added dropwise, followed by mesyl chloride (17.25 mL, 223 mmol, 1.20 equiv.). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was added to a cooled (0 °C) solution of sodium iodide (27.8 g, 186 mmol, 1.0 equiv.), lithium tert-butoxide (93 mL, 204 mmol, 1.10 equiv.), and ethyl acetoacetate (47.2 mL, 371 mmol, 2.00 equiv.) in 300 mL of anhydrous THF. The formed reaction mixture was stirred at 0° C. for 30 minutes and then at 50° C. for 3 hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc, washed with 0.2 M LiCl, and washed once with brine. The organic phase was dried over Na2SO4 and concentrated under reduced pressure to give ethyl 2-((2-chloro-3-fluoropyridin-4-yl)methyl)-3-oxobutanoate (54.5 g, 199 mmol, 107% yield) as a yellow oil.
[0362] LCMS (Method K): tR = 1.91 and 2.12 min; m / z calculated for [M+H]+ = 274.1, found = 274.0.
[0363] Compound D.4: To a solution of ethyl 2-((2-chloro-3-fluoropyridin-4-yl)methyl)-3-oxobutanoate (51.2 g, 187 mmol, 1.0 equiv.) in sulfuric acid (3-20 equiv.) was added diol 4 (2.00 equiv.). The formed reaction mixture was stirred at room temperature for 2-18 h. Water was added to the reaction mixture, and the product was filtered and washed with water and EtO. The residue was recrystallized from EtOH:HO 8:2 to give the coumarin as a solid.
[0364] Compound D.5: To a solution of coumarin (1.0 equiv.) in N,N-dimethylformamide (anhydrous) (0.15–0.4 M) was added 60% sodium hydride dispersion in mineral oil (1.40–1.60 equiv.) under a N atmosphere at 0°C. The resulting reaction mixture was stirred for 10–20 min, followed by the addition of dimethylcarbamoyl chloride (1.25–1.60 equiv.). The resulting reaction mixture was warmed to room temperature and stirred for 1–24 h. Water was added to quench the reaction mixture. The resulting suspension was stirred for 1 h, filtered, and washed with water and heptane. The residue was dried to give the dimethylcarbamate as a solid.
[0365] Compound D.6: To a solution of dimethyl carbamate (1.0 equiv.) and tert-butyl carbamate (1.40–10.0 equiv.) in 1,4-dioxane (0.1–0.2 M), Xantphos (0.10–0.20 equiv.), cesium carbonate (1.20–1.50 equiv.), and PdOAc2 (0.10 equiv.) were added under a nitrogen atmosphere. After purging with nitrogen for an additional 5 minutes, the resulting reaction mixture was stirred at 90 °C for 18 hours. The reaction mixture was filtered through Celite and washed with CHCl2. The filtrate was concentrated under reduced pressure, and the residue was then dissolved in CHCl2 (0.3–0.5 M). TFA (0.30–10.0 equiv.) was added, and the resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and coevaporated twice with CHCl2 to give an oil. This oil was purified by the "flash acid" method of reverse phase chromatography to give the aminopyridine as a solid.
[0366] Compound D.7: To a suspension of aminopyridine (1.0 equiv.) and pyridine (3.00 equiv.) in N,N-dimethylformamide (0.2-0.30 M) cooled in an ice bath (0 °C), a clear solution of methylsulfamoyl chloride (2.50 equiv.) in acetonitrile (anhydrous) (0.2 M) was added dropwise. After the addition was complete, the reaction mixture was warmed to room temperature and stirred for 16 h. Water was added to the reaction mixture, and the resulting suspension was stirred for 1 h. The suspension was filtered and washed with water and EtO. The residue was dried to give the sulfamoyl as a solid.
[0367] Compound D.8: A solution of sulfamoyl (1.0 equiv.) in tetrahydrofuran (anhydrous) (0.06 M) was cooled to −78° C. under a nitrogen atmosphere, and LiHMDS 1 M in THF (3.00 equiv.) was slowly added. After complete addition, the resulting reaction mixture was optionally diluted with some additional tetrahydrofuran (anhydrous), stirred for 30 minutes, and warmed to 0° C. This was added dropwise via cannula over 15 minutes to a cooled (−78° C.) solution of NCS or NBS (1.20 equiv.) in tetrahydrofuran (anhydrous) (0.04 M). The resulting reaction mixture was stirred at −78° C. for 1 hour. At −78° C., the reaction mixture was quenched with HCl 1 M and warmed to room temperature. Some additional water was added, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give the bromine or chlorine as a solid.
[0368] Example 5 General synthesis E [ka] Compound E.2: Bromine or chlorine (1.0 equiv.) was suspended in methanol (0.10-0.20 M). Amine (1-10 equiv.) was added and the reaction mixture was stirred at room temperature for 2-16 hours. The reaction mixture was filtered and purified by preparative HPLC (method: acidic prep or basic prep) to give the desired amine as a solid after lyophilization or Genevac™.
[0369] Compound E.3: Dimethylamine E.2 (1.0 equiv.) and pyridine (1.1–1.5 equiv.) were dissolved in CHCl (0.2–0.8 M). Sulfonyl chloride (1.2–1.7 equiv.) was added, and the resulting reaction mixture was stirred at room temperature for 2–18 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (CHCl / EtOAc = 1:0 → 6:4) using the "flash" method to afford sulfamoyl E.3 as a solid.
[0370] Compound E.4: A solution of sulfamoyl E.3 (1.0 equiv.) in 0.06 M anhydrous tetrahydrofuran was cooled to −78 °C under a nitrogen atmosphere, and 1 M LiHMDS (1–3 equiv.) in THF was slowly added. After complete addition, the resulting reaction mixture was optionally diluted with some additional anhydrous tetrahydrofuran, stirred for 30 min, and warmed to 0 °C. This was added dropwise via cannula over 15 min to a cooled (−78 °C) solution of NCS or NBS (1.2 equiv.) in 0.04 M anhydrous tetrahydrofuran. The resulting reaction mixture was stirred at −78 °C for 1 h. At −78 °C, the reaction mixture was quenched with 1 M H2SO4 and warmed to room temperature. Some additional water was added, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give bromide or chloride E.4 as a solid.
[0371] Compound E.5: Bromine or chlorine E.4 (1.0 equiv.) was suspended in methanol (0.10-0.20 M). An amine (1-10 equiv.) was added and the reaction mixture was stirred at room temperature for 2-16 h. The reaction mixture was filtered and purified by preparative HPLC (method: acidic prep or basic prep) to afford the desired amine E.5 as a solid after lyophilization or Genevac™.
[0372] Example 6 General synthesis F [ka] Phenol F.1 (1.0 equiv.) and potassium carbonate (2.0 equiv.) were dissolved in DMF (0.03-0.2 M). Acid chloride (1.0 equiv.) was added and stirred at room temperature for 1-18 h. The reaction mixture was purified by preparative HPLC (method: acidic prep or basic prep) to afford the desired F.2 as a solid after lyophilization or Genevac™.
[0373] Example 7 General synthesis G [ka] Compound G.2: To a solution of G.1 (1.0 equiv.) in DMF (0.1-0.2 M), the respective amine (1.5 equiv.) and EtN (2-5 equiv.) were added, each in a separate vial. The reaction mixture was stirred at room temperature for 2-18 hours. The reaction mixture was then filtered and purified by preparative HPLC (method: acidic prep or basic prep) to give the desired product G.2 as a solid after evaporation under vacuum in a Genevac™ at 40 °C.
[0374] Example 8 Synthesis of Compound 102 [ka] Compound 102 was prepared in five steps.
[0375] Step 1: Following the procedure of General Synthesis A, starting from ethyl 2-(2-fluoro-3-nitrobenzyl)-3-oxobutanoate 3 (48.9 g, 173 mmol) and resorcinol (1.04 equiv.), the residue was stirred in saturated aqueous NaHCO3 solution until effervescence ceased. The suspension was filtered again, washed with water, Et2O, and dried to give the corresponding coumarin 5 (50.3 g, 153 mmol, 98% yield) as a yellow solid.
[0376] Step 2: Following the synthesis procedure of compound 4, the corresponding dimethyl carbamate 6 (70.7 g, 166 mmol, yield: 109%) was obtained as a yellow solid.
[0377] Step 3: Following the procedure for the synthesis of compound 5 using Pd / C and EtOH / THF 1:2 (0.05 M) as solvent, the corresponding primary amine 7 (50.83 g, 130 mmol, yield: 77%) was obtained as a pale pink solid.
[0378] Step 4: Starting from 35 g, 90 mmol of 7, the synthesis procedure for compound 6 was followed. Methylsulfamoyl chloride (2.5 equivalents) was added to give the corresponding sulfamoyl 8 (37.8 g, 76 mmol, 84% yield) as a beige solid.
[0379] Step 5: Following the procedure of General Procedure E using NBS, except using 1N H2SO4 instead of 1N HCl, gave the title compound (23.9 g, 40.5 mmol, 56% yield) as a white solid.
[0380] Yield: The title compound was isolated as a white solid (40% over 5 steps).
[0381] Analysis: LCMS (Method U):t R =1.97 min;[M+H2O] + Calculated m / z for = 559.0 / 561.0, found = 559.0 / 561.0.
[0382] Example 9 Synthesis of compound 7 [ka] Compound 7 was prepared in four steps.
[0383] Step 1: The general synthesis of compound 4 was followed, starting from ethyl 2-(2-fluoro-3-nitrobenzyl)-3-oxobutanoate (48.9 g, 173 mmol) and resorcinol (1.04 equiv.). After filtration, the residue was stirred in saturated aqueous NaHCO until effervescence ceased. The suspension was filtered again, washed with water, EtO, and dried to give the corresponding coumarin 5 (50.3 g, 153 mmol, 98% yield) as a yellow solid.
[0384] Step 2: Following the general synthesis of compound 5, the corresponding dimethyl carbamate (70.7 g, 166 mmol, yield: 109%) was obtained as a yellow solid.
[0385] Step 3: The general synthesis of compound 6 was followed using Pd / C and EtOH / THF 1:2 (0.05 M) as solvent to give the corresponding primary amine (50.83 g, 130 mmol, yield: 77%) as a pale pink solid.
[0386] Step 4: The general synthesis of compound 7 was followed starting from 35 g, 90 mmol of 7. Methylsulfamoyl chloride was added in 2.5 equivalents to give the title compound (37.8 g, 76 mmol, 84% yield) as a beige solid.
[0387] Yield: The title compound was isolated as a beige solid (69% over four steps).
[0388] Analysis: LCMS (Method I):t R =1.98 minutes;[M+H] + m / z calculated value=464.1, measured value=464.1;1H NMR (400 MHz, CDCl3) δ 7.65 - 7.59 (m, 1H), 7.39 (td, J = 7.8, 1.7 Hz, 1H), 7.15 - 7.08 (m, 2H), 7.01 (t, J = 7.8 Hz, 1H), 6.95 (td, J = 7.9, 7.4, 1.8 Hz, 1H), 6.60 (d, J = 3.0 Hz, 1H), 4.44 (q, J = 5.4 Hz, 1H), 4.06 (s, 2H), 3.13 (s, 3H), 3.03 (s, 3H), 2.75 (d, J = 5.3 Hz, 3H), 2.44 (s, 3H).
[0389] Example 10 Synthesis of compound 9 [ka] Compound 9 was prepared in one step.
[0390] Step 1: Following the general synthesis of compound E.2, starting from 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (22.22 g, 34.79 mmol) and dimethylamine 2 M in MeOH. After complete conversion, the reaction was concentrated under reduced pressure. To the residue was added 1 M HCl, and the aqueous layer was extracted with CHCl. The aqueous layer was made basic with solid NaCO. The basic aqueous layer was extracted with CHCl. The organic layer from the basic extraction was washed with brine, dried over NaSO, filtered, and concentrated under reduced pressure to give the title compound (13.23 g, 25.7 mmol, yield: 74%) as a pale yellow solid.
[0391] Yield: Compound 9 was isolated as a pale yellow solid (74% over one step).
[0392] Analysis: LCMS (Method T):t R =1.53 minutes;[MH] + m / z calculated value=507.2, measured value=507.2;1H NMR (400 MHz, DMSO) δ 9.38 (s, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.28 (td, J = 8.0, 1.6 Hz, 1H), 7.25 - 7.18 (m, 2H), 7.15 (dd, J = 8.8, 2.4 Hz, 1H), 7.00 (t, J = 7.9 Hz, 1H), 6.90 - 6.77 (m, 1H), 4.04 (s, 2H), 3.64 (s, 2H), 3.06 (s, 3H), 2.93 (s, 3H), 2.52 (d, J = 4.9 Hz, 3H), 2.19 (s, 6H).
[0393] Example 11 Synthesis of compound 10 [ka] Compound 10 was prepared in two steps.
[0394] Step 1: Following the general synthesis of compound E.2 (with the addition of NEt (1.0 equiv.)), starting from 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (0.35 g, 0.59 mmol) and N-Boc piperazine, the product was purified by basic preparative separation. The desired fractions were combined and concentrated under reduced pressure to give the amine (0.414 g, 0.486 mmol, yield: 82%, purity: 76%) as a colorless oil.
[0395] Step 2: The amine was dissolved in 1,4-dioxane (3 mL), and HCl in dioxane (4 M, 16.7 equiv, 2.0 mL, 8.00 mmol) was added and stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure and co-evaporated twice with CHCl. The residue was dissolved in MeCN / water and lyophilized to give the title compound (304 mg, 0.49 mmol, 102% yield) as a white solid.
[0396] Yield: Compound 10 was isolated as a white solid (84% over two steps).
[0397] Analysis: LCMS (Method S):t R =1.00min;[MH] + m / z calculated value = 548.2, measured value = 548.2; 1H NMR (400 MHz, DMSO) δ 9.37 (s, 1H), 8.88 (s, 2H), 8.09 (d, J = 8.8 Hz, 1H), 7.32 - 7.19 (m, 3H), 7.17 (dd, J = 8.9, 2.4 Hz, 1H), 7.00 (t, J = 7.8 Hz, 1H), 6.86 - 6.78 (m, 1H), 4.04 (s, 2H), 3.86 (s, 2H), 3.07 (s, 3H), 2.95 (d, J = 14.4 Hz, 7H), 2.73 (s, 4H), 2.54 (d, J = 2.8 Hz, 3H).
[0398] Example 12 Synthesis of Compound 103 [ka] Compound 103 was prepared in five steps.
[0399] Step 1: To a solution of 3-(2-fluoro-3-nitrobenzyl)-7-hydroxy-4-methyl-2H-chromen-2-one (700 mg, 2.126 mmol, 1.0 equiv.) and 2-bromopyrimidine (2467 mg, 15.52 mmol, 7.3 equiv.) in N,N-dimethylformamide (0.1 M) was added potassium carbonate (588 mg, 4.25 mmol, 2.00 equiv.) at room temperature, and the reaction mixture formed was stirred at 80 °C for 1 h. The solvent was evaporated under reduced pressure. Water was added, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na SO , filtered, and concentrated under reduced pressure. The impure product was purified by column chromatography using the "flash" method (heptane / EtOAc = 4:1 → 1:4) to give 3-(2-fluoro-3-nitrobenzyl)-4-methyl-7-(pyrimidin-2-yloxy)-2H-chromen-2-one (470 mg, 1.154 mmol, yield: 51%) as a pale yellow solid.
[0400] Step 2: To a suspension of 3-(2-fluoro-3-nitrobenzyl)-4-methyl-7-(pyrimidin-2-yloxy)-2H-chromen-2-one (470 mg, 1.154 mmol, 1.0 equiv.) in N,N-dimethylformamide (anhydrous) (0.11 M) was added tin(II) chloride dihydrate (1302 mg, 5.77 mmol, 5.00 equiv.). The reaction mixture formed was stirred at 70° C. for 1.5 hours. The reaction mixture was concentrated under reduced pressure, and water was added to the residue. The product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give 3-(3-amino-2-fluorobenzyl)-4-methyl-7-(pyrimidin-2-yloxy)-2H-chromen-2-one (430 mg, 1.026 mmol, yield: 84%) as an orange oil.
[0401] Step 3: To a solution of 3-(3-amino-2-fluorobenzyl)-4-methyl-7-(pyrimidin-2-yloxy)-2H-chromen-2-one (430 mg, 1.026 mmol, 1.0 equiv.) and pyridine (0.373 ml, 4.61 mmol, 4.50 equiv.) in N,N-dimethylformamide (anhydrous) (0.1 M) at 0 °C, a solution of methylsulfamoyl chloride (0.203 ml, 2.359 mmol, 2.30 equiv.) in acetonitrile (3 ml) was added, and the resulting reaction mixture was stirred at room temperature for 2 h. Water was added, and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give the sulfamoyl (493 mg, 0.912 mmol, 89% yield) as an orange solid.
[0402] Step 4: Sulfamoyl (30 mg, 0.064 mmol, 1.0 equiv) was dissolved in tetrahydrofuran (anhydrous) (0.04 M), purged with argon, and cooled to −78° C. Next, LiHMDS (1 M in THF, 0.191 ml, 0.191 mmol, 3.00 equiv) was added, and the mixture was stirred for 30 min. A solution of N-bromosuccinimide (13.62 mg, 0.077 mmol, 1.20 equiv) in tetrahydrofuran (anhydrous) (0.5 ml) was added dropwise. The mixture was stirred at −78° C. for 30 min. Water was added to the reaction mixture. The product was extracted with EtOAc. The combined organic layers were washed with brine, dried over NaSO, filtered, and concentrated under reduced pressure to give the bromide (30 mg, 0.034 mmol, 53% yield) as an orange solid.
[0403] Step 5: Following the procedure of General Procedure P, starting from bromine (0.02 g, 0.037 mmol) and piperazine, basic prep was used to afford the title compound (11.1 mg, 0.02 mmol, 54% yield) as a white solid.
[0404] Yield: The title compound was isolated as a white solid (11% over 5 steps).
[0405] Analysis: LCMS (Method P):t R=1.12 minutes;[MH] + Calculated m / z for = 555.2, found = 555.2.
[0406] Example 13 Synthesis of Compound 104 [ka] Compound 104 was prepared in two steps.
[0407] Step 1: N-[3-Fluoro-4-[[4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl]methyl]-2-pyridinyl]-N'-methyl-sulfamide (20 mg, 0.042 mmol, 1.0 equiv.) was dissolved in tetrahydrofuran (anhydrous) (0.02 M), purged with argon, and cooled to -78 °C. LiHMDS (1 M in THF, 0.169 ml, 0.169 mmol, 4.00 equiv.) was then added, and the mixture was stirred for 30 minutes. A solution of N-bromosuccinimide (9 mg, 0.051 mmol, 1.20 equiv.) in tetrahydrofuran (anhydrous) (0.5 ml) was added dropwise. The mixture was stirred at -78 °C for 30 minutes. 1 M HCl was added to the reaction mixture. The product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to give the bromide (27 mg, 0.028 mmol, yield: 66%) as an orange solid.
[0408] Step 2: Following the general synthesis of compound G.2, starting from bromine (0.02 g, 0.037 mmol) and piperazine, basic preparative preparation was used to afford the title compound (7.8 mg, 0.0140 mmol, 38% yield) as a white solid.
[0409] Yield: The title compound was isolated as a white solid (25% over two steps).
[0410] Analysis: LCMS (Method P):t R =0.83min;[MH] + Calculated m / z for = 556.2, found = 556.2.
[0411] Example 14 Synthesis of Compound 105 [ka] Compound 105 was prepared in two steps.
[0412] Step 1: 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate) (0.3 g, 0.553 mmol, 1.0 equiv.) was dissolved in ammonia (0.5 M in THF, 20 mL, 10.0 mmol, 18 equiv.) and stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure to give 4-(aminomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate hydrobromide (331 mg, 0.592 mmol, 107% yield) as an off-white solid.
[0413] Step 2: 4-(aminomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate hydrobromide (40 mg, 0.072 mmol, 1.0 equiv.) was dissolved in CHCl (0.04 M). EtN (0.08 mL, 0.572 mmol, 8.0 equiv.) and trimethylsilyl isocyanate (0.077 mL, 0.572 mmol, 8.0 equiv.) were added, and the reaction mixture was stirred at room temperature for 18 hours. The product was purified by acidic preparative separation to give the title compound (6.5 mg, 0.012 mmol, 17% yield) as a white solid after lyophilization.
[0414] Yield: Compound 105 was isolated as a white solid (18% over two steps).
[0415] Analysis: LCMS (Method T):t R =1.20 minutes;[M+H] +Calculated m / z for = 522.2, observed = 522.4.
[0416] Example 15 Synthesis of Compound 106 [ka] Compound 106 was prepared in three steps.
[0417] Step 1: 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate) (0.3 g, 0.553 mmol, 1.0 equiv.) was dissolved in ammonia (0.5 M in THF, 20 mL, 10.0 mmol, 18 equiv.) and stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure to give 4-(aminomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate hydrobromide (331 mg, 0.592 mmol, 107% yield) as an off-white solid.
[0418] Step 2: To a solution of 4-(aminomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate hydrobromide (40 mg, 0.072 mmol, 1.0 equiv.) and 2-((tert-butyldimethylsilyl)oxy)ethyl(4-nitrophenyl)carbonate (31.7 mg, 0.093 mmol, 1.3 equiv.) in N,N-dimethylformamide (anhydrous) (2 mL), triethylamine (0.030 mL, 0.215 mmol, 3.0 equiv.) was added, and the reaction mixture was stirred at room temperature for 3 days. The mixture was diluted with EtOAc and water, the layers were separated, and the aqueous layer was extracted once with EtOAc. The combined organic layers were washed twice with water and brine, dried over Na2SO4, and concentrated. Water was added to the reaction mixture. The product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure product was purified by column chromatography (heptane / EtOAc = 4:1 → 1:4) using the "flash" method to give 3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(8,8,9,9-tetramethyl-3-oxo-4,7-dioxa-2-aza-8-siladecyl)-2H-chromen-7-yldimethylcarbamate (25 mg, 0.033 mmol, yield: 46%) as a white solid.
[0419] Step 3: To a solution of 3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-4-(8,8,9,9-tetramethyl-3-oxo-4,7-dioxa-2-aza-8-siladecyl)-2H-chromen-7-yldimethylcarbamate (25 mg, 0.037 mmol, 1.0 equivalents) in tetrahydrofuran (0.5 mL), hydrochloric acid (4N in dioxane, 0.092 mL, 0.367 mmol, 10 equivalents) was added, and the reaction mixture formed was stirred at room temperature for 30 minutes. The product was purified by basic preparative separation to obtain the title compound (9.6 mg, 0.017 mmol, yield: 46%) as a white solid after lyophilization.
[0420] Yield: The title compound was isolated as a white solid (23% over three steps).
[0421] Analysis: LCMS (Method T):t R =1.25 minutes;[M+H] + m / z calculated value = 567.2, measured value = 567.4; 1H NMR (400 MHz, DMSO) δ 9.38 (s, 1H), 7.94 (d, J = 8.9 Hz, 1H), 7.85 (t, J = 5.7 Hz, 1H), 7.32 - 7.22 (m, 2H), 7.19 (dd, J = 8.8, 2.4 Hz, 1H), 6.97 (t, J = 8.0 Hz, 1H), 6.81 (s, 1H), 4.71 (t, J = 5.3 Hz, 1H), 4.41 (d, J = 5.6 Hz, 2H), 4.12 (s, 2H), 3.96 (t, J = 5.1 Hz, 2H), 3.50 (q, J = 5.2 Hz, 2H), 3.07 (s, 3H), 2.93 (s, 3H).
[0422] Example 16 Synthesis of Compound 107 [ka] Compound 107 was prepared in one step.
[0423] Step 1: According to general synthesis E.3, starting from 3-(3-amino-2-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yldimethylcarbamate (0.1 g, 0.27 mmol) and ethanesulfonyl chloride, the title compound (46.8 mg, 0.10 mmol, yield: 37%) was obtained as a white solid.
[0424] Yield: Compound 107 was isolated as a white solid (37% over one step).
[0425] Analysis: LCMS (Method R):t R =1.57 min;[M+H2O] +m / z calculated value = 480.2, measured value = 480.1; 1H NMR (400 MHz, DMSO) δ 9.60 (s, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.29 - 7.22 (m, 2H), 7.19 (dd, J = 8.8, 2.3 Hz, 1H), 7.03 (t, J = 7.9 Hz, 1H), 6.95 (td, J = 7.9, 7.5, 1.7 Hz, 1H), 3.99 (s, 2H), 3.15 - 3.02 (m, 5H), 2.93 (s, 3H), 2.45 (s, 3H), 1.26 (t, J = 7.4 Hz, 3H).
[0426] Example 17 Synthesis of Compound 108 [ka] Compound 108 was prepared in four steps.
[0427] Step 1: Following the general synthesis of compound 4, starting from ethyl 2-(2-fluoro-3-nitrobenzyl)-3-oxobutanoate (1.0 g, 3.53 mmol) and 4-methylbenzene-1,3-diol (1.20 equiv.), the corresponding coumarin was obtained as an off-white solid (1.32 g, 3.68 mmol, yield: 104%).
[0428] Step 2: Following the general synthetic procedure for compound 5, the corresponding dimethyl carbamate (0.91 g, 2.06 mmol, yield: 54%) was obtained as a pale yellow solid.
[0429] Step 3: The general synthesis of compound 6 was followed. After filtration, the product was purified by column chromatography (CHCl / MeOH = 1:0 → 95:5) using the "flash" method to give the corresponding primary amine (0.54 g, 0.79 mmol, purity: 56%, yield: 35%) as a pale yellow solid.
[0430] Step 4: The general synthesis of compound 7 was followed. After filtration, 576 mg of impure compound was obtained. 50 mg was further purified by preparative LC (basic) to give the title compound (13.2 mg, 0.027 mmol, yield: 66%) as a white solid after lyophilization.
[0431] Yield: Compound 108 was isolated as a white solid (13% over 4 steps).
[0432] Analysis: LCMS (Method T):t R =1.58 minutes; [MH] + m / z calculated value = 476.1, measured value = 476.2; 1H NMR (400 MHz, DMSO) δ 9.38 (s, 1H), 7.76 (s, 1H), 7.30 - 7.24 (m, 1H), 7.22 (s, 1H), 7.13 (s, 1H), 6.99 (t, J = 7.9 Hz, 1H), 6.82 (t, J = 7.2 Hz, 1H), 3.96 (s, 2H), 3.09 (s, 3H), 2.94 (s, 3H), 2.44 (s, 3H), 2.23 (s, 3H).
[0433] Example 18 Synthesis of Compound 109 [ka] Compound 109 was prepared in four steps.
[0434] Step 1: Following the general synthesis of compound 4, starting from ethyl 2-(2-fluoro-3-nitrobenzyl)-3-oxobutanoate 3 (1.0 g, 3.53 mmol) and 4-chlorobenzene-1,3-diol (1.20 equiv.), the corresponding coumarin 5 (0.95 g, 2.57 mmol, yield: 73%) was obtained as an off-white solid.
[0435] Step 2: Following the general synthetic procedure for compound 5, the corresponding dimethyl carbamate (0.88 g, 1.95 mmol, yield: 75%) was obtained as a pale yellow solid.
[0436] Step 3: Following the general synthetic procedure for compound 6, the corresponding primary amine (0.51 g, 1.22 mmol, yield: 60%) was obtained as a pale yellow solid.
[0437] Step 4: The general synthesis procedure for compound 7 was followed. After filtration, 588 mg of impure compound was obtained. 50 mg was further purified by preparative LC (basic) to give the title compound (28.9 mg, 0.027 mmol, yield: 44%) as a white solid after lyophilization.
[0438] Yield: Compound 109 was isolated as a white solid (14% over 4 steps).
[0439] Analysis: LCMS (Method T):t R =1.63 minutes;[MH] + m / z calculated value = 496.1, measured value = 496.2; 1H NMR (400 MHz, DMSO) δ 9.40 (s, 1H), 8.03 (s, 1H), 7.50 (s, 1H), 7.28 (td, J = 7.9, 1.8 Hz, 1H), 7.10 (s, 1H), 6.98 (t, J = 7.9 Hz, 1H), 6.84 (t, J = 7.0 Hz, 1H), 3.97 (s, 2H), 3.10 (s, 3H), 2.95 (s, 3H), 2.45 (s, 3H).
[0440] Example 19 Synthesis of compound 19 [ka] Compound 19 was prepared in one step.
[0441] Step 1: Following the general synthesis procedure for compound E.2 (additionally, DIPEA (2.0 equivalents) was added during the reaction), starting from 4-(bromomethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (23.9 g, 44.1 mmol) and azetidine. After complete conversion, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (heptane / EtOAc = 1:0 → 0:1) using the "flash" method. The desired fractions were combined and concentrated under reduced pressure to give the title compound (11.8 g, 22.17 mmol, yield: 50%) as an off-white solid.
[0442] Yield: Compound 19 was isolated as an off-white solid (50% over one step).
[0443] Analysis: LCMS (Method T):t R =1.53 minutes;[MH] + m / z calculated value = 519.2, measured value = 519.2; 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.8 Hz, 1H), 7.38 (td, J = 7.8, 1.6 Hz, 1H), 7.15 - 7.03 (m, 2H), 6.99 (t, J = 8.1 Hz, 1H), 6.86 (t, J = 7.7 Hz, 1H), 6.68 (s, 1H), 4.58 (q, J = 5.3 Hz, 1H), 4.15 (s, 2H), 3.60 (s, 2H), 3.12 (s, 3H), 3.03 (s, 3H), 2.73 (d, J = 5.3 Hz, 3H), 2.26 (s, 6H).
[0444] Example 20 Synthesis of compound 21 [ka] Compound 21 was prepared in one step.
[0445] Step 1: Following the general synthesis of compound E.2, starting from 6-chloro-4-(chloromethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (50 mg, 0.094 mmol) and piperazine, the impure product was combined with other batches and purified by basic preparative separation to give the title compound (22 mg, 0.037 mmol, yield: 39%) as a white solid after lyophilization.
[0446] Yield: Compound 21 was isolated as a white solid (65% over one step).
[0447] Analysis: LCMS (Method R):t R =1.43 minutes;[M+H] + m / z calculated value = 582.2, measured value = 582.2; 1H NMR (400 MHz, DMSO) δ 8.30 (s, 1H), 8.27 (s, 1H), 7.48 (s, 1H), 7.31 - 7.19 (m, 2H), 6.99 (t, J = 7.9 Hz, 1H), 6.83 (t, J = 7.2 Hz, 1H), 4.03 (s, 2H), 3.70 (s, 2H), 3.10 (s, 3H), 2.95 (s, 3H), 2.64 (t, J = 4.6 Hz, 4H), 2.53 (d, J = 2.9 Hz, 3H), 2.40 (s, 4H).
[0448] Example 21 Synthesis of Compound 110 [ka] Compound 110 was prepared in four steps.
[0449] Step 1: Following the general synthesis procedure for compound D.4, starting from ethyl 2-((2-chloro-3-fluoropyridin-4-yl)methyl)-3-oxobutanoate (1.18 g, 4.31 mmol) and 4-methylbenzene-1,3-diol (1.20 equiv.). After completion of the reaction, water was added and the formed suspension was filtered. The residue was coevaporated with EtO. The residue was dried under reduced pressure at 40 °C overnight to give the corresponding coumarin (1.7 g, 4.53 mmol, yield: 105%, purity: 89%) as a beige solid.
[0450] Step 2: Following the general synthetic procedure for compound D.5, the corresponding dimethyl carbamate (1.94 g, 4.32 mmol, yield: 95%, purity: 90%) was obtained as a beige solid.
[0451] Step 3: Starting from 0.9 g (2.22 mmol) of compound D.5, the general synthesis procedure for compound D.6 was followed. Deprotection with TFA was not performed. The reaction mixture was filtered and concentrated under reduced pressure. The impure product was combined with another batch and purified by column chromatography (CHCl / MeOH = 1:0 → 94:6) using the "flash" method to give the corresponding primary amine D.6 (0.22 g, 0.303 mmol, yield: 14%, purity: 53%) as a brown solid.
[0452] Step 4: The general synthesis procedure for compound D.7 was followed. After complete conversion, the reaction mixture was quenched with water and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure product was diluted with CHCl2 and purified by column chromatography using the "flash" method (CHCl2 / MeOH = 1:0 to 96:4) to give 141 mg of a yellow oil. 25 mg of the impure product was purified by basic preparative separation to give the title compound (13.7 mg, 0.029 mmol, yield: 59%) as a white solid after lyophilization.
[0453] Yield: Compound 110 was isolated as a white solid (8% over 4 steps).
[0454] Analysis: LCMS (Method T):t R =1.58 minutes; [MH] + m / z calculated for = 479.1, found = 479.2; H NMR (400 MHz, DMSO) δ 10.34 (s, 1H), 7.89 (s, 1H), 7.78 (s, 1H), 7.23 (s, 1H), 6.94 (s, 1H), 6.77 (s, 1H), 4.00 (s, 2H), 3.10 (s, 3H), 2.94 (s, 3H), 2.46 (s, 3H), 2.23 (s, 3H).
[0455] Example 22 Synthesis of Compound 111 [ka] Compound 111 was prepared in four steps.
[0456] Step 1: Following the general synthesis procedure for compound D.4, starting from ethyl 2-((2-chloro-3-fluoropyridin-4-yl)methyl)-3-oxobutanoate (15.0 g, 46.0 mmol) and 4-chlorobenzene-1,3-diol (1.20 equiv.). After completion of the reaction, water was added and the formed suspension was filtered. The residue was coevaporated with EtOH and triturated with EtOH / EtO. The solid was filtered off to give the corresponding coumarin (4.8 g, 13.55 mmol, yield: 29%) as a white solid.
[0457] Step 2: Following the general synthetic procedure for compound D.5, the corresponding dimethyl carbamate (5.48 g, 11.86 mmol, yield: 87%, purity: 92%) was obtained as a pale yellow solid.
[0458] Step 3: Starting from 1.0 g (2.35 mmol) of compound D.5, the general synthesis procedure for compound D.6 was followed. Deprotection with TFA was not performed. The reaction mixture was filtered and concentrated under reduced pressure. The impure product was purified by column chromatography using the "flash" method (heptane / EtOAc = 9:1 → 1:4) to give the corresponding primary amine (0.12 g, 0.281 mmol, yield: 12%) as a beige solid.
[0459] Step 4: Starting from 400 mg, 0.789 mmol of the primary amine, the general synthesis procedure for compound D.7 was followed. After complete conversion, the reaction mixture was quenched with water. The product was extracted with EtOAc, and the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure product was purified by column chromatography (CHCl2 / MeOH = 1:0 to 96:4) using the "flash" method. The impure product was purified by basic preparative separation to give the title compound (27.5 mg, 0.054 mmol, yield: 7%) as a white solid after lyophilization.
[0460] Yield: Compound 111 was isolated as a white solid (0.2% over four steps).
[0461] Analysis: LCMS (Method T):t R =1.20 minutes;[M+H] + m / z calculated for = 499.1, found = 499.2; 1H NMR (400 MHz, DMSO) δ 10.34 (s, 1H), 8.04 (s, 1H), 7.95 - 7.86 (m, 1H), 7.51 (s, 1H), 6.95 (s, 1H), 6.81 (s, 1H), 4.01 (s, 2H), 3.11 (s, 3H), 2.95 (s, 3H), 2.47 (s, 3H).
[0462] Example 23 Synthesis of Compound 112 [ka] Compound 112 was prepared in three steps.
[0463] Step 1: The general synthesis of compound D.4 was followed, starting from ethyl 2-((2-chloro-3-fluoropyridin-4-yl)methyl)-3-oxobutanoate (10.0 g, 24.12 mmol) and resorcinol (2.00 equiv.). Sulfuric acid was used instead of perchloric acid. After complete conversion, the reaction mixture was cooled (0 °C) and quenched with saturated aqueous NaHCO to basic pH. The formed white suspension was washed with water, EtO, and dried to give the corresponding coumarin (8.61 g, 23.4 mmol, yield: 97%, purity: 87%) as an off-white solid.
[0464] Step 2: Following the general synthetic procedure for compound D.5, the corresponding dimethyl carbamate (9.33 g, 23.16 mmol, yield: 99%) was obtained as a beige solid.
[0465] Step 3: To a solution of dimethyl carbamate (200 mg, 0.512 mmol, 1.0 equiv.) and cyclopropanesulfonamide (93 mg, 0.768 mmol, 1.5 equiv.) in 1,4-dioxane (superhydrous) (0.1 M), Xantphos (59.2 mg, 0.102 mmol, 0.2 equiv.), cesium carbonate (250 mg, 0.768 mmol, 1.5 equiv.), and PdOAc (11.49 mg, 0.051 mmol, 0.1 equiv.) were added under a N atmosphere. The resulting reaction mixture was stirred at 100 °C for 16 h. The reaction mixture was filtered through a pad of Celite eluting with CHCl. The filtrate was concentrated and purified by column chromatography (CHCl / EtOAc = 1:0 → 6:4) using the "flash" method. The impure product was further purified by basic preparative separation to give the title compound (89 mg, 0.208 mmol, yield: 41%) as a white solid after lyophilization.
[0466] Yield: Compound 112 was isolated as a white solid (39% over three steps).
[0467] Analysis: LCMS (Method R):t R=1.43 minutes;[M+H] + m / z calculated value = 476.1, measured value = 476.2; 1H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 7.94 (d, J = 5.1 Hz, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.27 (d, J = 2.3 Hz, 1H), 7.20 (dd, J = 8.8, 2.4 Hz, 1H), 6.88 (d, J = 6.0 Hz, 1H), 4.02 (s, 2H), 3.17 (s, 1H), 3.07 (s, 3H), 2.93 (s, 3H), 2.48 (s, 3H), 1.16 - 0.93 (m, 4H).
[0468] Example 24 Synthesis of Compound 113 [ka] Compound 113 was prepared in one step.
[0469] Step 1: Following the general synthesis of compound E.3, starting from 3-(3-amino-2-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yldimethylcarbamate (0.1 g, 0.27 mmol) and cyclopropanesulfonyl chloride, the title compound (71.4 mg, 0.15 mmol, yield: 56%) was obtained as a white solid.
[0470] Yield: Compound 113 was isolated as a white solid (56% over one step).
[0471] Analysis: LCMS (Method R):t R =1.58 min;[M+H2O] +m / z calculated value = 492.4, measured value = 492.1; 1H NMR (400 MHz, DMSO) δ 9.58 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.31 - 7.22 (m, 2H), 7.19 (dd, J = 8.7, 2.3 Hz, 1H), 7.09 - 6.94 (m, 2H), 3.99 (s, 2H), 3.07 (s, 3H), 2.93 (s, 3H), 2.64 (tt, J = 7.9, 4.8 Hz, 1H), 2.45 (s, 3H), 1.00 - 0.80 (m, 4H).
[0472] Example 25 Synthesis of Compound 114 [ka] Compound 114 was prepared in three steps.
[0473] Step 1: The general synthesis of compound D.4 was followed, starting from ethyl 2-((2-chloro-3-fluoropyridin-4-yl)methyl)-3-oxobutanoate (10.0 g, 24.12 mmol) and resorcinol (2.00 equiv.). Sulfuric acid was used instead of perchloric acid. After complete conversion, the reaction mixture was cooled (0 °C) and quenched with saturated aqueous NaHCO to basic pH. The formed white suspension was washed with water, EtO, and dried to give the corresponding coumarin (8.61 g, 23.4 mmol, yield: 97%, purity: 87%) as an off-white solid.
[0474] Step 2: Following the general synthetic procedure for compound D.5, the corresponding dimethyl carbamate (9.33 g, 23.16 mmol, yield: 99%) was obtained as a beige solid.
[0475] Step 3: To a solution of dimethyl carbamate (100 mg, 0.256 mmol, 1.0 equiv.) and isopropylsulfonamide (47 mg, 0.384 mmol, 1.5 equiv.) in 1,4-dioxane (superhydrous) (0.1 M), Xantphos (29.6 mg, 0.051 mmol, 0.2 equiv.), cesium carbonate (125 mg, 0.384 mmol, 1.5 equiv.), and PdOAc (5.7 mg, 0.026 mmol, 0.1 equiv.) were added under a N atmosphere. The resulting reaction mixture was stirred at 100 °C for 16 h. The reaction mixture was filtered through a pad of Celite eluting with CHCl. The filtrate was concentrated and purified by column chromatography (CHCl / EtOAc = 1:0 → 6:4) using the "flash" method. The impure product was further purified by basic preparative separation to give the title compound (37 mg, 0.077 mmol, yield: 30%) as a white solid after lyophilization.
[0476] Yield: Compound 114 was isolated as a white solid (29% over three steps).
[0477] Analysis: LCMS (Method R):t R =1.47 minutes;[M+H] + m / z calculated value = 478.1, measured value = 478.2; 1H NMR (400 MHz, DMSO) δ 10.49 (s, 1H), 8.05 - 7.82 (m, 2H), 7.27 (d, J = 2.3 Hz, 1H), 7.20 (dd, J = 8.8, 2.3 Hz, 1H), 6.88 (s, 1H), 4.08 - 3.86 (m, 3H), 3.07 (s, 3H), 2.93 (s, 3H), 2.47 (s, 3H), 1.31 (d, J = 6.8 Hz, 6H).
[0478] Example 26 Synthesis of Compound 115 [ka] Compound 115 was prepared in one step.
[0479] Step 1: The general synthesis of compound E.3 was followed, starting from 3-(3-amino-2-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yldimethylcarbamate (0.1 g, 0.27 mmol) and 2-propanesulfonyl chloride. The reaction time was 3 days, and the product was purified by column chromatography (CHCl / EtOAc = 1:0 → 6:4) using the "flash" method to give the title compound (35.8 mg, 0.074 mmol, yield: 27%) as a white solid.
[0480] Yield: Compound 115 was isolated as a white solid (27% over one step).
[0481] Analysis: LCMS (Method R):t R =1.62 minutes;[M+H] + m / z calculated value = 477.1, measured value = 477.2; 1H NMR (400 MHz, DMSO) δ 9.58 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.31 - 7.22 (m, 2H), 7.19 (dd, J = 8.8, 2.3 Hz, 1H), 7.02 (t, J = 7.9 Hz, 1H), 6.97 - 6.88 (m, 1H), 3.98 (s, 2H), 3.22 (p, J = 6.8 Hz, 1H), 3.07 (s, 3H), 2.93 (s, 3H), 2.45 (s, 3H), 1.27 (d, J = 6.8 Hz, 6H).
[0482] Example 27 Synthesis of Compound 116 [ka] Compound 116 was prepared in one step.
[0483] Step 1: Following the general synthesis of compound E.2 (with the addition of 3.0 equivalents of NEt), starting from 4-(bromomethyl)-6-chloro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (45 mg, 0.075 mmol, y: 40%) and N-methylbenzylamine, the product was purified by basic preparative separation to give the title compound (12.8 mg, 0.021 mmol, y: 66%) as a white solid after lyophilization.
[0484] Yield: Compound 116 was isolated as a white solid (66% over one step).
[0485] Analysis: LCMS (Method T):t R =1.98 minutes;[M+H] + m / z calculated value=617.2 / 619.2, actual value=617.4 / 619.4;1H NMR (400 MHz, DMSO) δ 9.41 (s, 1H), 8.25 (s, 1H), 7.47 (s, 1H), 7.37 - 7.21 (m, 6H), 7.15 (s, 1H), 6.97 (t, J = 7.9 Hz, 1H), 6.80 (t, J = 7.2 Hz, 1H), 4.05 (s, 2H), 3.76 (s, 2H), 3.56 (s, 2H), 3.11 (s, 3H), 2.95 (s, 3H), 2.52 (d, J = 4.0 Hz, 3H), 2.06 (s, 3H).
[0486] Example 28 Synthesis of Compound 117 [ka] Compound 117 was prepared in one step.
[0487] Step 1: Following the general synthesis of compound E.2 (with the addition of 3.0 equivalents of NEt), starting from 4-(bromomethyl)-6-chloro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (45 mg, 0.075 mmol, y: 40%) and N-methylpropylamine, the product was purified by basic preparative separation followed by acidic preparative separation to give the title compound (3.8 mg, 0.007 mmol, y: 21%) as a white solid after lyophilization.
[0488] Yield: Compound 117 was isolated as a white solid (21% over one step).
[0489] Analysis: LCMS (Method T):t R =1.94 minutes;[M+H] + m / z calculated value = 569.2 / 571.2, measured value = 569.4 / 571.4;1H NMR (400 MHz, DMSO) δ 9.41 (s, 1H), 8.29 (s, 1H), 7.48 (s, 1H), 7.28 (t, J = 7.7 Hz, 1H), 7.15 (s, 1H), 6.98 (t, J = 7.9 Hz, 1H), 6.81 (t, J = 7.2 Hz, 1H), 4.04 (s, 2H), 3.71 (s, 2H), 3.10 (s, 3H), 2.95 (s, 3H), 2.52 (s, 3H), 2.35 (t, J = 7.0 Hz, 2H), 2.06 (s, 3H), 1.44 (h, J = 7.3 Hz, 2H), 0.82 (t, J = 7.3 Hz, 3H).
[0490] Example 29 Synthesis of Compound 118 [ka] Compound 117 was prepared in one step.
[0491] Step 1: Following the general synthesis of compound E.3, starting from 3-(3-amino-2-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yldimethylcarbamate (0.1 g, 0.27 mmol) and cyclobutanesulfonyl chloride, the reaction mixture was purified by the "basic preparative" method to give the title compound (8.0 mg, 0.016 mmol, yield: 6%) as a white solid after lyophilization.
[0492] Yield: Compound 117 was isolated as a white solid (6% over one step).
[0493] Analysis: LCMS (Method R):t R =1.65 minutes;[M+H] + m / z calculated value = 489.1, measured value = 489.4; 1H NMR (400 MHz, DMSO) δ 9.51 (s, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.28 - 7.15 (m, 3H), 7.06 - 6.88 (m, 2H), 3.98 (s, 2H), 3.90 (p, J = 8.2 Hz, 1H), 3.07 (s, 3H), 2.93 (s, 3H), 2.45 (s, 3H), 2.36 - 2.13 (m, 4H), 1.97 - 1.80 (m, 2H).
[0494] Example 30 Synthesis of Compound 119 [ka] Compound 119 was prepared in one step.
[0495] Step 1: According to the general synthesis of compound E.3, starting from 3-((2-amino-3-fluoropyridin-4-yl)methyl)-4-methyl-2-oxo-2H-chromen-7-yldimethylcarbamate (0.05 g, 0.135 mmol) and ethanesulfonyl chloride, the reaction mixture was purified by the "basic preparative" method to give the title compound (3.6 mg, 0.007 mmol, yield: 6%) as a white solid after lyophilization.
[0496] Yield: Compound 119 was isolated as a white solid (6% over one step).
[0497] Analysis: LCMS (Method R):t R =1.42 minutes;[M+H] + m / z calculated value = 464.1, measured value = 464.2; 1H NMR (400 MHz, DMSO) δ 10.54 (s, 1H), 8.01 - 7.80 (m, 2H), 7.27 (d, J = 2.3 Hz, 1H), 7.20 (dd, J = 8.8, 2.4 Hz, 1H), 6.88 (s, 1H), 4.02 (s, 2H), 3.63 - 3.42 (m, 2H), 3.07 (s, 3H), 2.93 (s, 3H), 2.47 (s, 3H), 1.26 (t, J = 7.4 Hz, 3H).
[0498] Example 31 Synthesis of Compound 120 [ka] Compound 120 was prepared in three steps.
[0499] Step 1: Following the general synthesis of compound E.3, starting from 3-(3-amino-2-fluorobenzyl)-4-methyl-2-oxo-2H-chromen-7-yldimethylcarbamate (0.516 g, 1.115 mmol) and ethanesulfonyl chloride, sulfamoyl (320 mg, 0.678 mmol, yield: 61%) was obtained as a white solid.
[0500] Step 2: The general synthesis procedure for compound E.4 was followed using NBS. After extraction, the impure product was purified by column chromatography using the "flash" method (heptane / EtOAc = 1:0 → 0:1) to give the corresponding bromo compound (324 mg, 0.53 mmol, yield: 79%, purity: 89%) as a white solid.
[0501] Step 3: Starting from 10 mg, 0.016 mmol of the bromine compound and 2 M dimethylamine in MeOH, the general synthesis procedure for compound E.5 was followed. The impure product was purified by basic preparative separation followed by SFC CEL-2 gradient to give the title compound (2.8 mg, 0.005 mmol, 33% yield) as a white solid.
[0502] Yield: Compound 120 was isolated as a white solid (16% over three steps).
[0503] Analysis: LCMS (Method T):t R =1.61 minutes;[M+H] + m / z calculated value = 506.2, measured value = 506.4; 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.8 Hz, 1H), 7.44 (td, J = 7.7, 1.2 Hz, 1H), 7.14 - 7.05 (m, 2H), 7.01 (t, J = 7.9 Hz, 1H), 6.90 (t, J = 7.2 Hz, 1H), 6.49 - 6.43 (m, 1H), 4.16 (s, 2H), 3.60 (s, 2H), 3.16 (q, J = 7.4 Hz, 3H), 3.13 (s, 2H), 3.04 (s, 3H), 2.27 (s, 6H), 1.40 (t, J = 7.4 Hz, 3H).
[0504] Example 32 Synthesis of Compound 121 [ka] Compound 121 was prepared in one step.
[0505] Step 1: Following the general synthesis of compound F.2, starting from phenol (20 mg, 0.046 mmol) and 4-morpholinecarbonyl chloride, purified by the "basic preparative" method to give the title compound (16 mg, 0.029 mmol, yield: 64%) as a white solid after lyophilization.
[0506] Yield: Compound 121 was isolated as a white solid (64% over one step).
[0507] Analysis: LCMS (Method P):t R =1.39 minutes;[M+H] + m / z calculated value = 549.2, measured value = 549.1; 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.8 Hz, 1H), 7.39 (td, J = 7.9, 1.6 Hz, 1H), 7.14 - 7.05 (m, 2H), 7.00 (td, J = 8.0, 1.2 Hz, 1H), 6.92 - 6.84 (m, 1H), 6.61 (d, J = 3.2 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 4.15 (s, 2H), 3.77 (dd, J = 5.5, 4.0 Hz, 4H), 3.70 (d, J = 7.4 Hz, 2H), 3.60 (d, J = 12.2 Hz, 4H), 2.76 (d, J = 5.3 Hz, 3H), 2.28 (s, 6H).
[0508] Example 33 Synthesis of Compound 122 [ka] Compound 122 was prepared in one step.
[0509] Step 1: Following the general synthesis of compound F.2, starting from phenol (20 mg, 0.046 mmol) and 4-morpholinecarbonyl chloride, purified by the "basic preparative" method to give the title compound (16 mg, 0.029 mmol, yield: 64%) as a white solid after lyophilization.
[0510] Yield: Compound 122 was isolated as a white solid (64% over one step).
[0511] Analysis: LCMS (Method P):t R =1.39 minutes;[M+H] +m / z calculated value = 549.2, measured value = 549.1; 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.8 Hz, 1H), 7.39 (td, J = 7.9, 1.6 Hz, 1H), 7.14 - 7.05 (m, 2H), 7.00 (td, J = 8.0, 1.2 Hz, 1H), 6.92 - 6.84 (m, 1H), 6.61 (d, J = 3.2 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 4.15 (s, 2H), 3.77 (dd, J = 5.5, 4.0 Hz, 4H), 3.70 (d, J = 7.4 Hz, 2H), 3.60 (d, J = 12.2 Hz, 4H), 2.76 (d, J = 5.3 Hz, 3H), 2.28 (s, 6H).
[0512] Example 34 Synthesis of compound 123 [ka] Compound 123 was prepared in one step.
[0513] Step 1: Starting from general synthesis step D.4 (155 mg, 0.356 mmol), this was dissolved in MeCN (1.8 mL) and DMAP (130 mg, 1.07 mmol, 3 equiv.) and dimethylthiocarbamoyl chloride (66 mg, 0.53 mmol, 1.5 equiv.) were added. The mixture was stirred at room temperature overnight and at 40 °C for 4 h. The reaction was directly purified by the "acid prep" method to give the title compound (163 mg, 0.31 mmol, 86% yield) as a white solid after lyophilization.
[0514] Analysis: LCMS (Method R):t R =0.951 min;[MH] +m / z calculated value = 523.2, measured value = 523.4; 1H NMR (400 MHz, DMSO) δ 9.38 (s, 1H), 8.08 (d, J = 8.9 Hz, 1H), 7.33 - 7.16 (m, 3H), 7.11 (dd, J = 8.8, 2.4 Hz, 1H), 7.00 (t, J = 7.9 Hz, 1H), 6.84 (t, J = 7.1 Hz, 1H), 4.05 (s, 2H), 3.65 (s, 2H), 3.41 - 3.30 (m, 6H), 2.55 - 2.52 (m, 3H), 2.20 (s, 6H).
[0515] Example 35 Synthesis of compound 124 [ka] Compound 124 was prepared in one step.
[0516] Step 1: According to the general synthesis of compound E.2, starting from 4-(chloromethyl)-3-((3-fluoro-2-((N-methylsulfamoyl)amino)pyridin-4-yl)methyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (390 mg, 0.391 mmol, purity: 50%) and dimethylamine 2 M in MeOH. The product was purified by the "basic preparative" method to give the title compound (80 g, 0.155 mmol, yield: 40%) as an off-white solid after lyophilization.
[0517] Yield: Compound 124 was isolated as an off-white solid (40% over one step).
[0518] Analysis: LCMS (Method R):t R =0.80min;[MH] +m / z calculated value = 508.2, measured value = 508.4; 1H NMR (400 MHz, DMSO) δ 10.34 (s, 1H), 8.09 (d, J = 8.9 Hz, 1H), 7.90 (d, J = 5.1 Hz, 1H), 7.24 (d, J = 2.3 Hz, 1H), 7.16 (dd, J = 8.8, 2.4 Hz, 1H), 6.96 (s, 1H), 6.79 (t, J = 5.1 Hz, 1H), 4.07 (s, 2H), 3.66 (s, 2H), 3.07 (s, 3H), 2.93 (s, 3H), 2.20 (s, 6H).
[0519] Example 36 Synthesis of compound 125 [ka] Compound 125 was prepared in three steps.
[0520] Step 1: The general synthesis of compound D.4 was followed, starting from ethyl 2-((2-chloro-3-fluoropyridin-4-yl)methyl)-3-oxobutanoate (10.0 g, 24.12 mmol) and resorcinol (2.00 equiv.). Sulfuric acid was used instead of perchloric acid. After complete conversion, the reaction mixture was cooled (0 °C) and quenched with saturated aqueous NaHCO to basic pH. The formed white suspension was washed with water, EtO, and dried to give the corresponding coumarin (8.61 g, 23.4 mmol, yield: 97%, purity: 87%) as an off-white solid.
[0521] Step 2: Following the general synthetic procedure for compound D.5, the corresponding dimethyl carbamate (9.33 g, 23.16 mmol, yield: 99%) was obtained as a beige solid.
[0522] Step 3: To a solution of dimethylcarbamate (200 mg, 0.512 mmol, 1.0 equiv.) and cyclobutanesulfonamide (104 mg, 0.768 mmol, 1.5 equiv.) in 1,4-dioxane (superhydrous) (0.1 M), Xantphos (59.2 mg, 0.102 mmol, 0.2 equiv.), cesium carbonate (250 mg, 0.768 mmol, 1.5 equiv.), and PdOAc (11.5 mg, 0.051 mmol, 0.1 equiv.) were added under a N atmosphere. The resulting reaction mixture was stirred at 100 °C for 16 h. The reaction mixture was filtered through a pad of Celite eluted with CHCl. The filtrate was concentrated and purified by basic preparative separation to give the title compound (53 mg, 0.107 mmol, 21% yield) as a white solid after lyophilization.
[0523] Yield: Compound 125 was isolated as a white solid (20% over three steps).
[0524] Analysis: LCMS (Method L):t R =3.71 minutes;[M+H] + m / z calculated value = 490.2, measured value = 490.1; 1H NMR (400 MHz, DMSO) δ 10.53 (bs, 1H), 8.00 - 7.79 (m, 2H), 7.26 (d, J = 2.3 Hz, 1H), 7.20 (dd, J = 8.7, 2.3 Hz, 1H), 6.84 (s, 1H), 4.50 (bs, 1H), 4.00 (s, 2H), 3.07 (s, 3H), 2.93 (s, 3H), 2.48 - 2.34 (m, 5H), 2.29 - 2.17 (m, 2H), 2.01 - 1.83 (m, 2H).
[0525] Example 37 Synthesis of Compound 126 [ka] Compound 125 was prepared in one step.
[0526] Step 1: Following the general synthesis of compound F.2, starting from phenol (20 mg, 0.046 mmol) and dimethylcarbamyl chloride, purified by the "basic preparative" method to give the title compound (9.7 mg, 0.018 mmol, 39% yield) as a white solid after lyophilization.
[0527] Yield: Compound 125 was isolated as a white solid (39% over one step).
[0528] Analysis: LCMS (Method P):t R =1.65 minutes;[M+H] + m / z calculated for = 535.2, found = 535.1; HNMR not available, compound generated from library.
[0529] Example 38 Synthesis of compound 127 [ka] Compound 126 was prepared in one step.
[0530] Step 1: Following the general synthesis of compound F.2, starting from phenol (20 mg, 0.046 mmol) and 4-methyl-1-piperazinecarbonyl chloride, purified by the "basic preparative" method to give the title compound (17.8 mg, 0.032 mmol, 70% yield) as a white solid after lyophilization.
[0531] Yield: Compound 126 was isolated as a white solid (70% over one step).
[0532] Analysis: LCMS (Method P):t R =1.33 minutes;[M+H] + m / z calculated for = 562.2, found = 562.1; HNMR not available, compound generated from library.
[0533] Example 39 Synthesis of compound 128 [ka] Compound 128 was prepared in one step.
[0534] Step 1: The general synthesis of compound F.2 was followed, starting from phenol (50 mg, 0.115 mmol) and azetidine-1-carbonyl chloride. DMAP (0.6 equiv.) and EtN (1.1 equiv.) were added, and the reaction was carried out in CHCl (0.11 M). After complete conversion, the reaction mixture was concentrated, and water was added to the residue. The product was extracted with CHCl. The combined organic layers were washed with brine, dried over NaSO, filtered, and concentrated under reduced pressure. The impure product was purified by the "basic prep" method to give the title compound (6 mg, 0.012 mmol, yield: 10%) as a white solid after lyophilization.
[0535] Yield: Compound 128 was isolated as a white solid (10% over one step).
[0536] Analysis: LCMS (Method T):t R =1.44 minutes;[M+H] + m / z calculated value = 519.2, measured value = 519.1; 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.8 Hz, 1H), 7.39 (td, J = 7.9, 1.6 Hz, 1H), 7.15 - 7.05 (m, 2H), 7.03 - 6.96 (m, 1H), 6.90 - 6.83 (m, 1H), 6.61 (s, 1H), 4.44 (q, J = 5.4 Hz, 1H), 4.25 (s, 2H), 4.15 (s, 4H), 3.59 (s, 2H), 2.75 (d, J = 5.3 Hz, 3H), 2.36 (p, J = 7.7 Hz, 2H), 2.27 (s, 6H).
[0537] Example 40 Synthesis of compound 129 [ka] Compound 129 was prepared in one step.
[0538] Step 1: To a solution of the phenol derivative (50 mg, 0.115 mmol, 1.0 equiv.) and 2-bromopyrimidine (30 mg, 0.19 mmol, 1.6 equiv.) in N,N-dimethylformamide (anhydrous) (2 ml), potassium carbonate (26 mg, 0.19 mmol, 1.6 equiv.) was added. The reaction mixture formed was stirred at 80 °C for 5 h. Water was added and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The impure product was purified by the "basic prep" method to give the title compound (8.0 mg, 0.016 mmol, yield: 14%) as a white solid after lyophilization.
[0539] Yield: The title compound was isolated as a white solid (14% over one step).
[0540] Analysis: LCMS (Method T):t R =1.34 minutes;[M+H] + m / z calculated value=514.2, measured value=514.1;1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 4.7 Hz, 2H), 8.11 (d, J = 8.8 Hz, 1H), 7.40 (td, J = 7.8, 1.6 Hz, 1H), 7.22 (d, J = 2.4 Hz, 1H), 7.17 (dd, J = 8.8, 2.4 Hz, 1H), 7.12 (t, J = 4.8 Hz, 1H), 7.01 (t, J = 8.0 Hz, 1H), 6.91 - 6.81 (m, 1H), 6.61 (s, 1H), 4.43 (q, J = 5.4 Hz, 1H), 4.17 (s, 2H), 3.62 (s, 2H), 2.77 (d, J = 5.2 Hz, 3H), 2.29 (s, 6H).
[0541] Example 41 Synthesis of Compound 130 [ka] Compound 130 was prepared in four steps.
[0542] Step 1: Following the general synthesis of compound 4, starting from ethyl 2-(2-fluoro-3-nitrobenzyl)-3-oxobutanoate (2.0 g, 7.06 mmol) and 4-fluorobenzene-1,3-diol (1.20 equiv.), the corresponding coumarin compound (2.85 g, 8.13 mmol, yield: 115%) was obtained as an off-white solid.
[0543] Step 2: The general synthesis procedure for compound 5 was followed. After a reaction time of 2.5 days, the corresponding dimethyl carbamate (2.28 g, 5.01 mmol, purity: 92%, yield: 61%) was obtained as a beige solid.
[0544] Step 3: Following the general synthetic procedure for compound 6, the corresponding primary amine (1.28 g, 3.11 mmol, yield: 57%) was obtained as a pale yellow solid.
[0545] Step 4: The general synthetic procedure for compound 7 was followed. After filtration, the impure product was purified by flash column chromatography (CH2Cl2 / MeOH=1:0 to 97:3) to give the title compound (1.043 g, 2.15 mmol, yield: 65%) as an off-white solid.
[0546] Yield: Compound 130 was isolated as an off-white solid (26% over 4 steps).
[0547] Analysis: LCMS (Method R):t R =1.55 minutes; [MH] +m / z calculated value = 480.1, measured value = 480.2; 1H NMR (400 MHz, DMSO) δ 9.37 (s, 1H), 7.86 (d, J = 11.2 Hz, 1H), 7.49 (d, J = 6.8 Hz, 1H), 7.28 (td, J = 7.8, 1.6 Hz, 1H), 7.21 (q, J = 5.1 Hz, 1H), 7.01 (t, J = 7.9 Hz, 1H), 6.91 - 6.83 (m, 1H), 3.98 (s, 2H), 3.08 (s, 3H), 2.94 (s, 3H), 2.53 (s, 3H), 2.43 (s, 3H).
[0548] Example 42 Synthesis of Compound 131 [ka] Compound 131 was prepared in one step.
[0549] Step 1: Following the general synthetic procedure for compound E.2 (with the addition of 3.0 equivalents of potassium carbonate), starting from 6-chloro-4-(chloromethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (20 mg, 0.038 mmol) and azetidine, the impure product was combined with other batches and purified by basic preparative separation to give the title compound (44 mg, 0.076 mmol, yield: 65%) as a white solid after lyophilization.
[0550] Yield: The title compound was isolated as a white solid (65% over one step).
[0551] Analysis: LCMS (Method R):t R =0.95 minutes;[M+H] +m / z calculated value = 553.1, measured value = 553.2; 1H NMR (400 MHz, DMSO) δ 9.39 (s, 1H), 8.20 (s, 1H), 7.48 (s, 1H), 7.33 - 7.19 (m, 2H), 7.00 (t, J = 8.0 Hz, 1H), 6.81 (t, J = 7.1 Hz, 1H), 4.09 (s, 2H), 3.82 (s, 2H), 3.16 (t, J = 6.9 Hz, 4H), 3.10 (s, 3H), 2.95 (s, 3H), 2.53 (d, J = 4.8 Hz, 3H), 1.91 (p, J = 7.0 Hz, 2H).
[0552] Example 43 Synthesis of compound 132 [ka] Compound 132 was prepared in three steps.
[0553] Step 1: Following the general synthesis of compound E.3, starting from 3-(3-amino-2-fluorobenzyl)-6-chloro-4-methyl-2-oxo-2H-chromen-7-yldimethylcarbamate (0.320 g, 0.585 mmol) and ethanesulfonyl chloride, the reaction mixture was combined with another batch during workup to give the sulfamoyl (350 mg, 0.704 mmol, 92% yield) as a white solid.
[0554] Step 2: The general synthesis procedure for compound E.4 was followed using NBS. After extraction, the impure product was purified by column chromatography using the "flash" method (heptane / EtOAc = 1:0 → 0:1) followed by acidic preparative separation to give the corresponding bromine (65 mg, 0.113 mmol, yield: 19%) as a beige solid.
[0555] Step 3: The general synthesis procedure for compound E.5 was followed using 2M dimethylamine in MeOH. The reaction mixture was quenched with water, and the product was extracted with CH2Cl2. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by acidic preparative separation to give the title compound (39 mg, 0.073 mmol, yield: 65%) as a white solid after lyophilization.
[0556] Yield: Compound 132 was isolated as a white solid (11% over three steps).
[0557] Analysis: LCMS (Method V):t R =3.92 minutes;[M+H] + m / z calculated value = 540.1 / 542.1, actual value = 540.1 / 542.1;1H NMR (400 MHz, DMSO) δ 9.67 (s, 1H), 8.21 (s, 1H), 7.48 (s, 1H), 7.25 (td, J = 7.8, 1.7 Hz, 1H), 7.03 (t, J = 7.8 Hz, 1H), 6.98 - 6.88 (m, 1H), 4.05 (s, 2H), 3.66 (s, 2H), 3.14 - 3.07 (m, 5H), 2.95 (s, 3H), 2.18 (s, 6H), 1.26 (t, J = 7.3 Hz, 3H).
[0558] Example 44 Synthesis of compound 133 [ka] Compound 133 was prepared similarly to compound 225 using chloride instead of bromide.
[0559] Step-1: 6-chloro-4-(chloromethyl)-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (300 mg, 0.564 mmol) and triethylamine (236 μL, 1.69 mmol, 3 equiv.) were stirred in DCM (7 mL) at 40 °C, and tert-butyl glycinate (308 μL, 2.25 mmol, 4 equiv.) was added. The next day, water was added, and the product was extracted with DCM (twice). The combined extracts were dried with brine and sodium sulfate, and evaporated. The residue was redissolved in 1 mL of DCM and purified by column chromatography using the "Basic Prep" method to give the intermediate tert-butyl ester (126 mg, 0.20 mmol, yield: 35%).
[0560] Step-2: The intermediate from the previous step (126 mg, 0.20 mmol) was stirred in 2 mL of DCM and 2 mL of 4N HCl (58 mmol, 287 equiv.) in dioxane. The next day, the volatiles were evaporated, the residue was stripped with DCM, and the crude product was redissolved in MeCN and purified by the "Basic Prep" method to give the title compound (94 mg, 0.16 mmol, yield: 81%) as an off-white solid.
[0561] Example 45 Synthesis of compound 134 [ka] Compound 134 was prepared in one step.
[0562] Step 1: Following the general synthesis of compound E.2 (with the addition of 3.0 equivalents of EtN), starting from 4-(chloromethyl)-6-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (30 mg, 0.058 mmol) and piperazine, the impure product was purified by basic preparative separation to give the title compound (17.3 mg, 0.029 mmol, 51% yield) as a white solid after lyophilization.
[0563] Yield: Compound 134 was isolated as a white solid (51% over one step).
[0564] Analysis: LCMS (Method T):t R =1.39 minutes;[M+H] + m / z calculated value = 566.2, measured value = 566.4; 1H NMR (400 MHz, DMSO) δ 8.04 (d, J = 11.8 Hz, 1H), 7.47 (d, J = 6.9 Hz, 1H), 7.28 (td, J = 7.9, 1.7 Hz, 1H), 7.24 - 7.12 (m, 1H), 6.99 (t, J = 7.9 Hz, 1H), 6.82 (t, J = 7.1 Hz, 1H), 4.03 (s, 2H), 3.66 (s, 2H), 3.08 (s, 3H), 2.94 (s, 3H), 2.63 - 2.55 (m, 4H), 2.55 - 2.52 (m, 3H), 2.41 - 2.28 (m, 4H).
[0565] Example 46 Synthesis of compound 135 [ka] Compound 135 was prepared in one step.
[0566] Step 1: According to the general synthesis of compound E.2, starting from 4-(chloromethyl)-6-fluoro-3-(2-fluoro-3-((N-methylsulfamoyl)amino)benzyl)-2-oxo-2H-chromen-7-yldimethylcarbamate (50 mg, 0.097 mmol) and dimethylamine 2 M in MeOH. The product was combined with another batch and purified by basic preparative separation to give the title compound (9.1 mg, 0.017 mmol, 18% yield) as a white solid after lyophilization.
[0567] Yield: The title compound was isolated as a white solid (18% over one step).
[0568] Analysis: LCMS (Method T):t R =1.63 minutes;[M+H] + m / z calculated value=525.2, measured value=525.2;1H NMR (400 MHz, DMSO) δ 9.38 (s, 1H), 8.00 (d, J = 11.7 Hz, 1H), 7.46 (d, J = 6.9 Hz, 1H), 7.32 - 7.25 (m, 1H), 7.18 (s, 1H), 6.99 (t, J = 7.9 Hz, 1H), 6.82 (t, J = 7.2 Hz, 1H), 4.04 (s, 2H), 3.63 (s, 2H), 3.08 (s, 3H), 2.94 (s, 3H), 2.54 - 2.51 (m, 3H), 2.18 (s, 6H).
[0569] Example 47 Synthesis of compound 136 [ka] Compound 136 was prepared in one step.
[0570] Step 1: Accordin...
Claims
1. Formula (IIa): 【Chemistry 1】 and pharma- ceutically acceptable salts thereof, each of which has the structure: R 2 is L; R 3 is fluorine; R 6 is H, deuterium, halogen, or C 1 ~C 6 is alkyl; R 8 But, C 1 ~C 6 is alkyl; L is -Z 1 -Z 2 and Z 1 But -CH 2 - and a) Z 2 But -NR 5 R 5’ is, or b) Z 2 is 【Chemistry 2】 and optionally substituted with methyl or halogen, and n is 1, 2, 3 or 4; or c) Z 2 is 【Chemistry 3】 is, or d) Z 2 is 【Chemistry 4】 and optionally substituted with methyl; Each R 5 and R 5’ are independently H, deuterium, C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, C 3 ~C 8 Carbocyclyl, C 6 ~C 10 Aryl, C 3 ~C 8 Heterocyclyl, or C 3 ~C 10 is heteroaryl; X is O; Y is O; Z is CH or N.
2. a) Z 2 -NR 5 R 5’ and each R 5 and R 5’ became independent and C 1 ~C 6 or each R 5 and R 5’ are independently H or CH 3 or each R 5 and R 5’ CH 3 is, or b) Z 2 but, 【Chemistry 5】 and optionally substituted with methyl, chlorine or fluorine, and n is 1, 2, 3 or 4; or c) Z 2 but, 【Chemistry 6】 or d) Z 2 but, 【Chemistry 7】 and optionally substituted with methyl.
3. R 8 But, CH 3 3. The compound according to claim 1 or 2,
4. R 6 is H, or R 6 The compound according to any one of claims 1 to 3, wherein is chlorine or fluorine.
5. 2. The compound of claim 1 selected from the following compounds: 【Chemistry 8】 【change】 【change】 【change】
6. 2. The compound of claim 1 which is the following compound or a pharma- ceutically acceptable salt thereof: 【Chemistry 9】
7. 2. The compound of claim 1 which is the following compound or a pharma- ceutically acceptable salt thereof: 【Chemistry 10】
8. 2. The compound of claim 1 which is the following compound or a pharma- ceutically acceptable salt thereof: 【Chemistry 11】
9. 2. The compound of claim 1 which is the following compound or a pharma- ceutically acceptable salt thereof: 【Chemistry 12】
10. 2. The compound of claim 1 which is the following compound or a pharma- ceutically acceptable salt thereof: 【Chemistry 13】
11. 2. The compound of claim 1 which is the following compound or a pharma- ceutically acceptable salt thereof: 【Chemistry 14】
12. 2. The compound of claim 1 which is the following compound or a pharma- ceutically acceptable salt thereof: 【Chemistry 15】
13. Z 2 But -NR 5 R 5’ and each R 5 and R 5 ' is independently C 1 -C 6 alkyl, or each R 5 and R 5 ' is independently H or CH 3 , or each R 5 and R 5 ' is CH 3 .
14. The compound of claim 13, wherein each R 5 and R 5' is CH 3 .
15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14.
Citation Information
Patent Citations
Coumarin compound with anti-tumor activity
CN103172606A
Coumarin derivatives useful as TNFα inhibitors
JP2004509855A
Preventive or therapeutic agent for diabetes, diabetes-related disease or diabetic complication
JP2012092038A
